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Abstract
Cellular interaction with the extracellular matrix influences basic processes such as 
proliferation, differentiation, migration and invasion. Matrix metalloproteinase (MMP) 
activity has been implicated in the remodelling of tissue associated with these events and in 
the migration of cells through tissue barriers. Evidence suggests that MMP expression and 
activation is influenced by the matrix components to which the cell is exposed.
The recognition sites of the integrins a lp l  and a2pl within collagen IV are located in the 
cyanogen bromide fragment CB3|TV] region, close to the reported gelatinase A (GLA) 
cleavage site. The susceptibility of solubilised forms of collagen IV to GLA cleavage and 
the concomitant effects on cell adhesion were assessed. Preparations of collagen IV 
monomers with disrupted intramolecular disulphide bonds in the CB3|TV] region were 
cleaved by GLA into the two characteristic 100nm-300nm fragments at 30®C and were 
totally degraded at 37®C. This resulted in the partial or total inhibition of cell adhesion to 
the collagen via integrin receptors. Preparations of monomers with intact disulphide bonds 
in the CB3|TV] region were not susceptible to GLA cleavage. Furthermore, no effect on 
binding of cells to the GLA-treated collagen could be detected after treatment at 37®C. 
Dimeric collagen IV with intact disulphide bonds in the CB3|TV] region was not degraded 
by GLA at 37®C. Tetrameric collagen was highly susceptible to GLA degradation at 
37®C, but this did not affect cell adhesion, indicating that the CB3|TV] region of the 
tetramers remained intact.
The effects of fibronectin and laminin-1 matrices on the activation of GLA was assessed. 
HT1080 fibrosarcoma cells cultured on fibronectin activated endogenous GLA to a level 
comparable with that elicited by phorbol ester treatment. In contrast, cells cultured on 
laminin-1 secreted mainly proGLA. Cells cultured on Augments of fibronectin derived 
from the central cell binding domain secreted levels of active GLA similar to those 
observed for full length fibronectin. A substrate of immobilised anti-a5 or anti-pi integrin 
antibodies promoted GLA activation, whereas an anti-a6 antibody did not. The data 
demonstrate that that signals via the aSpl integrin receptor may be involved in the 
fibruncciin-induccd up-rcgulatiun o f GLA activation.
The effect of fibronectin on the components of the putative MTl -MMP/TIMP-2 'receptor* 
complex for GLA was assessed. Levels of TIMP-2 protein expressed by HT1080 cells did 
not vary detectably between cells cultured on fibronectin or laminin-1. However, a 
fibronectin substrate increased the processing of MTl-MMP to a truncated 45 kDa form, 
which was concomitant with GLA activation. Inhibitor studies showed that the truncation 
of MTl-MMP to 45 kDa is MMP mediated, although not inhibited by TIMP-1. This study 
raises the possibility that truncation of MTl-MMP to 45 kDa form represents a regulatory 
end-point in the activation pathway of GLA.
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Chapter 1 
Introduction
Chapter 1 Introduction
1.1 Overview
The extracellular matrix has dynamic roles not only in supporting cells and tissues, but also 
in regulating basic cellular functions such as proliferation, differentiation and survival. 
Cellular interactions with the extracellular matrix (ECM) are mediated in part by the cell 
surface integrin receptors, which promote cell adhesion and transmit signals to the cells 
regarding the surrounding environment. Cells can exert control over their environment by 
synthesising proteolytic enzymes that degrade the structural framework of the ECM. This 
affects cell anchorage, and processes associated with anchorage such as cell migration and 
differentiation. Proteolysis also releases matrix bound growth factors and cytokines, and 
bioactive matrix fragments (reviewed by Werb, 1997). The matrix metalloproteinases 
(MMPs) are a family of ECM degrading enzymes implicated in the pericellular proteolysis 
of the ECM. These enzymes are tightly controlled in normal tissue remodelling events 
such as embryonic development or wound healing. In pathological conditions such as 
arthritis, cardiovascular disease or cancer, the excessive or inappropriate expression of 
MMPs is believed to play a major role in tissue destruction. The aim of this study was to 
investigate aspects of cell-matrix interactions that involve MMP activity. The first part of 
this study questions whether the proteolytic degradation of basement membrane collagen 
IV affects cell adhesion to the collagen. The second part investigates the cellular 
interactions with the ECM that lead to increased MMP activity.
1.2 The nmtrix metalloproteinases
The MMPs are zinc and calcium-dependent enzymes that function at neutral pH. They are 
synthesised by a wide variety of cell types, including mesenchymal, hemopoietic and 
tumour cells. All MMPs are synthesised as inactive zymogens and most members of the 
family are secreted in zymogen form. The latency of MMPs is maintained by an N- 
terminal propeptide, which inserts into the catalytic site. Following the proteolytic 
removal of the propeptide, the active MMPs are subject to inhibition by a family of MMP 
specific inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). Currently there are 
sixteen members of the mammalian MMP family, which can be divided on the basis of
2structure and substrate specificity into the coUagenases, stromelysins, gelatinases and 
membrane-type metalloproteinases (MT-MMPs).
The coUagenases (CL-1, CL-2, CL-3) have been named for their specificity for fibrillar 
collagens, however they do show some activity against other matrix molecules (see Table 
1.1). The gelatinases (GLA, GLB) cleave non-fibrillar and denatured coUagens (gelatins) 
and have been named the type IV coUagenases, based on their abUity to cleave solubilised 
preparations of collagen IV. The stromelysins (SL-1, SL-2, SL-3) have the broadest 
substrate specificities, cleaving proteoglycans, laminins, elastin, and a number of the 
coUagens, including coUagen IV. SL-3, however, shows only weak stromelysin-like 
activity and the substrates for this enzyme have not been identified. SL-3 is unique 
amongst the stromelysins as it is activated ihtracellularly by the furin family of enzymes. 
MMP-19 and MMP-20 have only recently been cloned, and to date there is no information 
on substrate specificity, however they have been included in the stromelysin family on the 
basis of structural similarities (Table 1.1). The MT-MMPs are grouped on the basis of 
structure rather than substrate specificity, as these MMPs possess a transmembrane domain 
that locates them to cellular membranes. FinaUy, metalloelastase and matrilysin have not 
been included in the major groupings, although they display strong stromelysin-like 
activity. MatrUysin is unique amongst the MMPs as it is lacking the C-terminal domain 
(MMP structure described below) and metalloelastase is unique as it undergoes both N- 
terminal and C-terminal processing to form an active 22 kDa enzyme.
1.2.1 The structure andfunction of MMP domains
Figure 1.1 shows a schematic representation of MMP domain-structure. All MMPs 
possess an N-terminal propeptide domain, a catalytic domain and a C-terminal domain 
(with the exception of matrilysin). The MT-MMPs have an additional transmembrane 
spanning region and a short cytoplasmic tail.
DetaUs of the structure of the propeptide domain have been provided by X-ray 
ciystallogiuphic studies of SL-1. The propeptide consists of a separate folding unit of three
3a-helices and an extended sequence, that protrudes into the active site cleft of the catalytic 
domain (Becker et al., 1995). The conserved amino acid sequence PRCGVPD in the 
propeptide region is a major determinant of enzyme latency, as the free cysteine residue 
coordinates the catalytic zinc. Propeptide removal is therefore an important step in the 
regulation of MMP activity. Details of the mechanism of MMP activation are given in 
Section 1.4.2.
The catalytic domain of the MMPs is characterised by the amino acid sequence 
HEXXHXXGXXH, which coordinates the catalytic zinc ion via the histidine residues. 
MMP catalytic domains have been studied in the presence or absence of inhibitors by X- 
ray crystallography (Bode et al., 1994; Dhanaraj et al., 1996; Femandez-Catalan et al., 
1998) and by NMR spectroscopy (Gooley et al., 1994). The catalytic domain has a 
characteristic spherical shape, notched by a shallow active site cleft close to the C-terminus 
of the domain. The main N-terminal region of the domain consists of a 5-stranded p sheet, 
flanked by 3 surface loops and 2 a-helices, the second helix termed the 'active-site helix'. 
The catalytic zinc ion is coordinated at the bottom of the active-site cleft. Proximal to the 
active site cleft is the ST pocket, which varies in depth between the MMPs, contributing to 
substrate specificity. Also coordinated in the catalytic domain is a second zinc ion, as well 
as 1-2 calcium ions, which most likely play a structural role. The gelatinases have an extra 
domain, comprising three fibronectin type Il-like repeats, which are inserted into the 
catalytic domain N-terminally to the active site. Homology modelling has suggested that 
these repeats are inserted at the right hand end of the active site cleft, close to the SI' 
pocket of the enzyme, and they are therefore thought to be crucial for proper orientation of 
the substrate relative to the catalytic site (Banyai et al., 1996). Several groups have 
expressed these repeats in isolation and have shown that they bind to denatured type I 
collagen (Collier et al., 1992; Banyai et al., 1994), denatured type IV and V collagens, 
elastin and native type I collagen (Steffensen et al., 1995).
The catalytic domain of the MMPs is separated from the C-terminal domain by a hinge 
region, which varies in length across the MMP classes. In the case of the coUagenases, the
4hinge region is rich in proline residues and may play a role in determining the specificity of 
these MMPs for fibrillar collagens.
The C-terminal domain of the MMPs bears strong sequence similarity with the hemopexin 
family of proteins. X-ray crystallographic studies of the C-terminal domain of porcine 
collagenase-1 (Li et al., 1995), human collagenase-3 (Gomis-Ruth et al., 1996) and human 
gelatinase A (Lisbon et al., 1995; Gohlke et al., 1996) have reported that this domain is 
comprised of four similar units that form a four-bladed p propellor structure. The blades of 
the propellor are formed fi"om antiparallel four-stranded p sheets and are arranged around a 
tunnel that contains cations (calcium) and anions (chloride) at the core. A disulphide 
bridge between the first and fourth propellor, which is conserved across all the MMPs, acts 
to stabilise the structure. Studies have shown that the substrate specificity of the 
coUagenases is determined by interactions between the fibriUar collagens and the C- 
terminal domain of the coUagenases (Murphy et al., 1992a; Gomis-Ruth et al., 1996; 
Knâuper et al., 1997). ModeUing experiments suggest that the relatively short hinge region 
of CL-1 allows the positioning of the C-terminal domain over the active site cleft, trapping 
triple hcUcal collagen between the N- and C-terminii of CL-1 (De Souza et al., 1996). For 
the other classes of MMPs, the C-terminal domain does not appear to be important in 
determining substrate specificity. However, it does play an important role in the initiation 
of TIMP binding to the gelatinases, and consequently affects the activation of GLA 
(discussed in detail below).
The MT-MMPs are clearly a unique class of the MMPs, as they possess a transmembrane 
domain that locates them to the plasma membrane and a cytoplasmic tail. In addition, the 
MT-MMPs have an insert in the catalytic domain, the function of which is unknown, but 
crystaUographic studies suggest that it forms an exposed loop (Femandez-Catalan et al., 
1998). The MT-MMPs also have a short basic peptide sequence RRKR in the propeptide 
that is a recognition sequence for the furin famUy of enzymes, which may contribute to the 
activation of MT-MMPs.
5L3 TheTIMPs
The major inhibitors of the MMPs in vivo are the TIMPs (reviewed by Edwards et al.,
1996). There are four members of the TIMP family, secreted by many cell types, including 
those of the connective tissue, and they play an important role in determining the 
effectiveness of tissue turnover by the MMPs. In normal tissue homeostasis the activity of 
MMPs is tightly controlled by the TIMPs, however in pathological conditions such as 
arthritis and cancer an imbalance between MMP and TIMP production has been linked 
with tissue destruction (Gomez et al., 1997).
TIMP-1 (Docherty et al., 1985; Carmichael et al., 1986) is a glycoprotein of 28.5 kDa and 
is the most ubiquitous of the TIMPs. The expression of TIMP-1 is influenced by many 
cytokines and growth factors. By comparison, TIMP-2 (Stetler-Stevenson et al., 1989; 
Boone et al., 1990) is a 21 kDa, non-glycosylated protein expressed constitutively by most 
cell types. TIMP-3 (21 kDa; may be glycosylated) is localised to the ECM (Pavloff et al., 
1992; Leco et al., 1994), and thus differs from other TIMP family members which are 
freely diffusible. The recently cloned TTMP-4 (22 kDa; non-glycosylated) is more closely 
related to TIMPs -2 and -3 than to TIMP-1 (Greene et al., 1996; Leco et al., 1997). Some 
distinct tissue distributions have been observed for the TIMPs, suggesting separate and 
individual roles for the TIMPs in tissue remodelling (reviewed by Edwards et al., 1996).
All four TIMPs form high affinity, non-covalent bonds with active MMPs, at a 1:1 
stoichiometry. MMP/TIMP complexes can be dissociated to give competent inhibitor 
(Murphy et al., 1989b), however complexes such as active GLA/TIMP-2 are very stable 
(Hutton et al., 1998) and binding is essentially irreversible. Overall, the TIMPs show 
relatively little selectivity in binding to the MMPs, however certain TIMPs do show 
specificity for some MMPs. GLA and GLB are more sensitive to inhibition by TIMP-2 
than TIMP-1 (Howard et al., 1991) and GLB is very effeetively inhibited by TIMP-3 
(Edwards et al., 1996). MTl-MMP and MT2-MMP do not appear to be sensitive to 
TIMP-1 inhibition, but are inhibited by TIMPs-2 and -3 (Will et al., 1996; Butler et al.,
1997). Interestingly, a recent study has shown that TNFa converting enzyme, a member of
6the ADAM family of metalloproteinases, is inhibited by TIMP-3 but not by TIMPs -1,-2 
and “4 (Amour et al.j 1998), This onzjine processes membrane bound proTNFa to yield 
mature TNFa, a major inflammatory mediator. This study and others (Smith et al., 1997; 
Hargreaves et al., 1998) implicate TIMP-3 as a regulator of a broader class of 
metalloproteinases.
1.3.1 The structure and function o f TIMP domains
The TIMPs are structurally similar, despite a low homology between their amino acid 
sequences. This is due to twelve conserved cysteine residues which form six disulphide 
bonded loops. These disulphide bonds confer resistance to protein dénaturation by changes 
in pH, temperature or ionic strength. The six loops can be divided into two structurally 
distinct domains. The N-terminal domain (loops 1-3) is autonomously folding and is 
sufficient for MMP inhibition (Murphy et al., 1991b). Recent studies by NMR 
spectroscopy (Muskett et al., 1998) and X-ray crystallography (Gomis-Ruth et al., 1997; 
Femandez-Catalan et al., 1998) of N-terminal or full length TIMPs complexed with 
catalytic domains of MMPs have confirmed that multiple regions on TIMP molecules are 
important for interaction with MMPs. A comparison between NMR studies of N-terminal 
TIMP-2 complexed with the catalytic domain of SL-1 (Muskett et al., 1998) and 
crystallographic studies of TIMP-1 complexed with catalytic domain of SL-1 (Gomis-Ruth 
et al., 1997) has revealed specific interactions between N-terminal TIMP-2 and SL-1 that 
do not occur between TIMP-1 and SL-1, which may contribute to TIMP specificities 
(Muskett et al., 1998).
Several activities have been mapped to the C-terminal domain (loops 4-6). Interactions 
between MMPs and TIMPs can be initiated by the 'docking' of the C-terminal domain of 
TIMPs with the C-terminal domain of MMPs (Willenbrock et al., 1993). These 
interactions are particularly important for the binding of TIMPs -1-2 and -4 with active 
GLA (Willenbrock et al., 1993), TIMP-1 with active GLB (O'Cormell et al., 1994), and 
TIMPs -1 and -3 with active CL-3 (Knâuper et al., 1997). However, for SL-1 the 
interactions between the C-terminal domain of TIMPs -1 and -2 and the C-terminal domain
7of the enzyme are negligible (Nguyen et al., 1994). Significantly, the C-terminal domain 
of the TIMPs also bind the latent gelatinases. The C-terminal domain of TIMP-1 
specifically binds the C-terminal domain of proGLB and the C-terminal domains of TIMPs 
-2 and -4 specifically bind the C-terminal domain of proGLA (Howard et al., 1991; 
Murphy et al., 1991b; Goldberg et al., 1992a, 1992b; Willenbrock et al., 1993; Bigg et al., 
1997). ProGLA bound to TIMP-2 can be activated in vitro by organomercurial agents in 
the same way as 'fi*ee' proGLA is activated (activation mechanisms are discussed below), 
although the specific activity is reduced in comparison with 'fi-ee' enzyme (Goldberg et al., 
1992b). TIMP-2 bound via its C-terminus retains its ability to inhibit active MMPs 
(Kolkenbrock et al., 1991). For GLA, the significance of these C-terminal domain 
interactions lies in the key role that they play in proGLA activation, which is discussed in 
more detail below.
TIMP-1 has also been described as erythroid-potentiating activity as it stimulates the 
growth of erythroid progenitor cells (Gasson et al., 1985). Several reports have 
demonstrated that TIMPs act as growth factors (reviewed by Gomez et al. 1997). Studies 
by Chesler et al. (1995) using N-terminal TIMP-1 point mutants that lacked MMP 
inhibitory activity demonstrated that the effects of TIMP-1 on erythroid progenitor cell 
growth were independent of MMP inhibition.
1,4 Regulation o f MMP activity
MMP activity is controlled at a number of levels. The transcription of MMP mRNA is 
regulated by a number of factors including cytokines, growth factors, and tumour 
promoters. The removal of the propeptide is a critical step in the control of MMP activity. 
Once they are activated MMPs are tightly controlled by the TIMPs and by a2- 
macroglobulin. Some aspects of MMP regulation are described below, with particular 
attention paid to the activation cascades that control MMP activity at the cell surface.
81.4.1 Regulation o f transcription
Most cell types normally synthesise negligible amounts of MMPs, but production can be 
stimulated by cytokines such as IL-1 and TNF-a, growth factors (EGF, PDGF and bFGF), 
hormones, tumour promoters and agents which disrupt the cytoskeleton, such as 
cytochalasin D (reviewed by Birkedal-Hansen, 1993). Evidence suggests that cells in 
culture also synthesise MMPs in response to ECM molecules and matrix fragments. For 
example, fibronectin fingments induce CL-1, GLB and SL-1 expression by rabbit synovial 
fibroblasts (Werb et al., 1989) and vitronectin induces the secretion of GLA by melanoma 
cells (Bafetti et al., 1998). Collagen lattices induce MTl-MMP and GLA expression 
(Gilles et al., 1997; Haas et al., 1998); these are the first reports to show that MT-MMP 
expression is induced by ECM. It is likely that many of the effects of ECM on MMP 
expression are mediated by integrin receptors, and this is discussed later in the chapter. All 
of the MMP promoters studied to date contain a binding site for the Fos/Jun containing 
complex AP-1, with the exception of GLA and SL-3. Studies have shown that AP-1 
activity is involved in the transcription of MMPs in response to IL-1, TNF-a, IFNp and 
fibronectin induction (reviewed by Crawford and Matrisian, 1996). MMP promoters also 
contain multiple PEA3 sites (with the exception of GLA), which bind the Ets family of 
nuclear protooncogenes. NF-kB binding sites are common in MMP promoters, and 
cooperativity for MMP expression between AP-1 and PEA3 binding sites (Gutman and 
Wasylyk, 1990; Wasylyk et al., 1990) and between AP-1 and NF-kB binding sites has been 
documented (Gum et al., 1996). The similarity between the MMP promoters allows for 
coordinated transcription of the MMPs. However, differential transcription of the MMPs is 
also achieved and this most likely occurs as a result of the differing arrangements of 
binding elements between the promoters, as well as the number of Fos/Jun/Ets family 
members, each of which could have a different effect on MMP transcription (reviewed by 
Crawford and Matrisian, 1996).
1.4.2 MMP activation
MMP latency is maintained by the presence of the propeptide domain that extends into the 
active site of the enzyme. The free cysteine in the conserved PRCGVPD sequence
9coordinates the catalytic zinc in the active site cleft. Activation of MMPs involves the 
disruption of this bond. This can be achieved in vitro by thiol reactive agents such as the 
organomercurial APMA, or by dénaturants such as SDS and urea. Stepwise intramolecular 
and bimolecular cleavages then complete the removal of the propeptide (reviewed by 
Nagase, 1997). The 'cysteine switch hypothesis' predicts that in vivo, the first step in 
activation is the cleavage of a protease-sensitive 'bait region' between the first and second 
a-helices of the propeptide. This destabilises the interaction between the propeptide and 
the catalytic domain, and allows the coordination of a water molecule to the catalytic zinc. 
Further processing firom the intermediate to the fully active form of the MMP is then 
completed by an MMP (reviewed by Nagase, 1997; Knâuper and Murphy, 1998). The bait 
sequence dictates which proteinases activate a particular MMP. The potential 
physiological activators of the MMPs include plasmin, plasma kallikrein, cathepsin B, 
cathepsin G, neutrophil elastase and the MMPs themselves (Murphy, 1995).
Most MMPs are secreted as latent zymogens and are activated extracellularly. SL-3 and 
the MT-MMPs are an exception, as they are activated intracellularly. These enzymes have 
the characteristic basic sequence motif RXK/RR, immediately N-terminal to the start of the 
catalytic domain. This, sequence is recognised by the furin-type convertases, which are 
localised to the trans-Golgi network, and studies have implicated furin in the activation of 
SL-3 and MTl-MMP (Pei and Weiss, 1995; Pei and Weiss, 1996). The activation of MTl- 
MMP by furin is the subject of some controversy, however, as studies have shown that 
coexpression of recombinant full-length MTl-MMP and furin in COS cells has no effect 
on the molecular mass of the membrane-associated form, suggesting that proMTl-MMP is 
not a substrate for furin (Gao et al., 1996).
L4,2a Cell surface activation cascades: the role o f plasntin
The serine proteinase plasmin is considered to be one of the key enzymes in the activation 
of the MMPs. Active plasmin is generated by cleavage of plasminogen by the 
plasminugcn oelivaiurs urukinasc-pldsminugen aetivaiur (uPA) ur tissue-lype plasminogen 
activator (tPA). uPA is implicated in the generation of plasmin at the cell surface. Briefly,
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the inactive pro-uPA is secreted by connective tissue cells in response to inflammatory 
mediators (such as IL-1) and binds to a specific cell-surface receptor (uPAR). Receptor 
bound pro-uPA is then cleaved to give uPA, which in turn cleaves plasminogen to plasmin. 
Plasmin can activate several MMPs, as shown in Figure 1.2. SL-1 is particularly 
susceptible to plasmin activation and once activated can potentiate CL-1 activity (reviewed 
by Murphy, 1995), thus contributing to the activation cascade (Fig. 1.2). Control of these 
activation cascades may be exerted by the plasminogen activator inhibitors (PAIs) and to a 
certain extent by the TIMPs, which can slow down or inhibit MMP autocatalytic cleavages 
(Murphy, 1995).
L4.2b Cell surface activation cascades: the role o f MTl-MMP
ProGLA is resistant to activation by a range of endopeptidases (Okada et al., 1990). 
Although CL-1 and matrilysin have been shown to activate proGLA, the rate of activation 
is very slow (Crabbe et al., 1994; Sang et al., 1996). Several recent studies have suggested 
that the uPA/plasmin system can activate GLA (Baramova et al., 1997; Mazzieri et al.,
1997) although this remains the subject of controversy. Early studies with membranes 
isolated firom concanavalin A treated fibroblasts or phorbol ester treated fibrosarcoma cells 
showed that proGLA was activated by a membrane-dependent mechanism (Ward et al., 
1991b; Strongin et al., 1993). Activation was prevented by the deletion of the C-terminal 
domain of GLA (Murphy et al., 1992b) and excess TIMP-2 inhibited proGLA activation, 
suggesting an MMP dependent activation process (Ward et al., 1991b). The first MT- 
MMP was cloned in 1994 (MTl-MMP) and was identified as a potential activator of 
proGLA (Sato et al., 1994). Studies with a recombinant transmembrane deletion mutant of 
MTl-MMP in solution showed that MTl-MMP performs the initial cleavage of the GLA 
propeptide, and activation is then completed by bimolecular autolysis (Atkinson et al.,
1995). Strongin et al., (1995) were the first to suggest that TIMP-2 might aid in the 
location of GLA to the cell surface. These authors noted that proGLA activation is 
exquisitely sensitive to TIMP-2 concentrations, with high levels of TEMP-2 inhibiting GLA 
activation, whereas low levels facilitated activation. By cross-linking studies, Strongin and 
coworkers identified MTl-MMP/TIMP-2 complexes, and hypothesised that the N-terminal
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domain of TIMP-2 binds the active site of MTl-MMP, leaving the C-terminal domain of 
TIMP-2 available for binding the C-terminal domain of proGLA. The concept of an MTl- 
MMP/TIMP-2 complex acting as a 'receptor' for proGLA has since been supported by 
several studies (Imai et al., 1996; Butler et al., 1997; Kinoshita et al., 1998). A hypothesis 
for GLA activation has emerged from these studies, that predicts that MTl-MMP/TIMP-2 
complexes on the cell surface act as receptors for proGLA, and cleavage of the propeptide 
of GLA is initiated by an adjacent 'TIMP-2' free MTl-MMP molecule that is catalytically 
active. GLA activation is then completed by bimolecular autolysis (Butler et al., 1998). 
Figure 1.3 is a schematic representation of this hypothesis.
Studies in our laboratory have shown that CL-3 is also activated by a cell membrane- 
mediated process, involving MTl-MMP. Activation is enhanced by the presence of 
proGLA (Knâuper et al., 1996b), however it is unlikely that C-terminal interactions 
between CL-3 and TIMP-2 are involved (Knâuper et al., 1997). Studies with a 
chondrosarcoma cell line have shown that active MTl-MMP, GLA and CL-3 in turn 
activate proGLB (Cowell et al., 1998), implying an MTl-MMP initiated MMP activation 
cascade (see Fig. 1.2).
1,4.3 Inhibition o f MMP activity
Specific inhibition of the MMPs by the TIMPs was discussed in section 1.3.1. The other 
physiological inhibitor of the MMPs is plasma a2-macroglobulin, which is a general 
proteinase inhibitor. This 780 kDa inhibitor has a proteinase sensitive bait region, and 
cleavage within this region initiates a conformational change that traps the enzyme and 
prevents access to large substrates (Starkey and Barrett, 1977). Inhibition by a2- 
macroglobulin is irreversible.
1.5 The extracellular nuUrix
The extracellular matrix components that are important to this study are reviewed in the 
following sections. Collagen IV and laminin create the structural finmework that imparts
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strength and flexibility to the basement membrane. Fibronectin is associated with the 
fibrillar collagens in the coimective tissue stroma, where it promotes a wide range of 
cellular activities, including cell adhesion and migration.
1.5.1 Basement membrane
The basement membrane is a thin sheet of matrix proteins, in direct contact with cells, that 
provides both structural support and an interactive surface for cell adhesion, migration and 
differentiation (reviewed by Timpl and Brown, 1996; Yurchenco and O'Rear, 1993). 
Basement membranes divide tissue compartments and are found underlying epithelial and 
endothelial cell layers, and surrounding muscle cells and peripheral nerve axons. They are 
chiefly comprised of type IV collagen and laminin, both of which self assemble to form 
large irregular networks. These networks are linked by nidogen (entactin), and include 
heparan sulphate proteoglycans, SPARC (osteonectin, BM-40) and the fibulins. Some of 
the principle components of the basement membrane are described below.
1.5.1a Type IVcollagen
Type rV collagen is a major constituent of basement membranes (reviewed by Timpl and 
Brown, 1996; Kühn, 1994). The major isoform consists of two ai(TV) chains and one 
a2(IV) chain that interact to form a 400 nm long flexible monomer with a globular, non 
collagenous (NCI) domain at the C-terminus (see Fig. 1.4). The triple helical domain of 
collagen IV is characterised by fi'equent non-triple helical interruptions. Collagen IV self­
associates to form a dense meshwork, stabilised by covalent crosslinking. Iiisight into the 
molecular interactions that contribute to network formation was gained by partial 
proteolysis of basement-membranes derived fi’om the murine Engelbreth-Holm-Swarm 
(EHS) tumour and human placenta. Electron microscopy revealed that dimers were formed 
by bonding between C-terminal NCI domains, and tetramers were formed by parallel and 
antiparallel alignment of the N-terminal 7S domains. Studies of human amniotic 
membranes by electron microscopy also showed that lateral associations occur between the 
central triple helical portion of the molecule, and these lead to superhelical twisting 
between the laterally associated segments (Yurchenco and O'Rear, 1993). A schematic
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representation of the network is shown in Figure 1.4B. Distinct kinks in the triple helical 
region of the molecule are caused by the non-triple helical interruptions, which vary in 
length between the a  [IV] chains, and contribute to the flexibility of the molecule. These 
networks are stabilised by disulphide linkages and/or non-reducible lysine-aldehyde 
derived cross-links in the 7S and NCI domains, and this renders the molecule highly 
insoluble.
Cells interact with type IV collagen via a lp l  and a2pi integrin receptors. The integrin 
binding sites have been mapped to a triple helical region of the molecule CB3[TV], located 
100 nm from the N-terminus (see Fig. 1.4A; Eble et al., 1993). Integrin recognition is 
dependent upon triple helical conformation, which is stabilised by intramolecular 
disulphide bonds in the CB3[TV] region. Further details on integrin recognition sites in 
collagen IV are given in Chapter 4.
1.5.1b Laminin
Laminin is a large glycoprotein comprising three chains a, p and y (also designated A, B1 
and B2 respectively) that associate to form a cross-shaped heterotrimer. The three short 
arms each have 2-3 globular domains that may be important for self-assembly (reviewed by 
Yurchenco and O'Rear, 1993). The chains of the long arm twist together to form an a- 
helical coiled-coil, and is terminated by à large C-terminal globular domain that is involved 
in cellular interaction (see Fig. 1.5). To date, 5 a  chains, 3 p chains and 2 y chains have 
been identified which combine to form 11 isoforms (reviewed by Aumailley and Smyth,
1998). Laminin-1 is the most extensively studied isoform, as it is easily purified from the 
murine EHS tumour, however it should be noted that in humans laminin-1 has a restricted 
expression. Although all isoforms possess a similar domain organisation, certain isoforms 
have a tissue-specific distribution, which suggests that the isoforms contribute to the 
functional diversity of basement membranes.
Laminin network formation has been studied by the in vitro polymerisation of laminin-1. 
Formation of oligomers is both concentration and divalent cation dependent. The network
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is formed by end-to-end association of laminin molecules, in which each short arm binds to 
two or three neighbouring arms to form an hexagonal oligomer. The binding affinity 
between the laminin molecules is low, indicating that the laminin network lacks the 
strength of the collagen IV network. However, laminin networks are more dynamic 
structures and may be important in newly formed basement membranes that lack type IV 
collagen (reviewed by Yurchenco and O'Rear, 1993).
Cellular interaction with laminin has been mapped by proteolytic fragmentation of laminin, 
with most data derived from laminin-1 (see Fig. 1.5). Interactions with the short arms are 
mediated by a lp l  and a2pl integrins (Pfaff et al., 1994) and recently the binding site has 
been mapped to the VI domain of the a-chain (Colognato et al., 1997). An integrin 
binding site has been mapped to the cross region of the three short arms, recognised by 
avp3 integrin, however this site is cryptic in murine laminin-1 and absent in human 
laminin-1 (Horton et al., 1994). The major cell binding site for laminin-1 is in the 
proteolytic fragment E8, in the C-terminal globular domain. The a6pl integrin recognises 
this region (Sonnenberg et al., 1990) and is regarded as the classical laminin receptor. 
Other integrins that recognise this region are the a7pi, a6p4 and a3pi integrins, although 
the binding of a6p4 integrin is controversial (Eble et al., 1998; reviewed by Aumailley and 
Smyth, 1998).
Interactions with laminins control cell adhesion and migration, differentiation and polarity, 
proliferation and cell fate, and affect gene expression. Laminins are crucial in 
mesenchymal-epithelial and mesenchymal-endothelial transitions that occur during 
embryonic development (reviewed by Dziadek, 1995). Diseases which are characterised 
by the absence or alteration of various laminin chains lead to skin blistering (epidermolysis 
bullosa) and muscular dystrophy (reviewed by Aumailley and Smyth, 1998).
L S.lc Architecture o f the basement membrane
There is no evidence to suggest that the laminin and collagen IV networks interact with 
each other directly, however other basement membrane components such as nidogen may
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act as Imkers. Nidogen (150 kDa) has a rod-like structure with three globular domains, 
two situated at the N- and C-terminii (G1 and G3) and one in the middle (G2). A high 
affinity interaction occurs between laminin and the G3 domain. The G2 domain can 
interact simultaneously with collagen IV or perlecan, the main heparan sulphate 
proteoglycan of basement membranes. These ternary complexes connect the two major 
networks, thus it is likely that nidogen plays a crucial role in the assembly of basement 
membranes (reviewed by Dziadek, 1995).
1.5.2 Fibronectin
Fibronectins are found in most body fluids, soft connective tissue matrices and granulation 
tissues. They are involved in a diverse range of cellular processes including cell adhesion, 
migration, differentiation, proliferation and survival and are implicated in oncogenic 
transformation (reviewed by Mohri, 1997). The importance of fibronectin in development 
is underscored by the observation that a transgenic mouse lacking fibronectin dies during 
embryonic development (Watt and Hodivala, 1994). There are two classes of fibronectin: 
plasma fibronectin and cellular fibronectin, which are very similar in structure and 
properties. Fibronectin is a disulphide bonded dimer of ~450 kDa, consisting of two 
similar subunits of -225 kDa, composed of homologous repeating subunits designated type 
I, n and in repeats (Figure 1.6). It is encoded by a single gene, with variations in the 
structure arising from alternative splicing of the primary transcript. Three alternatively 
spliced regions have been identified, two of which consist of type IE repeats ED-A and 
ED-B (also called EUIA, EDI and EIIIB, EDII) which can be included or excluded by exon 
skipping (Figure 1.6). The third region, termed the connecting segment or UICS region, is 
more complex and comprises a number of separate and independently spliced segments. 
Plasma fibronectin, which is secreted by hepatocytes and abundant in blood (300 pg/ml), 
does not contain the ED regions, and is smaller in size than cellular fibronectins. The 
cellular fibronectins may or may not contain the ED regions and exhibit various 
permutations of the IIICS region (Mohri, 1997).
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Fibronectin has been shown to bind a number of matrix macromolecules, including 
collagen (and gelatin), heparin, heparan sulphate proteoglycans and fibrin (Figure 1.6). 
These interactions may play an important role in wound healing, for soluble fibronectin 
that is deposited on damaged collagen and/or fibrin serves as a guide for inwardly 
migrating fibroblasts (Greiling and Clark 1997). Other molecules that are reported to bind 
to fibronectin are DNA (although the physiological significance of this is unclear), IgG, C3 
complement, thrombospondin, plasminogen and plasminogen activator (reviewed by 
Mohri, 1997).
Fibronectin interacts with cells via cell-surface receptors, controlling cell adhesion, 
cytoskeletal organisation and intracellular signalling. The most extensively studied cell 
attachment site maps to the type III repeats, known as the central cell binding domain 
(CCBD). A tetrapeptide of amino acid sequence RGDS in Fn III repeat no. 10 (Fn EH 10) 
is essential for recognition by a number of integrin receptors (Figure 1.6) and a 
pentapeptide sequence in Fn HI 9 synergises with the RGD site to promote full adhesion 
activity (Danen et al., 1995). Integrin dependent cell adhesion has also been mapped to the 
alternatively splieed HICS region, whieh is reeognised by integrins with a4 subunits. 
Studies using synthetic peptides spanning the entire HICS region identified cell attachment 
sites in the peptides CS-1 and CS-5. Both sites have sequences based on the RGD-motif, 
with LDV acting as the active sequence in the CS-1 peptide and REDV the active sequence 
in the CS-5 peptide (Komorya et al., 1991; Mould et al., 1991). A third sequence ID APS 
in the C-terminal heparin binding region of fibronectin is a homologue to the LDV 
sequence of the CS-1 peptide and interacts with the a4 integrin subunit (Mould and 
Humphries, 1991). Several sites in fibronectin promote RGD-independent cell adhesion. 
One has been mapped to the alternatively spliced ED-A region, (Xia and Culp, 1995) and 
another is located to the C-terminal heparin binding domain (Figure 1.5) which interacts 
with cell surface heparan sulphate proteoglycan to augment cell attachment and focal 
adhesion formation (McCarthy et al., 1990).
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Fibronectin is a highly flexible molecule and its shape can be markedly affected by 
solution conditions such as pH and ionic strength. Electron microscopy has shown that 
plasma fibronectin adopts a range of shapes, from a compact structure to an elongated rod­
like structure, and the deposition of fibronectin onto surfaces can result in irreversible 
unfolding to form an extended conformer (Erickson and Carrell, 1983; Tooney et al., 
1983). In vivo, fibronectin forms a matrix of disulphide cross-linked fibrils. Fibril 
formation is initiated by the capturing of secreted fibronectin onto integrins a5pl and 
avp3, and is completed by assembly and reorganisation of the cell-surface associated 
fibronectin into fibrils. Fibronectin self-association via FN III 1 is important in promoting 
this matrix assembly (reviewed by Magnusson and Mosher, 1998).
In vitro, it has been shown that certain fimctional domains of fibronectin are buried in the 
intact molecule and become fully exposed upon surface-adsorption, dénaturation or 
binding to gelatin and heparin (Homandberg, 1987; Underwood et al., 1993; Ugarova et al.,
1995). Fibronectin has a number of protease sensitive regions, and MMPs, cathepsins, 
plasminogen activators, plasmin and thrombin have all been shown to degrade fibronectin 
in vitro (Liotta et al., 1981; Fukai et al., 1995; Marchina and Barlati, 1996; Ugarova et al.,
1996). Proteolytic cleavage of fibronectin also results in the release of functional domains 
(Homandberg, 1987; Ugarova et al., 1995). An interesting study by Fukai et al. (1995) 
showed that degradation of plasma fibronectin by MMPs resulted in the liberation of the 
CCBD, as well as the N-terminal and C-terminal fibrin-binding domains, the latter which 
stimulated RGD-independent fibroblast migration. It is well documented that firagments of 
fibronectin have biological activities distinct from full length fibronectin, with reports 
showing that various fragments increase cartilage aggrecan degradation and promote SL-1 
expression by chondrocytes (Homandberg et al., 1992; Bewsey et al., 1996), control SL-1, 
CL-1 and GLB expression by rabbit synovial fibroblasts (Werb et al., 1989; Huhtala et al., 
1995) and stimulate adipocyte differentiation and fibroblast migration (Fukai et al., 1995).
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1.6 Integrin receptors
The integrins are a family of cell surface proteins that mediate cell adhesion, cytoskeletal 
organisation and the bidirectional transfer of information across the outer cell membrane. 
They are heterodimeric glycoproteins composed of non-covalently associated a  and p 
subunits. To date 16 a  and 8 p subunits have been described, which pair to form more 
than 22 receptors (see Table 1.2).
1.6.1 Integrin stucture
Electron microscopy has shown that each integrin subunit has an N-terminal globular 
domain which projects from the cell by virtue of a rod-like 'stalk' (Carrell et al., 1985). 
Each subunit has a single transmembrane spanning region and a short cytoplasmic tail (see 
Fig. 1.7), with the exception of the p4 subunit, which has an extended tail (Tamura et al.,
1990). A 7-fold repeat structure at the N-terminus of the integrin a  subunit contributes to 
both ligand recognition and divalent cation binding, although the two activities probably 
map to different regions within the structure (reviewed by Schwartz et al., 1995; 
Humphries, 1996). Integrin-ligand recognition is cation dependent and it has been 
predicted that there are at least 3 cation binding sites, with each showing a preference for 
the type of cation (e.g. Mn^^, Mg2+, Ca^+). Although it has yet to be determined how 
cation binding affects ligand binding, it is likely to be by effecting changes in integrin 
conformation (Humphries, 1996).
A subset of integrins (a l, a2, aD, aE, aL, aM, aX) have an insertion between repeats II 
and III of the seven-fold repeat structure, named the A-domain (or I-domain) for its 
homology with the A-domain of voh-Willebrand factor (reviewed by Dickeson and 
Santoro, 1998). The A-domain is an autonomously folding unit, as evidenced by studies 
showing that isolated A-domain binds to ligand (Tuckwell et al., 1996; Messent et al., 
1998). Data indicate that the A-domain is the major collagen I and collagen IV binding 
site of the a l  pi and a2pi integrins (Calderwood et al., 1997). Furthermore, substituting 
the A-domain of the a  1 integrin subunit with the A-domain of the a2 subunit results in an 
integrin with collagen specificities reflecting that of a2pl integrin rather than a ip i
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integrin (Kern and Marcantonio 1998), indicating the importance of this domain in 
determining the ligand specificities of these integrins.
The ligand binding site on the p integrin subunit has yet to be characterised, however a 
conserved region near the N-terminus of this subunit has been identified as a putative pA 
domain (Tuckwell and Humphries, 1997). The epitope for a function-blocking p antibody 
has been mapped to this site (Ryan et al., 1998) and mutagenesis studies indicate that this 
region bears some similarities to the aA domain (Lin et al., 1997).
1.6.2 Integrin function 
1.6.2a CeU adhesion
Individual integrins often bind more than one ECM ligand and equally, individual ligands 
are recognised by more than one integrin (see Table 1.2). Most commonly the integrins 
recognise the amino acid sequence RGD, identified as the ligand recognition site in 
fibronectin and vitronectin. However, other sequences homologous to the RGD tripeptide 
are also recognised by integrins and some integrin-ligand interactions appear to be RGD 
independent (see Table 1.2). Some integrins also mediate cell-cell adhesion by binding to 
integral membrane proteins of the immunoglobulin superfamily (e.g. VCAM-1 and 
ICAMs).
1.6.2b Integrin signalling
Integrin receptors mediate bidirectional signals across the plasma membrane, firom the 
'outside-in' and from the 'inside-out'. Outside-in signalling is the subject of intense study 
and there is now a wealth of information regarding the signalling and cytoskeletal 
molecules that are involved in integrin-mediated signal transduction (reviewed by Howe et 
al., 1998; Vuori, 1998; Yamada and Geiger, 1997). Integrin transduced signals include 
Ca^ '*" influx, pH changes, protein-tyrosihe phosphorylation, inositol lipid metabolism and 
activation of MAP kinases.
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In cell culture, ligand binding induces integrins to cluster, forming a close apposition 
between the cell membrane and the underlying substrate, causing the formation of stress 
fibres within the cell. These contacts, known as 'focal adhesions', have provided a 
convenient model for analysing integrin signalling. However, focal adhesions are rare in 
vivo, where other adhesive structures occur, such as 'ECM-contacts'. In these contacts, 
integrins cluster along ECM fibrils, forming distinct cytoskeletal structures (Chen and 
Singer, 1982). Nevertheless most integrin signalling studies are based on observations of 
focal adhesions, and information from these studies is detailed here.
Integrin ligation drives the formation of complex protein aggregates, in which actin stress 
fibres are tethered to the cytoplasmic face of the membrane, via interactions with integrin 
cytoplasmic domains. Integrins are clustered within these structures (focal adhesions) and 
a variety of signal transduction molecules are induced to accumulate in the plane of the 
membrane. These can include focal adhesion kinase (FAK), Src family kinases, Ras, Raf 
and MAP kinases, each depending upon the integrin and the nature of the ligand to which it 
is bound. Tyrosine phosphorylation is a requirement for the aggregation of some 
signalling and cytoskeletal molecules (reviewed by Yamada and Geiger, 1997). In 
addition, the presence of receptors for the growth factors EGF, PDGF and bFGF in integrin 
induced transmembrane protein aggregates has been documented (Miyamoto et al., 1996). 
A number of the signalling mechanisms employed by integrin receptors are common to 
growth factor receptors and a growing number of reports describe synergism between 
integrin and growth factor signalling pathways (reviewed by Yamada and Geiger, 1997; 
Dedhar and Hannigan, 1996).
Integrins can adopt low affinity and high affinity states for ligand binding, and the 
regulation of integrin affinity is an important aspect of integrin function. Changes from 
low affinity to high affinity can be initiated by signals from other cellular receptors, sueh as 
ehemokine, chemoattraetant and antigen reeeptors (reviewed by Sugimori et al., 1997). 
Modulation of integrin affinity is then mediated by the binding of eytoplasmie proteins to 
the eytoplasmie domains of the integrin subunits. A conformational change is induced.
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such that the integrin adopts an active, high affinity state, competent for ligand binding 
(termed inside-out signalling). Several amino acid sequences have been identified in 
integrin a  and P subunits that are implicated in maintaining the integrin in an active or 
inactive state (reviewed by Dedhar and Hannigan, 1996). Perhaps the best documented 
example is the sequence KXGFFKR in the a2 subunit cytoplasmic tail. This holds the 
a2pl integrin in an inactive state, probably via a salt-bridge with an adjacent region of the 
pi subunit. The binding of calreticulin (a calcium binding protein) to the KXGFFKR 
apparently disrupts this salt bridge, such that a2pi integrin is activated (Dedhar and 
Hannigan, 1996).
1,6.2c Cytoskeletal organisation
Integrins work with the Rho family of GTP-ases to regulate the structure of the actin 
cytoskeleton. Cdc42, Rac and Rho control the formation of filopodia, lamellipodia, and 
stress fibres and focal adhesions respectively (reviewed by Howe et al., 1998). The 
assembly of focal adhesions with well developed stress fibres requires both Rho GTPases 
and integrin ligation (for anchorage and counter tension). Rho-responsive serine/threonine 
kinase phosphorylation leads to the activation of myosin ATP-ase activity and 
actinomyosin contractility, which contribute to the tension of the stress fibres. In addition, 
Rho family members can stimulate signal transduction cascades leading to the activation of 
a number of transcription factors (Howe et al., 1998).
1.6.2d Matrix assembly
As mentioned earlier, integrin receptors play a role in fibronectin matrix assembly. It has 
been shown that anti-a5 and anti-pl subunit antibodies block fibril formation (Akiyama et 
al., 1989) and transfection of a5 subunit into transformed Chinese hamster ovary cells 
results in a large increase in fibronectin matrix assembly (Giancotti and Ruoslahti 1990). 
Interestingly, in the latter study fibronectin matrix formation was associated with the loss 
of the transformed phenotype and a decrease in cell motility. Several observations suggest 
that only high affinity aSpi integrin receptors participate in fibronectin fibrillogenesis 
(reviewed by Magnusson and Mosher, 1998; Schwartz et al., 1995). There is a close
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correlation between actin stress fibre formation, cell contraction and fibronectin assembly 
indicating that fibrillogenesis may require tension transmitted by integrin binding, and the 
Rho family of GTPases have been implicated in this process (Magnusson and Mosher, 
1998).
L6.2e Integrin regulation of MMP e^qjression
A growing body of evidence implicates integrin receptors in the regulation of MMP gene 
expression. Many studies have shown that MMPs are regulated by matrix components, 
and work with anti-integrin antibodies has confirmed that integrin receptors can mediate 
signals firom the matrix that regulate MMP expression. It has emerged jfrom these studies 
that the response to integrin ligation is cell type specific. For instance, ligation of the a3pl 
integrin receptor by soluble anti-a3 and anti-pl integrin antibodies induced GLB synthesis 
in human mucosal kératinocytes, but did not affect GLA expression (Laqava et al., 1993), 
whereas ligation of the a3 subunit by anti-a3 antibodies in human glioma cells led to the 
induction of GLA expression, but not GLB (Chintala et al., 1996). Treatment of the human 
melanoma cells A375M with anti-avp3 antibodies up-regulated the synthesis of GLA, but 
anti-aSpl antibodies had no effect (Seftor et al., 1992). In contrast, however, the highly 
invasive human melanoma cell C8161, which express low levels of avp3 integrin, 
responded to anti-aSpi antibodies with increased GLA synthesis (Seftor et al., 1993). 
These studies highlight the fact that cellular response to ECM is dependent both on integrin 
repertoire and on the intracellular signalling pathways induced in individual cell types. 
Furthermore, combinations of integrins may act together to regulate MMP expression, as 
demonstrated by Huhtala et al. (1995) who reported that a5pl and a4pi act 
antagonistically to regulate CL-1, SL-1 and GL-B expression in rabbit synovial fibroblasts. 
Ligation of the a5pi integrin receptor with anti-a5 subunit antibodies or fibronectin 
fi-agments induced MMP expression, whereas the simultaneous ligation of a5pl and a4pl 
integrins down-regulated a5pi mediated MMP induction.
Advances have been made using the well-characterised culture model of three-dimensional 
collagen lattices, to which cultured fibroblasts adhere and then contract the collagen
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network. This process is accompanied by a fundamental change in fibroblast morphology, 
indicated by a down-regulation of collagen I synthesis and an up-regulation of MMP 
activity. Langholz et al (1995) demonstrated that the a2pl integrin mediates signals from 
collagen I that up-regulate CL-1 mRNA expression, whereas signals from the a lp l  
integrin cause the down-regulation of collagen I mRNA expression. Others have reported 
increases in MTl-MMP synthesis and GLA activation by endothelial cells cultured in 
collagen lattices (Haas et al., 1998). Tomasek et al. (1997) showed that the activation of 
GLA by cells cultured in collagen lattices may be linked to the level of mechanical stress 
placed on cells, implying that the mechanical properties of the ECM and cytoskeletal 
organisation act together to regulate MMP expression. These studies are of significance, as 
they show that signals from the matrix via integrin receptors can determine whether a cell 
enters matrix synthesis or matrix destruction mode.
Few studies have addressed the intracellular signalling pathways associated with integrin 
mediated regulation of MMP expression. However, Langholz et al., (1995) showed that 
the a2pl mediated induction of CL-1 in collagen lattices was accompanied by tyrosine 
phosphorylation, and collagen-stimulated induction of keratinocyte CL-1 has been reported 
to be mediated by tyrosine kinase and PKC activities (Sudbeck et al., 1994). Most 
recently, a comprehensive study by Kheradmand et al. (1998) has dissected out the 
contribution of the Rho family of GTP-ases in the a5 pi mediated up-regulation of CL-1 by 
rabbit synovial fibroblasts. Briefly, Rac 1 activity was induced by soluble anti-a5 integrin 
antibodies, which in turn promoted the NF-xB-dependent transcription of IL-1, and IL-1 
induced CL-1 expression. This study is discussed in more detail in later chapters.
1.6.2f Integrin gene ablation studies
Most of the integrin genes have been mutated in mice. Null mutations in the genes for the 
integrin subunits involved in fibronectin ligation (a5, av, a4) all caused either embryonic 
or early post-natal death in mice. By comparison null mutations in the fibronectin gene 
resulted in abnormalities in gastrulation, thus none of the phenotypes from the fibronectin 
integrin receptor gene ablation studies reflected the range of defects associated with
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fibronectin gene gene ablation (reviewed by Fâssler et al. 1996). Based on the pairing of 
the pi integrin subunit with 10 a  subunits, it was predicted that the phenotype for the pi 
gene null mutation would be severe, and indeed this mutation resulted in peri-implantation 
lethality (Fâssler et al., 1995). Null mutations in the a 6  gene (laminin receptor) produced 
viable mice, but with severe skin blistering similar to the human disease epidermolysis 
bullosa (Fâssler et al., 1996). In contrast, null mutations in the a l  gene (another laminin 
receptor) were viable and fertile but displayed progressive muscular dystrophy, starting 
soon after birth (Mayer et al., 1997). This reflects the restricted expression of a 7 p l 
integrin in skeletal and cardiac muscle. Interestingly, gene ablation of the a l  integrin 
subunit apparently conferred no phenotype, and these mice were both viable and fertile, 
despite the inability of embryonic fibroblasts derived firom these mice to migrate on 
collagen IV (Gardner et al., 1996). This suggests that other integrins with overlapping 
substrate specificities may be compensating for a i p i  loss.
1.7 CeU migration
The movement of cells within the matrix provides an example of how matrix, integrins, 
growth factors and MMPs work together to coordinate cellular function. Cell migration 
involves a number of distinct events, including membrane protrusion to form a leading 
edge; formation of stable contacts between the cell and the ECM; cytoskeletal contraction, 
forward movement of the cell body; and release of contacts at the rear (Palecek et al., 
1998). Integrin receptors are central to this process as they couple the cytoskeleton to the 
substratum and provide traction for the applied stress firom the cytoskeleton 
(Lauffenburger, 1996). Forward movement involves the transfer of integrin receptors 
attached to the cytoskeleton fi"om the leading edge to the trailing edge. This has been 
demonstrated clearly by Felsenfeld et al. (1996) who used videomicroscopy to track 
colloidal gold particles coated with the fibronectin fragment Fn III 7-10. These particles 
adhered to fibronectin integrin receptors on the surface of migrating fibroblasts, diffused 
randomly for less than a second, before being transported rapidly to the rear of the cell. 
Current models for cell migration predict that the same intracellular motile forces that send
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integrins to the rear also control the recruitment of integrins to the leading edge, thus 
maintaining cell motility (reviewed by Lauffenburger, 1996; Huttenlocher et al. 1995). To 
allow locomotion, cell/substratum linkages at the rear of the cell are severed, by 
intracellular or extracellular fracture of the integrin/substratum bonds. The integrins are 
then recycled to the leading edge of the cell or deposited on the matrix at the rear of the cell 
(Palecek et al., 1998).
Many studies have shown that maximum migration rates occur at intermediate levels of 
attachment (DiMilla et al., 1993; Keely et al., 1995; Palecek et al., 1998). At low 
adhesiveness, cells are unable to generate the traction needed for locomotion whereas at 
high adhesiveness the cytoskeletal forces are insufficient to break cell-substratum 
attachment. The strength of cell adhesion to the substratum is determined by multiple 
factors: by the number and type of integrin receptors expressed, by the affinity of the 
integrin for the ligand and by the concentration and type of the ECM ligand involved. To 
address the last point, the type of ECM presented to a cell can have a profound affect on 
migration. Some matrix proteins such as the tenascins and SPARC are described as anti- 
adhcsivc, and have surfaces which promote cell rounding and detachment from the 
substratum. Tenascin-C is spatially and temporally regulated during embryogenesis and is 
re-expressed in adult tissues in regions where ECM remodelling and cell migration occurs 
(reviewed by Chiquet-Ehrismann et al., 1995). Tenascin-C binds fibronectin specifically, 
and tenascin-C is often expressed in conjunction with fibronectin. Since it has been shown 
that tenascin-C bound to fibronectin disrupts integrin adhesion to fibronectin, it has been 
suggested that tenascin-C mediates cell migration during embryogenesis and remodelling 
by reducing cell adhesion to fibronectin (Chiquet-Ehrismann et al., 1995).
Interestingly, a combined substrate of fibronectin and tenascin-C induces CL-1, SL-1 and 
GLB synthesis by rabbit synovial fibroblasts cultured in vitro, whereas fibronectin alone 
has no effect (Tremble et al., 1994). Similarly the addition of SPARC to synovial 
fibroblasts cultured on fibrillar collagens induces CL-1 expression (Tremble et al., 1993). 
Many studies have shown that MMPs are expressed at sites of cell migration, but few have
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provided clues as to how the MMPs might act to promote migration. Proteolysis of ECM 
by MMPs may lead to the exposure of cryptic sites, as reported by Gianelli et al. (1997) 
who showed that GLA treatment of laminin-5 leads to the exposure of a cryptic sequence 
that promotes the migration of breast epithelial cells. Pilcher et al. (1997) demonstrated 
that collagen I substrates induced CL-1 synthesis by human kératinocytes, and the addition 
of blocking anti-CL-1 antibodies in these studies revealed that CL-1 activity was a 
requirement for keratinocyte cell migration on collagen I. Furthermore, a substrate of 
collagen I with a mutated CL-1 cleavage site was not conducive to keratinocyte migration. 
The authors speculated that kératinocytes migrating on collagen leave behind a trail of CL-
1-cleaved denatured collagen, which provides directionality to the cells, since sustained 
migration can only be maintained by moving forward onto intact collagen I. This has 
important implications for wound healing, where basal kératinocytes at the edge of the 
wound migrate in an organised manner over the viable dermis and wound bed during re- 
epithelialisation.
Cross-talk between growth factor receptors and integrin receptors also regulates cell 
migration. The integrin avP3 has been found to associate with activated insulin and PDGF 
receptors to potentiate PDGF dependent chemotaxis of NIH 3T3 fibroblasts (Schneller et 
al., 1997). Similarly, the migration and proliferation of endothelial cells is promoted by 
the coordinated activities of bFGF and avp3 integrin, in a process mediated by MAP 
kinase signalling (Eliceiri et al., 1998). Human pancreatic carcinoma cells readily migrate 
on collagen I using a2pi integrin, but do not migrate on vitronectin unless the EGF 
receptor is ligated. PKC and tyrosine phosphorylation were implicated in this case 
(Klemke et al., 1994).
Clearly control of cell migration is a complex process involving integrin receptors, 
associated cytoskeletal proteins and signalling molecules, growth factors and proteolysis of 
matrix components. Cell migration is an integral step in tumour metastasis, and aspects of 
tumour biology are discussed in the last section of this chapter.
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1.8 The role o f MMPs in tumour invasion
Malignant transformation of tumour cells is accompanied by metastasis of the cells from 
the primary tumour to secondary sites within the body. The exact processes which govern 
the formation of métastasés at distant sites are unknown, but some general properties apply 
(reviewed by Chambers and Matrisian, 1997; Ray and Stetler-Stevenson, 1994). Firstly, 
the transformed cell must be able to break free of existing ECM contacts, in order to invade 
the tissue stroma and gain access to the vascular or lymphatic system. This involves 
breaching the basement membranes that surround these tissues. Secondly, the invading 
cell must survive the circulation, arrest at a distant site and extravasate. Finally, the new 
environment must be suitable for tumour cell proliferation. Angiogenesis is critical for this 
last stage.
In many ways, tumour progression corresponds to normal tissue remodelling: the matrix 
environment controls cell migration and invasion, and protease activity is up-regulated. 
Many families of proteases have been linked with malignancy, including serine proteases 
and matrix metalloproteinases (reviewed by Edwards and Murphy, 1998; Chambers and 
Matrisian, 1997; Kramer ct al., 1995). This discussion is restricted to the contribution of 
the MMPs. There is an extensive literature demonstrating a statistically significant 
association between MMP expression and tumour spread. Techniques such as 
immunolocalisation and in situ hybridisation of tissue samples, and ELISA studies of the 
body fluids of cancer patients have been used to show that all MMP classes are implicated 
in tumour progression (Ray and Stetler-Stevenson, 1994). MMPs are found associated 
with tumour cells as well as the surrounding stroma. It is postulated that MMPs produced 
by stromal cells are recruited to the surface of tumour cells to facilitate pericellular 
proteolysis (Werb, 1997). Evidence that MMP activity is important in malignant 
progression has been provided by inhibitor studies. Injection of human recombinant 
TIMP-1 into mice inhibited amnion invasion and lung colonisation by B16-F10 melanoma 
cells (Schultz et al., 1988). Furthermore, the transfection of antisense TIMP-1 encoding 
plasmids into NIH 3T3 cells resulted in cell lines üiat were more invasive than the parent 
line (Khokka et al., 1989). The synthetic MMP inhibitor marimastat is now undergoing
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clinical trials, and the preclinical data suggests that invasion, metastasis and angiogenesis 
are all reduced by marimastat treatment (Rasmussen and McCann, 1997).
Although there is abundant causal evidence to suggest that MMPs play a role in malignant 
progression, the precise contribution of MMPs needs to be clarified. Early hypotheses 
predicted that MMPs were involved in the proteolytic dissolution of basement membrane 
and stromal matrices during the initial stages of metastasis (Liotta and Stetler-Stevenson,
1991). However, studies have shown that the MMPs may have a more subtle effect on the 
surrounding matrix. Montgomery et al. (1994) showed that although human melanoma 
cells use a2pl integrin to bind collagen lattices, their survival is dependent upon avp3 
integrin ligation. MMP degradation of collagen I apparently exposed cryptic RGD sites, 
that were ligated by avp3 integrin, thus promoting melanoma cell survival. support of 
this, melanoma cells expressing avp3 integrin are highly invasive compared with those 
that lack avp3 (Marshall et al., 1991). As mentioned earlier, GLA cleavage of laminin-5 
exposes a cryptic site that promotes cell migration (Gianelli et al., 1997), thus MMP 
activity may be important for remodelling of matrix molecules that would otherwise be 
refi-actory to tumour cell survival and migration.
Recent studies have indicated that the major contribution of MMPs to metastatic 
progression may not be in the early stages of extravasation. Evidence fi*om intra-vital 
videomicroscopy studies suggests that h^fPs may be involved in the growth of tumours at 
secondary sites (reviewed by Chambers and Matrisian, 1997). This technique monitors the 
microvasculature of living animals. Cells are injected into chick embryo chorioallantoic 
membrane and extravasation is monitored in real time Studies investigating the metastasis 
of transformed NIH-3T3 cells gave the surprising results that the timing of extravasation 
for transformed cells was similar to the parent (untransformed) line, indicating that 
transformation conferred no advantage on cell migration fiom the primary tumour. 
However, the transformed cells proliferated more rapidly post-extravasation than the parent 
cells (Koop et al., 1996). Similarly, B16-F10 cells engineered to overexpress TIMP-1 
extravasated at the same rate as parent cells, but the effects of TIMP-1 were manifest in the
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reduction in size and numbers of tumours after 7 days (Koop et al., 1994). Studies such as 
these implicate MMPs in tumour growth, however the mechanisms by which MMPs 
regulate growth have yet to be characterised. Future studies should address whether 
degradation of the ECM frees cells from ECM-induced cell cycle arrest, or facilitates 
dedifferentiation, or promotes the release of growth factors and angiogenic factors 
(reviewed by Werb, 1997).
i.P Aims and scope o f this thesis
It is evident that a complex interplay occurs between matrix, integrin receptor and MMPs 
during cell migration and invasion. More information is needed to aid understanding of the 
precise roles of MMPs in these processes. Early hypotheses for tumour invasion predicted 
that MMPs were required during metastasis to degrade basement membrane barriers. 
However, new evidence suggests that the action of MMPs may be more subtle, and may 
involve the proteolytic modification of ECM molecules to expose new matrix fragments 
that promote cell migration, survival or proliferation.
Cell motility assays have shown that maximum migration is maintained on matrices which 
promote an intermediate level of cell adhesion. A tumour cell that successfully negotiates 
the basement membrane may be able to modulate adhesion to collagen IV. Studies for this 
thesis examined the novel hypothesis that MMPs cleave integrin recognition sites on 
collagen IV, thus affecting cell adhesion to the molecule. Solubilised collagen IV 
preparations were treated with GLA in vitro and cell adhesion via integrin receptors to the 
cleaved collagen was monitored. These studies are reported in Chapter 3.
Tumour cell invasion has been linked with the expression of MTl-MMP and active GLA, 
however little is known of the signals that regulate GLA activation. Tumour cells invading 
through the stroma encounter a range of ECM molecules, including collagen and 
fibronectin. Collagen matrices have been shown to up-regulate GLA activation, but the 
effects of fibronectin on activation have not been investigated. Studies for Chapter 4 and 5 
of this thesis examined the effect of fibronectin on the expression of MTl-MMP and the
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activation of GLA by a human fibrosarcoma cell line. The role of fibronectin integrin 
receptors in mediating the up-regulation of GLA was investigated.
These studies identified a processed form of MTl-MMP that appeared concomitantly with 
GLA activation. Studies for Chapters 5 and 6 were aimed at characterising this form of 
MTl-MMP, to shed some light on its role in GLA activation pathways.
î
I
i  IOS
OIS
iS
I
gI■s
II
Ia
I
I
II
aII
0>
I
H
I
•I
l - l
X
X a j
I
u o fil
en 00 00«Ti ^
m  m  O»n vo t  1— 1«o »n c^  c-
o
1 1
8
1
8
I
*2
I!
CN m
• É  - É
I l  I f
00 ao oc/3 c/3 Ü M
O  1—' OS O
1—4 1“H »-H
•I t
0>
tN OS
ü d
.E >
•9] T3
l - l  
•I •I
-I1—^ cO
en
•I Q Q
O  sn  
(N  TT
00 ^  <N «n
O
il
«n vo r-
Propeptide N-terminal domain 
(catalytic)
o - c
c x
Gelatin binding domain 
(fibronectin-like repeats) ^
O -C
5
insert
Zn
Zn
Zn
C-terminal domain 
(hemopexin-like repeats)
matrilysin
collagenase -1, -2, -3 
stromelysin-1, -2, -3 
metalloelastase 
MMP-19, enamelysin
gelatinase-A
gelatinase-B
membrane-type 
metalloproteinase 
6 (MT1-4 MMP)
transmembrane 
domain
Figure 1.1 Domain structure of the MMPs
MMPs have a propeptide domain (1) that maintains enzyme latency and a catalytic domain (2) with a 
coordinated zinc in the active site. All MMPs (with the exception of matrilysin) also have a C-terminal 
domain (3) that determines substrate specificity (collagenases), matrix binding properties (collagenases, 
stromelysin) or interaction with TIMPs (collagenase-3, gelatinases). The gelatinases have an insert o f three 
fibronectin type II repeats in the catalytic domain (4) which determines their specificity for gelatins. The MT- 
MMPs have an extra insert in the catalytic domain (5) o f unknown function and a transmembrane domain (6) 
which locates these enzymes to cell membranes.
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Figure 1.2 Cell surface MMP activation cascades
Urokinase-plasminogen activator (uPA) bound to the uPA receptor generates active plasmin from the 
precursor plasminogen. Plasmin activates several MMPs, initiating an MMP activation cascade. MTl-MMP 
is activated intracellularly and locates to the cell surface, where it initiates the activation of progelatinase A 
and procollagenase-3. TIMP-2 bound to MTl-MMP is implicated in progelatinase A activation.
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Figure 1.3 Cellular activation of progelatinase A
This figure represents a current hypothesis for the activation of progelatinase A at the cell surface. The N- 
terminal domain o f TIMP-2 binds to the catalytic domain of MTl-MMP at the cell surface, leaving the C- 
terminal domain free for interaction with the C-terminal domain o f progelatinase A. An adjacent, TIMP-2- 
free MTl-MMP which is catalytically active then cleaves the propeptide of progelatinase A and activation is 
completed by gelatinase A bimolecular autolysis. Excess TIMP-2 inhibits activation, by binding all MTl- 
MMP molecules at the cell surface.
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Figure 1.4 Schematic representation of collagen IV and the collagen IV network
(adapted from Eble et al., 1996; Timpl and Brown 1995)
A. The collagen IV monomer, showing the N-terminal triple helical 78 region, the CB3[IV] region of the 
triple helix, and the non collagenous NCI domain at the C-terminus.
B. Collagen IV network assembly. The single lines represent triple helices.
(1) The N-terminal 78 domains associate to form tetramers.
(2) Dimers form from the C-terminal NCI globules.
(3) Lateral association between the triple helices form twisted superhelices.
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Figure 1.5 Schematic representation of laminin-I
Laminin-1 is a heterotrimer o f a , (3 and y chains which associate in an a-helical coiled-coil to form the long 
arm of the molecule (represented by straight lines). Short arms consist o f the N-terminal portion of each 
chain. The recognition sites for integrin receptors have been marked.
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Figure 1.7 Schematic representation of integrin domain structure
The structures of the a and P subunits are shown, with the extracellular domains to the left o f the plasma 
membrane. The three sites implicated in ligand binding are ringed. The sites for binding of divalent cations 
are marked by a +.
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Table 1.2 The integrin receptor family and their extracellular ligands
(compiled from Sugimori et al., 1997; Mohri, 1996;  ^Eble et al., 1998; and  ^Knight et al. 
1998)
a l p l laminins, collagens I, IV VI -
a 2 p i collagen I-IV, laminins, vitronectin. GFP*GERGVEGPP*GPA
tenascin where * is hydroxyproline^
a3 p i laminins ^ -
a4 p l fibronectin, VCAM-1 LDV, IDSP
a5 p l fibronectin RGD
a 6 p i laminins -
a 7 p l laminins -
aS p i fibronectin, tenascin, vitronectin -
a9 p l tenascin -
aV p i fibronectin, vitronectin RGD
aLP2 ICAM-I, -2, -3 LDV
aM p2 ICAM-I, -2, -3, fibrinogen, heparin, 
factor X, lipopolysaccharide
LDV
aX p2 fibrinogen, lipopolysaccharide
aOP2 ICAM-3
allp3 fibronectin, fibrinogen, vitronectin, 
thrombospondin, collagens, denatured 
collagen, PEC AM-1, von-Willebrand 
factor
RGD
KQAGDV
aVp3 fibronectin, fibrinogen, vitronectin, 
thrombospondin, SPARC, tenascin, 
denatured collagen, von-Willebrand 
factor
RGD
a6p4 laminin
aVp5 fibronectin, vitronectin RGD
aVP6 fibronectin, tenascin RGD
a4P7 fibronectin, MadCAM-1 LDV
aEp7 E-cadherin
aVp8 vitronectin
Chapter 2 
Materials and Methods
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Chapter 2 Materials and Methods
2.1 Reagents
The majority of chemicals were obtained from Sigma Chemical Co. The manufacturers of 
specialist materials are referred to in the text below.
2.1.1 Recombinant human MMPs and MMP inhibitors
The following recombinant MMPs and TIMPs were kindly provided by Prof. G. Murphy 
(University of East Anglia, Norwich, UK): proGLA (Murphy et al., 1992b); proGLB 
(O'Connell et al., 1994); proSL-1 (Murphy et al., 1992a); TIMP-1 (Williamson et al., 
1990); TIMP-2 (Willenbrock et al., 1993); A127-I84 TIMP-1 (N-TIMP-1; Murphy et al., 
1991b). proCL-3 (Knâuper et al., 1996a) was a kind gift from Dr V. Knâuper, University 
of East Anglia, Norwich, UK. The following recombinant MT-MMPs were kindly 
provided by Dr H. Will (InVitek GmbH, Berlin-Buch, Germany): the catalytic domain of 
MTl-MMP (A269-559 MTl-MMPcaf Will et al., 1996); the C-terminally truncated MTl- 
MMP, lacking the transmembrane domain and cytoplasmic domain (A 5 0 2 -5 5 9  TM-MTl- 
MMP; d'Ortho et al., 1997); and the catalytic domain of MT2-MMP (A27o_628 TM-MT1 - 
MMP; Butler et al., 1997). ATM-MT3-MMP was kindly provided by Dr M. Fox, 
University of East Anglia, Norwich, UK. The catalytic domain of MT4-MMP (ATM- 
MT4-MMP) was kindly provided by Dr M. Butler, University of East Anglia, Norwich, 
UK. The MMP inhibitor CT1746 (Nl-(1 -(S)-carbamoyl-2,2-dimethylpropyl)-N4-hydroxy-
2-(R)-[3-(4-chlorophenyl)propyl]succinamide) was a gift from Dr A. Docherty, Celltech 
Research, Slough, UK.
2.1.2 Extracellular matrix proteins and peptides
The following preparations of type IV collagen were generously provided by Prof. K. 
Kühn (Max-Planck-Institut fiir Biochemie, Martinsried, Germany): murine monomeric 
type rV collagen isolated from EHS tumour (Kleinmann et al., 1982); human dimeric type 
rv  collagen isolated from placenta (Timpl et al., 1981); human tetrameric type IV collagen
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isolated from placenta (Timpl et al., 1981). Type I collagen prepared from rat skin 
(Cawston and Murphy, 1981) was kindly provided by Prof. G. Murphy, University of East 
Anglia, Norwich, UK. Murine laminin-1 was purchased from Sigma Chemical Company. 
Human plasma fibronectin was purchased from Bioproducts, Elstree, Hertfordshire, UK. 
Purified fibronectin (contaminating gelatinases removed; Smilenov et al., 1992) was 
generously provided by A.J. Messent, Strangeways Research Laboratory, Cambridge, UK. 
The fibronectin peptides Fn III 6-10 (wild type) and Fn in 6-10 SPSDN (synergy site 
mutant) were a kind gift from Dr S. Aota and Dr K.M. Yamada (National Institute of 
Dental Research, National Institutes of Health, Bethesda, Maryland) and were prepared as 
described (Danen et al., 1995). The 120 kDa and 110 kDa fibronectin fi-agments were 
generously provided by Prof. L. Zardi (Instituto Nazionale per la Ricerca sul Cancro, 
Genoa, Italy) and were prepared by thermolysin digestion of human fibronectin as 
described (Borsi et al., 1986). The RGD peptide GRGDdSP was purchased from Gibco 
BRL and its inactive partner GRGESP was purchased from Sigma.
2,1.3 Antibodies
2.1.3a Anti-MMP and anti-TIMP antibodies
The polyclonal sheep anti-human TIMP-2 antibody (H225; Ward et al., 1991a) and the 
polyclonal sheep anti-human GLA antibody (X670; Hipps et al., 1991) were kindly 
provided by Prof. G. Murphy and Dr R. Hembry, University of East Anglia, Norwich, UK. 
The preparation of a new sheep anti-GLA antibody (K399) is described in detail in section 
2.2. The mouse monoclonal antibody VB3, to the C-terminal domain of GLA was 
provided by Dr H. Birkedal-Hansen, National Institute of Dental Research, National 
Institutes of Health, Bethesda, Maryland. The polyclonal antibody N175 to human MTl- 
MMP was raised and characterised, also as described in section 2.2. The mouse 
monoclonal antibodies to rat MTl-MMP 3A10, 4G6, and 2G12 were gifts from Dr P. 
Basset, Université Louis Pasteur, Strasbourg, France. The antibodies 3A10 and 4G6 were 
raised to a recombinant fi*agment of rat MTl-MMP, residues 112-508, produced in E. coli 
and recognise the catalytic domain and the hemopexin domain human MTl-MMP 
respectively. 2G12 was raised to a recombinant fi-agment from the prodomain of rat MTl-
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MMP, residues 47-66, but failed to react with proMTl-MMP and was used as a negative 
control for the mouse monoclonals.
The rabbit polyclonal antibody to MT2-MMP, raised to a recombinant fragment of human 
MT2-MMP (residues 91-305) was kindly provided by Dr. H. Will, InVitek GmbH, Berlin- 
Buch, Germany. The mouse monoclonal antibody against human MT3-MMP (raised to a 
peptide of residues 168-181) was a gift from Dr K. Iwata, Fuji Chemical Industries, 
Toyama, Japan. The following rabbit anti-MT4-MMP antibodies were gifts from Dr C. 
L6pez-0tin (Departamento de Bioquimica y Biologia Molecular, Facultad de Medecina, 
Universidad de Oviedo, Oviedo, Spain): anti-KLH-PEEP, raised to a peptide in the hinge 
region; anti-KLH RTLR, raised to a peptide in the C-terminal domain; and a rabbit 
polyclonal raised to a ft-agment of the C-terminal domain of MT4-MMP. The polyclonal 
antibody N33 was kindly provided by Dr M. Butler, University of East Anglia, Norwich, 
UK. This antibody was raised to the catalytic domain of human MT4-MMP, produced in 
E. coli, with N- and C-terminal histidine tags and a c-myc tag.
2,L3b Antibodies to integrins
The mouse monoclonal to the a2pl integrin Gi9 was purchased from Immunotech, 
Marseille, Cedex-9, France. The mouse monoclonal to a6 integrin subunit GoH3 was 
from TCS Biologicals, Botolph Claydon, Buckinghamshire, UK. The monoclonal 
antibody HP2/1 to the a4 subunit was purchased from Serotec, Oxford, UK. The rat 
monoclonal antibodies to the a5 integrin subunit, mAbs 16 and 11 (Akiyama et al., 1989; 
LaFlamme et al., 1992) and to the pi subunit mAb 13 (Akiyama et al., 1989) were 
generous gifts from Dr K.M. Yamada, National Institute of Dental Research, National 
Institutes of Health, Bethesda, Maryland.
2.1,3c Secondary antibodies and conjugates
Peroxidase-conjugated sheep anti-mouse IgG was from Sigma; peroxidase-conjugated 
donkey anti-sheep and donkey anti-rabbit IgG antibodies were purchased from Jackson 
Immunoresearch Laboratories Inc. The FITC-conjugated sheep anti-mouse IgG was fix)m
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Sigma and the FITC-conjugated pig anti-sheep IgG was kindly provided by Dr R. Hembry, 
(University or East Anglia, Norwich, UK) prepared as described by Hembry et al. (1985).
2.2 Putification and chatactetisaiion o f antibodies to MTl-MMP and GLA
2.2.1 Anti-MTl-MMP antibody N175
Sheep antiserum to recombinant human MTl-MMP was prepared by Dr M. P. d'Ortho 
(INSERM U492, Faculté de Médecine de Créteil, Créteil, France) and Dr R. Hembry 
(University of East Anglia, Norwich, UK). A GST-A511.582 TM-MTl-MMP fusion 
protein was prepared and expressed in E. coli as described (d'Ortho et al., 1998). GST- 
ATM-MT1 -MMP was purified from inclusion bodies, subjected to reducing SDS-PAGE 
and electro-eluted, also as described (d'Ortho et al., 1998). GST-A5 11.582 TM-MTl-MMP 
(150 pg protein) was emulsified in 1 ml complete Freund's adjuvant and injected 
intramuscularly into Clun sheep. Booster injections of 100 pg were given on days 42 and 
307 and blood was removed on days 7,10 and 14 following each boost injection.
Immunoglobulins were purified from antiserum by triple ammonium sulphate precipitation 
fi-om the bleed with the highest titre (bleed 6). A solution of 4 M (NH4)2S04 (6.7 ml) was
added dropwise to 10 ml antisera and the mixture stirred for 10 minutes at room 
temperature. The precipitate was collected by centrifugation and resuspended in 10 ml 
distilled H2 O. Precipitation with 6.7 ml of 4 M (NH4)2S04 was repeated twice more as
described above. The final precipitate was resuspended in 3 ml PBS and dialysed 
overnight against two changes of PBS. The optical density of the IgG solution was 
determined at 280 nm and the protein concentration calculated using the extinction 
coefficient of 1.4 (Harlow and Lane, 1988). IgG was then filter sterilised (0.2 pM) and 
stored at -20°C.
N175 antibody was further purified by adsorption to Protein-G Sepharose. One ml of 
Protein-G Sepharose (Sigma) was washed with 20 ml H2 O, followed by 20 ml wash buffer
(50 mM Tris-HCl, pH 7.5). The Sepharose was packed into a disposable column, and
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washed with a further 5 ml of wash buffer. IgG (20 mg protein from an ammonium 
sulphate precipitation) was diluted to 3 ml with the wash buffer and then applied to the 
column. Fractions of 0.5 ml were collected. The column was washed with 6 ml of wash 
buffer and then bound proteins were eluted with 0.1 M glycine, pH 2.7 containing 1 mM 
EGTA. Eluted proteins were immediately neutralised using a 2 M Tris-HCl solution, pH 
8. Fractions were subjected to 10% SDS-PAGE followed by silver stain, to confirm the 
presence of purified IgG in the glycine eluates. Pooled IgG was dialysed against PBS, 
filter sterilised and the protein concentration determined as described above.
Affinity purified N175 was prepared by adsorption of the IgG to the catalytic domain of 
MTl-MMP as described in d'Ortho et al., (1998). A269-559 MTl-MMPcat (300 pg) was 
adsorbed onto both sides of a 2 cm x 5 cm piece of nitrocellulose (Hybond ECL, 
Amersham Life Sciences). The nitrocellulose was then blocked for one hour with 5% 
(w/v) skimmed milk powder in wash buffer: 10 mM Tris-HCl, pH 7.4, 145 mM NaCl, 
0.05% (v/v) Tween 20, 0.02% (w/v) sodium azide. 50 mg of ammonium sulphate purified 
N175 IgG was added to a solution of 2.5% (w/v) skimmed milk powder in wash buffer (50 
ml) and incubated with the nitroeellulose overnight at 4^C. The nitroeellulose was then 
washed extensively with wash buffer, diced into 3 mm squares, and bound IgG was eluted 
from the nitrocellulose using 0.2 M glycine, pH 2.8 containing 1 mM EGTA and 0.02% 
(w/v) sodium azide. Elution fractions of 1 ml were immediately neutralised with a 2 M 
Tris-HCl solution, pH 8. The protein concentration of the eluted factions was determined 
as described above. Purifed N175 IgG was stored at 4°C for one month, or frozen at 5 
pg/ml in a solution of 2.5% (w/v) skimmed milk powder in wash buffer, ready for use in 
Western blot analysis.
2,2,2 Anti-GLA antibody K399
Sheep antiserum to recombinant human GLA was prepared by Prof. G. Murphy and Dr R. 
Hembry (University of East Anglia, Norwich, UK) according to the method published 
previously for anti-GLA antibody X670 (Hipps et al., 1991). Immunoglobulins were 
purified from antiserum by triple ammonium sulphate precipitation from the bleed with the
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highest titre as described above. K399 IgG was further purified by adsorption to Protein-G 
Sepharose as detailed above for N175.
2.3 Activation o f MMPs
Recombinant MMPs were activated essentially as described by Murphy et al. (1991a). 
Briefly, proGLA and proGLB were activated by incubation with 2 mM APMA for 1 hour 
at 37°C. proCL-3 was also activated with 2 mM APMA for 1 hour at 37°C. proSL-1 was 
activated by incubation with trypsin (5.0 pg/ml) for 30 minutes at 25°C, the cleavage was 
stopped by addition of aprotinin or soybean trypsin inhibitor (SBTI), and the mixture was 
incubated on ice for 30 minutes. ATM-MTl-MMP was activated by incubation with active 
MTl-MMPcat (Butler et al., 1998). Briefly, proMTl-MMPcat (30 pg/ml) was incubated 
with 5 pg/ml trypsin at 25°C for 15 minutes. The trypsin was then inactivated with SBTI 
and the mixture was added to ATM-MTl-MMP at 1:20 w/w ratio; activation was 
completed by incubation of the mixture for 16 hours at 25°C. One batch of ATM-MTl- 
MMP was activated simply by incubation at 37°C for 4 hours.
2.4 Determination o f binding affinity o f gelatinase A to matrix proteins by ELISA
The ELISA method used to determine MMP binding affinity for matrix molecules is 
described by Murphy et alv (1994), Matrix components were air dried onto plastic wells at 
100 pg/ml and cross-linked with glutaraldehyde. Pro- and active gelatinase A were added 
to the wells at 100 nM and incubated for 2 hours at 4°C. Bound enzyme was revealed by 
adding a polyclonal antibody to gelatinase A (X670) and incubating for 2 hours at 4°C, 
followed by a peroxidase-conjugated second antibody and 3,3', 5,5'-tetramethylbenzidine 
substrate (Kirkegaard and Perry, Maryland, USA). Optical density of the wells was read at 
450 nm.
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2.5 Cleavage of type IV  collagen with matrix metaUoproteinases
Type rv  collagen preparations were dialysed into a buffer of 50 mM Tris-HCl pH 7.6, 150 
mM NaCl and 0.02% azide prior to cleavage. Gelatinases A or B were added to type IV 
collagen at an enzymeisubstrate ratio of 1:8. To activate the gelatinase, APMA was added 
to the collagen/gelatinase mixture to achieve a final concentration of 0.7 mM. The mixture 
was incubated for 20 hours at 30°C or 37°C, after which the cleavage was stopped by 
placing the tube on ice and adding TIMP-1 at a 3:1 molar ratio with gelatinase. The 
digestion of type IV collagen was assessed by SDS-PAGE using 6-10% polyacrylamide 
gels.
Type rv  collagen was cleaved with collagenase-3 using the same protocol as for the 
gelatinases. Cleavage with stromelysin-1 also followed the same protocol, except that the 
stromelysin was pre-activated with trypsin as described above. APMA was not included in 
the stromelysin cleavages. Appropriate controls included incubation of collagen IV with 
APMA alone, or with trypsin/SBTT mixture.
2.6 Electrophoresis and silver stain
Proteins were analysed by SDS-PAGE (Laemmli and Favre, 1973) using IDEA Scientific 
mini gel electrophoresis equipment. Reagents were purchased fix)m BioRad Laboratories, 
Hemel Hempstead, UK, with the exception of SDS, which was purchased fix)m Serva.
Electrophoresed proteins were stained using silver nitrate. Briefly, gels were fixed in a 
solution of 40% (v/v) methanol, 10% (v/v) acetic acid for 30 minutes, followed by 2 x 15 
minute incubations in 10% (v/v) ethanol, 5% (v/v) acetic acid. Gels were then incubated in 
potassium dichromate (1% w/v) for 5 minutes, followed by 2 x 5 minute rinses in water 
(250 ml/rinse). A solution of silver nitrate (2% w/v) was added to the gels for 20 minutes. 
To develop the stain, the silver nitrate solution was poured off, the gels rinsed briefly in 
water and then incubated in a solution of 2.9% (w/v) Na2C0 3  containing 0.02% (v/v)
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formaldehyde until protein bands were visible. The developing reaction was stopped by 
the addition of a 5% (v/v) acetic acid solution.
2.7 Cell Culture
The HT1080. human fibrosarcoma cell line was purchased fi"om the European Collection of 
Animal Cell Cultures, Wiltshire, UK. These cells were used for the adhesion assays 
detailed in Chapter 3. A second HT1080 line that is N-ras transformed (Paterson et al., 
1987) was a gift fi-om Dr C. Marshall, Institute of Cancer Research, London, UK. These 
cells were used for the studies in Chapters 4-6 as their constitutive expression of the 
gelatinases was greater. Processing of GLA and MTl-MMP by the N-ras transformed 
HT1080 cells cultured on ECM substrates was compared with HT1080 cells fi-om the 
European Collection. Both cell lines responded similarly. HT1080 cells were maintained 
in DMEM (Gibco BRL or imperial Laboratories) supplemented with 10% PCS 
(Globepharm, Surrey, UK), 2 mM glutamine, 100 units/ml penicillin and 100 pg/ml 
streptomycin (Gibco BRL). A third HT1080 cell line, stably transfected with wild-type 
MTl-MMP (Green et al., 1994) was a gift from Dr J. Clements, British Biotech 
Pharmaceuticals Ltd., Oxford, UK. These cells were maintained in a selection medium of 
DMEM supplemented with 10% PCS, 4 mM glutamine, 100 units/ml penicillin, 100 pg/ml 
streptomycin, HT supplement (Gibco), 20 pM mycophenolic acid and 2 mM xanthine. 
The rat glioma cell line RuGLi was provided by Prof. K. Kühn, Max-Planck-Institut fiir 
Biochemie, Martinsried, Germany. The line was maintained in DMEM, 10% PCS, 2 mM 
glutamine, 100 units/ml penicillin and 100 pg/ml streptomycin. Human foreskin 
fibroblasts (HFFS) were prepared by S. Atkinson (University of East Anglia, Norwich, 
UK) using the method described in Heath et al. 1982. Cells were maintained in DMEM 
10% PCS and used at passage 4-8. HL60 cells (human myeloid leukaemic cell line) were 
purchased from the European Collection of Animal Cell Cultures, Wiltshire, UK and 
maintained in RPMI 1640 supplemented with 10% PCS, 2 mM glutamine, 100 units/ml 
penicillin and 100 pg/ml streptomycin. All cell lines were maintained in an atmosphere of
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5% C02 Adherent cells were passaged using trypsin/EDTA (Gibco BRL) according to 
standard procedures. Cells were routinely passaged 24-48 hours prior to experiment.
2,8 Immunolocalisation
For immunolocalisation studies, cells were seeded onto uncoated Labtek 8-well slides 
(Nunc), or onto slides coated with fibronectin or laminin-1 according to the procedure 
outlined in section 2.11 below. Cells were maintained for 24-48 hours in DMEM 10% 
FCS (uncoated slides) or DMEM 0.1% BSA (coated slides) prior to staining.
2.8.1 Surface staining
Cells were rinsed in serum-firee DMEM and fixed in fi-eshly prepared 4% (w/v) 
paraformaldehyde in PBS for 5 minutes. The fixative was rinsed fi-om the cells using PBS 
(3 x 5  minute washes). Primary antibody (50 pg/ml for polyclonal antibodies, 5 pg/ml for 
monoclonal antibodies) was added in a solution of PBS with 5% serum added as a 
blocking agent. Blocking serum was chosen to match the species in which the secondary 
antibody was raised. Cells were incubated with the primary antibody for 30-60 minutes at 
room temperature, unbound antibody was aspirated and the cells washed three times with 
PBS. The FITC-conjugated secondary antibody was added in PBS with 5% blocking 
serum for 30 minutes at room temperature. Unbound antibody was aspirated, the cells 
washed three times with PBS and mounted in Citifiuor (City University, London).
2.8.2 Intracellular staining
To increase the intracellular concentration of antigen, cells were incubated with the 
ionophore monensin. This reagent prevents protein secretion but not protein production, 
and causes an increase in the concentration of protein at the Golgi apparatus and secretory 
vesicles (Hembry et al., 1985). Monensin (5 pM; Sigma) was added to the cells for the last 
3 hours of culture. Cells were fixed as described above and then permeabilised by 
incubation with a solution of 0.1% (v/v) Triton-X-100 in PBS, for 5 minutes at room
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temperature. The cells were then washed with PBS three times, and treated with antibodies 
as described above.
Stained cells were viewed with a fluorescence microscope (Zeiss photomicroscope III; Carl 
Zeiss, Thomwood, New York). Photographs were taken using Kodak Panther 1600 ASA 
film. Staining was also analysed by Dr R. Hembry (Strangeways Research Laboratory, 
Cambridge, UK), using an MRC 600 confocal microscope with a krypton/argon laser. 
Data was collected by two methods: i) scanning the 488 nm FITC channel with a confocal 
aperture of 0.5 and Kalman averaging over 10 scans, at slow scan speed; ii) by collecting a 
Z-series of serial 1 pM sections through the cells and merging images with BioRad Comos 
software using false colour. Images were taken fi:om the screen using Agfapan 25 film.
2.9 Flow cytometric analysis
HT1080 cells were removed fi-om culture flasks using PBS containing 5 mM BDTA. 
HL60 cells were collected by centrifugation. Cells (1 x 10  ^cells) were washed with PBS 
containing 0.8% BSA (w/v) and incubated on ice in antibody buffer (PBS containing 0.8% 
BSA, 0.02% azide w/v), with or without the monoclonal antibody HP2/1 to the a4 integrin 
subunit at 10 pg/ml. After 30 minutes, the cells were collected by centrifiigation, washed 
in ice-cold antibody buffer and resuspended in antibody buffer containing sheep anti- 
mouse-FITC IgG at 1:50 dilution. Cells were incubated for a further 30 minutes on ice and 
then collected by centrifugation, washed with ice-cold antibody buffer before fixing with 
PBS containing 2% (v/v) formaldehyde. Staining was assessed by a Becton Dickinson 
FACS-Caiibur flow cytometer, using CellQuest version 3.1 software (Becton Dickinson).
2.10 Cell attachment assay v
The method for the attachment assays is detailed in Vandenberg, ct al. (1991). For the type 
rv  collagen studies, untreated or GLA treated type IV collagen were adsorbed to 96 well 
tissue culture plates as a 1 pg/ml solution in PBS at 4°C overnight. Free binding sites were 
blocked with 1% (w/v) heat-denatured BSA in PBS for 2 hours at 4®C. Cells were seeded
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onto coated wells at 6x10^ cells/well in serum free medium and allowed to attach for 35 
minutes at 37°C. Attached cells were washed twice with serum free medium and then 
fixed with 4% paraformaldehyde (v/v) in 0.15 M NaCl, pH 7.4. Cells were stained with 
1% (w/v) methylene blue in 0.01 M borate buffer, pH 8.5. After washing extensively with 
distilled water the dye incorporated in the cells was solubilised with a solution of 0.05 M 
HCl, 50% (v/v) ethanol and the optical density was read at 630 nm.
For the studies with fibronectin, a coating concentration of 5 pg/ml fibronectin was used. 
Wells were washed and blocked as detailed above. HT1080 cells were pre-incubated with 
anti-integrin antibodies (10 pg/ml) for 30 minutes at 37°C prior to seeding onto the 
fibronectin coated wells (in the presence of the antibodies). Following incubation at 37°C 
for 35 minutes, the attached cells were fixed and stained as detailed above.
2.11 Preparation of extracellular nmtrix and antibody substrates
Culture plates (24 well; Costar) were coated with human plasma fibronectin, firagments of 
fibronectin, or laminin-1 following the method of Tremble et al. (1994). ECM was added 
to culture plates at 30 pg/ml in PBS and incubated overnight at 4®C. The solution was 
aspirated the following day, the wells washed with PBS and blocked with 1% (w/v) heat- 
denatured BSA in PBS for 1 hour at room temperature. Wells were then washed with PBS 
and used the same day. The following monoclonal antibodies to integrin subunits were 
coated to culture plastic at 100 pg/ml: anti-a5, mAbs 16 and 11; anti-pi, mAb 13; and 
anti-a6, GoH3 (sources of antibodies described above). The antibody-coated wells were 
washed with PBS and blocked with BSA according to the protocol above.
2.12 Culture o f cells on substrates and preparation of conditioned media
Subconfiuent cultures o f cells were trypsinised and centrifuged, firstly in seruni-COUtainhlg 
medium, followed by two washes in serum-fiee medium. Cells were seeded at 1 x 10  ^
cells/well onto uncoated 24 well tissue culture wells or substrate coated wells, and cultured 
for 48 hours in DMEM supplemented with 0.1% BSA (Fraction V, culture grade.
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purchased from Sigma). This concentration of BSA was sufficient for cells to survive on 
ECM components in serum-free medium. Reagents (antibodies, MMP inhibitors) were 
added to the wells at cell seeding, or after the first 2 hours in culture (PMA, MMP 
inhibitors). At harvest, cells were trypsinised and the number of cells per well determined 
by counting the cells with a Neubauer haemocytometer.
2.13 Preparation o f ceU lysates
Cell monolayers were washed with cold PBS, and lysed according to the method of Lohi et 
al. (1996). The lysis buffer contained 50 mM Tris-HCl, pH 8.0, 0.15 M NaCl, 1% (v/v) 
Triton-X-100, 0.02% (w/v) azide, with the protease inhibitors pepstatin A (1 pg/ml ), E-64 
(1 pg/ml), PMSF (100 pM), and EDTA (10 mM). A volume of 25 pi lysis buffer was used 
per well of a 24 well culture dish. Cells were scraped into the lysis buffer, aspirated 
through a Gilson 200 pi pipette tip and then centrifuged in a microfuge for 10 minutes at 
4°C. The supernatant was collected and stored at -70°C until required. Total protein in the 
cell lysates was estimated using the bicinchoninic acid assay (Sigma), following the 
manufacturer's instructions.
2.14 Zymography
Gelatin degrading activity was assessed by zymography, according to the method of 
Heussen and Dowdle (1980). Samples of conditioned medium from tissue culture wells 
were loaded according to the number of cells/well at the end of the culture period. 
Samples were electrophoresed under non-reducing conditions on 7% SDS-PAGE gels 
containing 0.5 mg/ml type I calf skin collagen (Sigma) that had been heat-denatured (20 
minutes, 60°C). Non-reduced samples were separated by electrophoresis, after which the 
gels were washed twice with 2% (v/v) Triton-X 100 at room temperature, 15 minutes per 
wash, to remove the SDS. Under these eonditious, enzymes partially refold within the gel 
matrix, such that both pro- and active MMPs are capable of degrading gelatin. The gels 
were then rinsed in water and incubated overnight at room temperature in 100 mM Tris- 
HCl pH 7.9, 30 mM CaCl2, 0.04% (v/v) Brij and 0.02% (w/v) sodium azide (TCB buffer).
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The gels were stained with Coomassie brilliant blue to reveal white zones of lysis, which 
corresponded to gelatin degrading activity.
MMP-inhibitory activity was detected by adding an additional incubation step to the 
protocol, following the Triton-X-100 washes, as previously described (Herron et al., 1986). 
Briefly, gels were incubated in a preparation of active rabbit skin gelatinase (7 units/ml) for 
40 min at 37°C, before incubation overnight in TCB buffer at room temperature. 
Coomassie blue staining revealed dark zones of metalloproteinase-inhibitory activity 
against a lighter background.
2.15 Western Blot
Lysate proteins (25 pg protein/lane), membrane proteins (10 pl/lane), column fractions 
(10-20 pl/lane) or cleavage reaction mixtures (10 pl/lane) were separated by 10% SDS- 
PAGE under reducing conditions. Proteins were transferred to nitrocellulose (Hybond 
ECL, Amersham Life Sciences) by electroblotting (Towbin et al., 1979) using a BioRad 
blotting apparatus. The transfer of protein was confirmed by Ponceau S staining, using a 
solution of 0.1% (w/v) Ponceau S in 5% (v/v) acetic acid. Ponceau S stain was then 
removed by rinsing the membrane repeatedly in wash buffer (10 mM Tris-HCl, pH 7.4, 
145 mM NaCl, 0.05% (v/v) Tween 20). The membrane was blocked in 5% (w/v) skimmed 
milk powder in wash buffer for 1 hour at 37®C. Specific antibodies (5-50 pg IgG/ml of 
2.5% (w/v) skimmed milk powder in wash buffer) were incubated with the membrane for 3 
hours at room temperature, or alternatively overnight at 4°C. Unbound antibody was 
removed by rinsing in wash buffer and the membrane blocked a second time as detailed 
above. The membrane was then incubated with a peroxidase conjugated secondary 
antibody in a solution of 2.5% (w/v) skimmed milk powder in wash buffer for 1 hour at 
room temperature. Following several rinses in wash buffer, bound antibodies were 
revealed by incubating the membrane with a chemiluminescent substrate (Supersignal^^ 
CL-HRP Substrate System; Pierce). Luminescence was detected by exposure to 
autoradiographic fihn (Hyperfilm-ECL, Amersham Life Sciences), which was developed
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using standard procedures. Densitometric scanning of Western blots was performed using 
a Stratagene Eagle-Eye II, and analysed using EagleSight software version 3.2.
2.16 Gelatin-ùgùtose putification of GLA/TIMP-2 complexes
TIMP-2 complexed with GLA was purified from the conditioned medium by adsorption to 
gelatin-agarose (Butler et al., 1998). Gelatin-agarose (Sigma) was prepared by rinsing 
three times with wash buffer: 50 mM Tris-HCl, pH 7.5, 10 mM CaCl2, 0.025% (v/v) Brij
35, 0.02% (w/v) sodium azide. Washed gelatin-agarose was added to conditioned medium 
at 10% v/v and the mixture rotated end-on-end for 2 hours at 4°C. The gelatin-agarose was 
then washed twice with the wash buffer, and bound material was eluted using Laemmli 
reducing sample buffer. Eluted material was analysed for TIMP-2 by Western blot.
2.17 Biosynthetic labelling and immunoprécipitation o f MMPs and TIMPs
Cells were cultured on ECM substrates as detailed above. For labelling, the cells were 
washed twice with serum free, methionine/cysteine fi-ee DMEM (ICN Pharmaceuticals). 
Cells were ineubated in this medium, eontaining 70 pCi/ml p^Sj-methionine/eysteine 
(Amersham Life Sciences) for 8 hours. The conditioned medium was harvested and the 
cells lysed with a 50 mM Tris-HCl buffer, pH 8.0, containing 0.15 M NaCl, 1% (v/v) 
Triton-X-100, 0.02% (w/v) azide, 10 mM EDTA, 100 pM PMSF, 1 pg/ml pepstatin A and 
1 pg/ml E-64. The conditioned medium or cell lysates were first pre-cleared with normal 
sheep IgG (50 pg IgG/ml sample) for 1 hour at 4°C. Protein-G Sepharose (Sigma) was 
washed with buffer A: 50 mM Tris-HCl, 300 mM NaCl, 0.02% (w/v) azide, 0.5% (v/v) 
Triton X-100 and then added to the mixtures at 10% (v/v). The solution was mixed end on 
end at 4°C for one hour, centrifuged and the supernatant retained for immunoprécipitation. 
A polyclonal antibody raised in sheep to recombinant human gelatinase A (X670) was 
added to the supernatants at 50 pg/ml and incubated for 3 hours at 4°C. Protein-G 
Sepharose was added for a further 1 hour incubation and the pellet collected by 
cenlrilugatiua. The pcllcl was washed three times with buffer A and then boiled in 
Laemmli reducing sample buffer. Solubilised proteins were separated by SDS-PAGE, the
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gel stained with Coomassie brilliant blue and treated with a fluorographic reagent 
(Amplify, Amersham Life Sciences). The gel was dried under vacuum and exposed to 
Hyperfilm-MP (Amersham Life Sciences) at -70°C for 3-5 days. Film was developed 
using standard procedures.
2.18 Isolation ofRNA and Northern blot analysis
HT1080 cells were cultured in DMEM 0.1% (w/v) BSA on plastic or ECM coated dishes. 
Cells were cultured for 24 hours prior to lysis and extraction of total cellular RNA by the 
guanidinium thiocyanate method (Chomczynski and Sacchi, 1987). RNA samples (5 
pg/lane) were separated on a 1% (w/v) agarose, 2.2 M formaldehyde gel, transferred to a 
nylon membrane and cross-linked with uv light as described by Sambrook et al. (1989). 
The membrane was prehybridised for 1 hour at 68®C in hybridisation buffer: 0.75 M NaCl, 
80 mM sodium citrate pH 7.0, 50% (v/v) formamide, 2% (w/v) Blocking Reagent 
(Boehringer Mannheim), 0.33% (v/v) Sarkosyl, 0.02% (w/v) SDS and 100 pg/ml 
denatured herring sperm DNA. Digoxygenin-labelled antisense riboprobes to MTl-MMP 
and MT4-MMP (Cowell, 1997) were kindly provided by Dr S. Cowell, Strangeways 
Research Laboratory, Cambridge, UK. Membranes were hybridised overnight at 68°C 
with the riboprobes, which were added to hybridisation buffer at a concentration of 50 
ng/ml for the MTl-MMP probe, and 12.5 ng/ml for the GAPDH probe. The hybridisation 
solution was then removed, and the blots were washed at room temperature for 2 x 5 
minutes in a buffer of 0.3 M NaCl, 32 mM sodium citrate, pH 7.0, containing 0.1% (w/v) 
SDS. Blots were then washed for 2 x 15 minute washes in 15 mM NaCl, 1.5 mM sodium 
citrate, pH 7.0 containing 0.1% (w/v) SDS at 68°C. The membrane was rinsed in maleate 
buffer (100 mM sodium maleate, pH 7.4, 150 mM NaCl) and blocked with a solution of 
1% (w/v) Blocking Reagent in maleate buffer for 30 minutes at room temperature. To 
detect bound riboprobe, the membrane was incubated for 30 minutes at room temperature 
with an alkaline phosphatase conjugated anti-digoxigenin polyclonal antibody (Boehringer 
Mannheim) diluted 1/10 000 in blocking buffer. Excess antibody was removed by 2 x 15 
minute washes in maleate buffer and the membrane equilibrated in a solution of 100 mM
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Tris, pH 9.5,100 mM NaCl, 50 mM MgCl2 (TMN). The membrane was then soaked with 
the chemiluminescent reagent CSPD (Boehringer Mannheim), diluted 1/100 in TMN. 
Excess reagent was drained from the membrane, and the membrane was sealed in plastic 
and incubated at 37°C for 15 minutes. Luminescence was detected by exposure to 
autoradiographic film (Hyperfilm-ECL, Amersham Life Sciences). Film was developed 
using standard procedures.
2,19 Preparation of ceil membranes
Cell membranes were prepared according to the method of Ward et al. (1991b). Cell
monolayers were washed twice with ice-cold serum firee DMEM and then scraped into
DMEM containing the protease inhibitors pepstatin A (1 pg/ml), E-64 (1 pg/ml) and
PMSF (100 pM). The mixture was centrifuged (2500 g, 10 minutes, 4°C), washed twice
with DMEM containing the inhibitors and the cell pellet frozen at -70°C. For the
preparation of membranes, thawed pellets were homogenised in a buffer of 5 mM Tris-
HCl, pH 7.6, 0.02% (w/v) sodium azide containing the inhibitors as indicated above. The
mixture was centrifuged at 10 000 g for 10 minutes at 4°C and the supernatant was
subjected to further ultra-centrifugation at 43 000 rpm (Sorvall rotor TFT 80.4) for 1 hour 
at 4°C. The pellet was resuspended in 20 mM Tris- HCl, pH 7.8, 10 mM CaCl2 , 0.025%
(v/v) Brij 35, 0.02% (w/v) sodium azide containing the inhibitors. Protein concentration in 
the membrane preparation was estimated by measuring optical density at 280 nm and 
assuming an extinction coefficient of 1.0.
HIT080 cell membranes enriched in the 60 kDa form of MTl-MMP were prepared from 
HT1080 cells stably transfected with wild-type MTl-MMP (Green et al., 1994). 
Processing of MTl-MMP to the 45 kDa form was prevented by culturing the cells in the 
presence of CT1746 inhibitor (1 pM) for 48 hours prior to harvest (Butler et al., 1998). To 
remove excess CT1746 at harvest, the cells were washed with ice-cold DMEM (containing 
inhibitors) with a pH adjusted to 9.0. After the cells were scraped, the pellet was washed 
twice with this DMEM solution, using 25 ml solution/175 cm^ cell monolayer/wash. The
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amount of protein in the membrane preparation was estimated by the bicinchoninic acid 
assay to be 2.6 mg/ml and the amount of active MTl-MMP present in the membrane 
preparation was assessed by a quenched fluorescent peptide assay, kindly performed by Dr 
G. Butler, University of East Anglia, Norwich, UK. The concentration of active MTl- 
MMP was calculated using a k^\!Km value of 1.9 x 10  ^M"l s’  ^ obtained for soluble ATM 
MTl-MMP (Butler et al., 1998).
2,20 In vitro cleavage of recombinant MTl-MMP and native MTl-MMP
Recombinant MMPs were activated as detailed above. Active MMPs were added to either 
i) recombinant ATM-MTl-MMP (0.1-0.2 pg; d'Ortho et al., 1997) or ii) 10 pi of a 60 kDa 
MTl-MMP enriched cell membrane preparation. Mixtures were incubated at 37°C for the 
times indicated. The cleavage reaction was stopped by the addition of Laemmli reducing 
sample buffer. The molecular mass of the resulting ATM-MTl-MMP fragments were 
estimated by SDS-PAGE, followed by i) silver stain or ii) Western blot analysis using anti- 
MTl-MMP antibody N175 as described above.
For the cleavage of ATM-MTl-MMP complexed with TIMP-2, active ATM-MTl-MMP 
was pre-incubated with an equimolar concentration of recombinant TIMP-2 for one hour at 
25°C. A three molar excess of active GLA was then added to the ATM-MT1 -MMP/TIMP- 
2 mixture, and the solution incubated for a further five hours at 37°C. The molecular mass 
of the resulting ATM-MTl-MMP fragments was estimated by SDS-PAGE, followed by 
silver stain.
2,21 Immunoprec^itation o f MTl-MMP
HT1080 cells were cultured in 175 cm^ flasks in DMEM 10% FCS until nearly confluent. 
The cultures were then changed to serum free medium supplemented with PMA (10 ng/ml) 
and incubated for a further 24 hr. Cells were lysed according to the protocol described in 
section 2.13 above, using 800 pi lysis buffer/175 cm^ cells. For N-terminal sequencing, 
the Triton-X-100 in the lysis buffer was replaced with Surfact-Amps X-100 (Pierce,
57
Rockford, Illinois). Pre-immune sheep IgG and anti-MTl-MMP antibody were purified by 
Protein-G Sepharose chromatography (section 2.2) prior to use in immunoprécipitation. 
Lysates were pre-cleared with pre-immune sheep IgG (20 pg/ml) for 1 hour at 4°C. 
Protein-G Sepharose was washed with buffer A: 50 mM Tris-HCl, 300 mM NaCl, 0.02% 
(w/v) azide, 0.5% (v/v) Triton X-100 (or Pierce Surfact-Amps X-100 for sequencing 
projects) and then added to the mixtures at 10% (v/v). The solution was mixed end on end 
for 1-2 hours at 4®C, centrifuged, and the supernatant retained for immunoprécipitation 
with the polyclonal antibody to MTl-MMP (N175; 20 pg/ml) overnight at 4°C. The 
mixture was loaded on a column of Protein-G Sepharose, pre-equilibrated in buffer A. 
Unbound proteins were washed fi-om the column with buffer A, and bound proteins eluted 
with i) Laemmli reducing buffer (for Western blot) or ii) 25 mM Tris-HCL, pH 7.5, 
containing 8 M guanidinium hydrochloride (for reverse-phase HPLC).
2,22 Transfer o f N175 inununoprecipitates to PVDF membrane
Lysates prepared fi-om six 175 cm^ flasks of PMA treated HT1080 cells were purified by 
immunoprécipitation, followed by Protein-G Sepharose chromatography, as described 
above. A 10% SDS polyacrylamide separating gel was poured and allowed to stand at 
room temperature overnight (to allow reactive species to dissipate). The stacking gel was 
then added, the gel set in the tank, and pre-electrophoresed for 20 minutes with the addition 
of reduced glutathione (50 pM) to the upper reservoir buffer. Following the pre­
electrophoresis, the upper reservoir buffer was discarded and replaced with firesh reservoir 
buffer containing sodium thioglycollate (100 pM). Inununoprecipitates were then loaded 
on the gel and electrophoresed as normal.
Proteins in the gel were transferred to PVDF membrane (Immobilon, Millipore) by 
electroblotting at 100 mA, overnight at 4°C. A transfer buffer of 10 mM CAPS, pH 11, 
containing 10% (v/v) methanol was used. After transfer, the PVDF membrane was stained 
with Ponceau S (see section 2.15 above). A band at approximately 45 kDa was positively 
identified as MTl-MMP by concurrent Western blot analysis. The band was excised fi-om
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the membrane and subjected to automated sequencing using an Applied Biosystems 470A 
sequencer, performed by Dr Bryan Smith, Celltech Research, Slough, UK (Will et al., 
1996).
2.23 Reverse-phase HPLC purification ofN175 inununoprecipitates 
Lysates prepared from six 175 cm^ flasks of PMA treated HT1080 cells were 
immunoprecipitated as described above. Inununoprecipitates were applied to a column of 
Protein-G Sepharose, and eluted with a buffer of 25 mM Tris-HCL, pH 7.5, containing 8 M 
guanidinium hydrochloride. The proteins eluted were separated by reverse-phase HPLC 
(performed by Dr William English, University of East Anglia, Norwich, UK). A Dionex 
HPLC equipped with a diode array detector was used. 100 pi of eluted inununoprecipitate 
was applied to a C4 column (AllTec 24 x 0.46 cm), which had been pre-equilibrated with 
starting buffer (H2O/0.1% trifluoroacetic acid). A continuous gradient from 0-100% A-B 
(where A= H2O/0.1% trifluoroacetic acid and B= 60% isopropanol/40% acetohitrile/0.1% 
trifluoroacetic acid) was applied to the column over 50 minutes. Peak fractions were 
collected and dried down under vacuum. Proteins in the peak fractions were resuspended 
in buffer (50 mM TrisrHCl, pH 7.4 containing 1 mM EDTA) to 1/10 of the volume of the 
original fraction, and analysed by 10% SDS-PAGE followed by silver stain.
Chapter 3
Matrix metalloproteinase cleavage of collagen 
IV: implications for cell adhesion
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Chapter 3 Matrix metalloproteinase cleavage o p  collagen IV: implications fo r cell 
adhesion
3,1 Introduction
Type rv  collagen is a major structural component of basement membranes, and forms a 
network with other basement membrane constituents to provide a mechanically stable 
support for cells. Localised remodelling of basement membranes is an integral feature of 
wound repair and mammary gland involution, and is essential for the invasion of tumour 
cells to distant sites. One popular hypothesis for tumour invasion attributes the invading 
cell with a battery of enzymes capable of degrading type IV collagen, a requirement for 
moving through basement membranes (Liotta and Stetler-Stevenson, 1991). Fessier et al. 
(1984) reported that a mouse tumour MMP cleaved intact type IV collagen (derived from 
cell culture) into two fragments, 100 nm and 300 nm in length. Others, working with 
purified GLA and GLB, reported Augments of a similar size generated by proteolytic 
cleavage of type IV collagen preparations in vitro (Salo et al., 1983; Collier et al., 1988; 
Murphy et al., 1989a). This supported the concept that the gelatinases are 'type IV 
collagenases' (Liotta et al., 1981).
Cells interact with type IV collagen via the a lp l  and a2pi integrin receptors. The 
integrin binding sites occur within a 40 nm long section of the molecule, which can be 
isolated as a triple helical cyanogen bromide Augment CB3[TV]. The CB3[TV] region is 
located 100 nm from the N-terminus of collagen IV (Vandenberg et al., 1991), and the 
exact location for a lp l  binding has been mapped to an aspartate residue (Asp 461) of the 
al(TV) and an arginine residue (Arg 461) o f  the two a2(TV) chains (Eble et al., 1993;
Fig.3.1). a lp l  integrin binding is entirely dependent upon triple helical conformation, 
requiring amino acid residues on adjacent a(TV) chains. The stability of the triple helix in 
this region is maintained by interchain disulphide bridges, with the a ip i  binding site 
occuring between two disulphide knots (Fig. 3.1). On either side of these two disulphide 
knots, in the relaxed triple helical end regions of CB3[TV], are the recognition sites for the 
a2pl integrin (Kern et al., 1993).
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GLA cleaves type IV collagen 100 nm from the N-terminus, in close proximity to the 
CBSpV] region. This led to the question of whether GLA treatment alters the ability of 
collagen IV to interact with a lp l  and a2pi integrins. Chapter 3 reports a test of the 
hypothesis that cell attachment to type IV collagen (via a ip i  and a2pi integrins) is 
impaired by prior treatment of the collagen IV with GLA. Preparations of collagen IV 
isolated from the murine EHS tumour, or from human placenta, were incubated with GLA 
and the fragments generated assessed by SDS-PAGE. Cell adhesion to the collagen IV 
fragments generated by GLA treatment was compared with adhesion to intact collagen IV. 
As predicted, collagen IV preparations (in which the interchain disulphide bonds had been 
reduced during purification) were susceptible to cleavage in the CB3[IV] region, and cell 
attachment via a2pi and a lp l was greatly reduced. However, preparations of type IV 
collagen in which the interchain disulphide bonds remained intact, or reformed during 
purification, were not susceptible to GLA cleavage of integrin binding sites.
This work was done in collaboration with Prof. K. Kühn and his group (Max-Planck- 
Institut fur Biochemie, Martinsried, Germany), who provided preparations of collagen IV; 
N-terminal sequence information for cleaved collagen IV; and worked with isolated 
integrins in a collagen IV binding assay to confirm the observations made here with the 
cell adhesion assays.
3.2 Extraction and purification o f type IV  collagen
Data from this chapter shows that cell adhesion to GLA cleaved type IV collagen is 
entirely dependent upon the methods used to extract and purify the collagen. All 
preparations of type IV collagen were supplied by Prof. K. Kühn. The different procedures 
used in his laboratory to isolate type IV collagen are discussed below.
3.2.1 Preparation o f type IV  collagen nutnomers
Type rv  collagen monomers were extracted from murine EHS tumour by treating the 
tissue with guanidine HCl containing dithiothreitol (DTT) to solubilise the collagen. 
Solubilised collagen IV was purified by DEAE cellulose chromatography, using 4M urea
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and 2 mM DTT in the elution buffer (Kleinmann et al., 1982). Under the reducing 
conditions used for extraction, intermolecular disulphide bonds were broken to yield 
monomeric collagen IV. The intramolecular disulphide bonds in the CB3[IV] region and 
the N-terminal telopeptides were also susceptible to reduction, with variation between 
batch preparations. This resulted in preparations of type IV collagen in which the 
intramolecular disulphide bonds were either completely reduced (preparation A) or 
remained intact (preparation B; see Fig. 3.2) and some preparations which contained 
mixtures of both (Eble et al., 1996).
3.2.2 Preparation o f type IV  collagen dimers
Dimeric collagen IV was extracted from human placenta after a mild treatment with 
bacterial coUagenase (Timpl et al., 1981). Bacterial collagenase (Worthington, Freehold, 
New Jersey) was added to minced tissue suspended in Tris-buffered saline and incubated 
for 24 hours at 4°C. Collagen IV was then precipitated from the mixture by adding NaCl 
(2-3 M) and further purified by DEAE-cellulose chromatography (Timpl et al., 1981). The 
purified collagen IV dimers still contained traces of collagenase, which continued to 
degrade the collagen IV during incubation at 37®C. This problem was addressed by 
removing the collagenase using molecular sieve chromatography, on an agarose 5.0m 
(BioRad) column (Eble et al., 1996).
Bacterial collagenase cleaves the collagen IV network 100 nm away from the N-terminus 
(Timpl et al., 1981). The resulting dimers are missing 100 nm of their N-termini, and are 
connected via the C terminal NCI domains (Fig. 3.2). Intramolecular disulphide bonds in 
the CB3[TV] remain intact (Eble et al., 1996).
3.2.3 Preparation of type IV  collagen tetramers
Tetrameric collagen IV was extracted from human placenta by treatment with porcine 
pepsin (Vandenberg et al., 1991). Minced tissue was rinsed in saline, suspended in 0.5 M 
acetic acid and incubated with pepsin for 20 hours at 4®C. Type IV collagen was separated
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from the protein mixture by precipitation with a buffer containing 1 M NaCl, followed by 
precipitation with a buffer containing 1.7 M NaCl (Vandenberg et al., 1991). The 
precipitated protein was further purified by DEAE-cellulose chromatography (Timpl et al., 
1981).
Tetrameric collagen IV consists of four strands connected by covalent linkages at the 7S 
domain (Timpl et al, 1981; Fig. 3.2). The initial site for pepsin cleavage is located at the 
C-terminal end of the strands, just N-terminal to the NCI globular domain. Rotary 
shadowing of the tetramers has shown that pepsin treatment destroys the NCI globular 
domain, leaving the ends of the strands free (Timpl et al., 1981).
All collagen IV preparations were dialysed against acetic acid (0.2 M), lyophilised and 
stored at -70°C. Prior to experimentation, collagen preparations were redissolved in acetic 
acid, and dialysed against cleavage buffer as described in Chapter 2.
3.3 Results
3.3.1 MMP cleavage o f collagen IV  monomers
Monomeric type IV collagen was incubated with GLA for 20 hours, at 30°C arid 37°C. 
Intact (untreated) collagen IV and collagen IV fragments were separated by SDS-PAGE 
and visualised by silver stain. Intact collagen IV (preparation A) migrated as a doublet of 
approximately 180 kDa (Fig. 3.3A lane 1), corresponding to the pro-ai(TV) and pro- 
a2(TV) chains respectively (Fessier et al., 1984). Considerable amounts of protein were 
retained in the stacking gel (Fig. 3.3A lane 1), most likely due to intermolecular lysine 
aldehyde-derived cross-linkages, causing the formation of multimers. Preparation A was 
cleaved by GLA at 30®C to generate two bands of 3/4 length of the monomer (Fig. 3.3A, 
lane 3), corresponding to die two a(IV) chains of the 300 nm long fragment (Fessier et al., 
1984). Incubation of preparation A with GLA at 37°C led to complete degradation of the 
monomer (Fig. 3.3B, Imie 3). Both 30°C and 37®C incubations with GLA resulted in a
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clearance of protein from the stacking gel, indicating enzymatic degradation of the cross- 
linked multimers.
Surprisingly, preparation B was not susceptible to GLA action. SDS-PAGE analysis 
showed that GLA did not cleave preparation B at 30®C (data not shown), nor did it cleave 
at 37°C (Fig. 3.4). The molar ratio of GLA to preparation B was raised to 1:2, however 
even at this high ratio GLA failed to cleave preparation B (data not shown). Differences 
between preparations A and B were highlighted by electrophoresis under non-reducing 
conditions. The ai(IV) and a 2(IV) chains of untreated preparation A entered the 
separating gel under non-reducing conditions (Fig. 3.5, lane 1), however, in contrast with 
preparation A, unincubated preparation B did not enter the separating gel (Fig. 3.5, lane 5). 
Incubation of preparation A at 30®C with GLA or GLB resulted in the generation of 
several lower molecular mass fragments (Fig. 3.5, lanes 3 and 4), and increasing the 
incubation temperature to 37°C caused a smearing of fragments upon separation by non­
reducing SDS-PAGE (Fig. 3.6, lanes 3 and 4). Treatment of preparation B with GLA or 
GLB at 30°C failed to fragment the collagen (Fig. 3.5, lanes 7 and 8), however several 
fragments entered the separating gel when preparation B was treated with GLA or GLB at 
37°C (Fig. 3.6, lanes 7 and 8). These data, and the data from the reducing SDS-PAGE 
(Figs. 3.3 and 3.4), indicated that despite apparently identical extraction conditions, there 
was a fundamental difference in the levels of disulphide bonding between preparation A 
and preparation B.
Experiments carried out in Prof. K. Kühn's laboratory confirmed the differences between 
the two preparations. Preparation B was treated with a reducing agent (DTT) and 
subjected to SDS-PAGE. The resulting profile on the gel was similar to preparation A. 
Likewise, treatment of preparation A with an oxidising agent (oxidised glutathione) led to 
an SDS-PAGE profile similar to preparation B (Eble et al., 1996). It was concluded that 
during some extractions the interchain disulphide bonds either remained intact, or reformed 
during purification, resulting in a preparation 'B'.
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The commercial extraction of EHS type IV collagen is based on the same procedures used 
by Prof. Kühn's laboratory (Kleinmann et al., 1982). Preparations of type IV collagen from 
Sigma Chemical Company, and from Collaborative Biomedical Products (Becton 
Dickinson), were cleaved with GLA, and the fragments assessed by reducing and non- 
reducing SDS-PAGE. Sigma collagen IV was particularly susceptible to MMP action. 
Treatment with gelatinases at 30°C resulted in complete degradation of the a(TV) chains, 
as evidenced by reducing SDS-PAGE (Fig. 3.7). Collagen IV purchased from 
Collaborative Biomedical was not cleaved by gelatinases at 30®C (data not shown), but the 
a 2(TV) chain was cleaved at 37°C by both GLA and GLB (Fig. 3.8). Clearly, the extent of
intramolecular disulphide bonding also varied between commercial preparations.
3.3.2 Cell attachment to collagen IV  monomers
Conditions for the attachment assay : Cell lines were chosen for attachment assays on the 
basis of integrin expression. The HT1080 human fibrosarcoma cell line expresses a2pi 
integrin, but not a lp l  (Petermann et al., 1993) and binds to type IV collagen via a2pi 
integrin (Vandenberg et al., 1991). This was confirmed in our laboratory by using an anti- 
a2pi integrin antibody to inhibit cell adhesion to collagen IV (Fig. 3.9). In contrast, the 
mouse glioma cell line RuGLi expresses a ip i ,  but not a2pl integrin (Petermann et al., 
1993), and adheres to type IV collagen solely via the a lp l  integrin (Vandenberg et al., 
1991). The conditions for the cell attachment assay were optimised by time course studies, 
and by serially diluting cell number and substrate concentrations (data not shown). Briefly, 
maximum attachment of cells to collagen IV occured after 20 minutes incubation at 37°C; 
assays were routinely run for 35 minutes. A concentration of 6 x 10  ^cells/well was chosen 
for both HT1080 and RuGLi cells, as it fell within the linear portion of the dose response. 
Half maximal binding of HT1080 cells was achieved at 0.1 pg/ml type IV collagen 
monomers, with a maximum at 1 pg/ml. Half maximal binding of RuGLi cells was at 0.1 
pg/ml and maximum at 0.4 pg/ml type IV collagen monomers. A concentration of 1.0 
pg/ml was chosen for the assay. Fragments of type IV collagen generated from treatment 
with MMPs were also plated at 1 pg/ml. The amount of intact or GLA-cleaved type IV 
collagen adsorbed to the plastic was determined by radiolabelling the collagen with l^^I-
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iodine. Approximately 10-13% of the collagen added to the wells adsorbed to the plastic 
in both intact collagen IV controls as well as GLA cleaved collagen IV (data not shown). 
Finally, to control for MMPs and TIMP-1 present in cleaved collagen IV preparations, 
identical concentrations of MMPs and TIMP-1 were tested alone for adhesion promoting 
activity. Neither MMPs nor TIMP-1 promoted HT1080 or RuGLi cell adhesion (data not 
shown).
Type rv  collagen preparation A was pre-incubated with GLA, and cell attachment to the 
GLA treated collagen compared with attachment to intact monomers. When collagen IV 
was pre-incubated with GLA at 30°C, neither HT1080 nor RuGLi cell adhesion to the 
collagen was affected (Fig. 3.10). When the temperature of the pre-incubation was raised 
to 37®C, both RuGLi and HT1080 cell attachment to GLA-cleaved-preparation A was 
severely affected (Fig. 3.10). RuGli cell adhesion was commonly reduced to 40-60% of 
the control (preparation A incubated in the absence of GLA), whereas HT1080 cell 
adhesion to preparation A pre-treated with GLA at 37°C was 0-10% of the control. The 
data suggested that the a2pi integrin binding sites were degraded by GLA treatment at 
37°C, but that some a ip i  integrin binding was still possible.
In contrast to the preparation A results, treatment of preparation B with GLA at 3i7®C did 
not affect HT1080 or RuGLi cell adhesion (Fig. 3.10). Cell adhesion to GLA treated 
preparation B could be inhibited by the addition of an anti-pi integrin subunit antibody 
(mAb 13, added at 5 pg/ml; data not shown). The combined data indicated that the 
integrin binding sites on preparation B remained intact following treatment with GLA, a 
result consistent with the lack of fragmentation observed following GLA treatment (Fig. 
3.4).
3.3.3 GLA treatment o f collagen IV dimers and cell attachment to the GLA treated 
dimers
Dimeric collagen IV was incubated with GLA for 20 hours at 37°C. Analysis of the 
cleavage reaction mixture by reducing SDS-PAGE showed that the dimers were not
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degraded by GLA (Fig. 3.11). However, when the dimers were stored at 4°C for periods 
longer than three weeks, they became particularly susceptible to GLA action, and some 
degradation was observed upon incubating the dimers alone (data not shown).
Freshly dialysed dimeric collagen IV was pre-incubated with GLA, and cell attachment to 
the GLA treated collagen compared with attachment to intact dimers. Figure 3.12 ' 
demonstrates that HT1080 and RuGLi cell attachment to collagen IV dimers was 
minimally affected by GLA pre-treatment of the collagen, indicating that a ip i  and a2pi 
integrin binding sites were left mainly intact.
3.3.5 MMP cleavage o f collagen IV  tetramers and cell attachment to the cleaved 
tetramers
Tetrameric collagen IV migrated as several bands on SDS-PAGE, with apparent molecular 
mass between 130 and 190 kDa, as has been reported by others (Mackay et al., 1990). 
Incubation of tetramers with GLA at 30°C for 20 hours resulted in minor fragmentation 
(data not shown). Incubation at 37°C, however, induced marked degradation by GLA (Fig. 
3.13). Furthermore, SL-1 and CL-3 also degraded the tetramers, and patterns were 
significantly different for each enzyme (Fig. 3.13). Surprisingly, despite the degradation of 
the tetramers induced by the MMPs, neither HT1080 nor RuGLi cell attachment was 
affected (Fig. 3.14).
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3.4 Discussion
Many studies have shown that the expression of the gelatinases is up-regulated in tumour 
tissues, and that the appearance of active gelatinases is closely correlated with tumour 
metastasis (reviewed by Sato and Seiki, 1996). These enzymes are referred to as 'type IV 
coUagenases', and it has been hypothesised that they aid cellular invasion by proteolytic 
dissolution of the basement membrane, allowing movement of the cell through the digested 
barrier (Stetler-Stevenson et al., 1993). However, clear evidence that the basement 
membrane is breached by invading cells has been difficult to obtain. It is possible that the 
action of the gelatinases is more subtle, and may involve destruction of points of contact 
between the cell and the substratum, allowing the migrating cell to move on.
Cleavage of collagen IV into two fragments by a gelatinase was first demonstrated by Salo 
et al (1983) and Fessier et al (1984). Similar patterns of type fV collagen fragmentation 
were reported by others, using gelatinases A and B purified from varied sources (Collier et 
al., 1988; Murphy et al., 1989a; Wilhelm et al., 1989). We speculated that the close 
proximity of the gelatinase cleavage site may be used by the invading tumour cell to 
penetrate basement membranes. Cells attached to basement membrane collagen IV via 
a ip i  and a2pl integrins may secrete gelatinases that cleave the collagen IV network and 
degrade the integrin binding sites. This could then lead to cell detachment and penetration 
of the cell through the basement membrane at the site of proteolysis.
It was of concern to us that there are divergent reports concerning the ability of gelatinases 
to degrade type IV collagen. Several reports show little degradation of collagen IV by the 
gelatinases (Murphy et al., 1982; Rantala-Ryhanen et al., 1983; Hibbs et al., 1987; Mackay 
et al., 1990). Direct comparison of these studies with those reporting defined 
fragmentation is difficult, as studies were carried out using gelatinases purified, or partially 
purified, from a range of cell types. It was clear to us that the incubation conditions for 
GLA cleavage studies may be critical. Gelatinase activity on collagen IV appeared to be 
temperature-sensitive, ranging fix)m little or no degradation at 30®C, to complete
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degradation at 37°C (Murphy et al., 1991a; Okada et al., 1992). Indeed, Mackay et al. 
(1990) were unable to reproduce the 1/4, 3/4 fragmentation of EHS collagen IV with GLA 
or GLB at 25, 30 or 37°C, and suggested that the gelatinases were in fact not true type IV 
coUagenases.
Therefore, to begin this study, the action of GLA on collagen IV was reassessed using a 
preparation of collagen IV monomers derived from the EHS tumour. This preparation was 
termed 'preparation A' (in retrospect) to distinguish it from other preparations. At 30°C 
GLA cleaved preparation A into the characteristic 1/4 and 3/4 fragments, as reported by 
others (Salo et al., 1983; Fessier et al., 1984; Collier et al., 1988; Murphy et al., 1989a; 
Wilhelm et al., 1989). At 37°C, preparation A was degraded by GLA action, resulting in a 
number of low molecular mass fragments. In contrast, a second preparation of monomers 
termed 'preparation B' was not susceptible to GLA action at 30®C. Even at 37®C, which is 
close to the triple helical dénaturation temperature for coUagen IV (38°C; Kühn, 1994), 
preparation B was resistant to GLA attack. In Prof. Kühn's group, treatment of preparation 
B with GLA at 37°C did result in some cleavage N-terminal to the CB3[TV] region, as well 
as degradation of the monomers from the C-terminal end (Eble et al., 1996). However in 
our hands preparation B proved to be repeatedly resistant to GLA attack. The reason for 
the differences between the studies is not known. Comparing preparation A and 
preparation B by non-reducing SDS-PAGE confirmed that despite identical purification 
procedures, preparation B retained a greater level of intramolecular disulphide bonding. 
As the CB3[rV] region is the only segment within the triple-helical domain that is 
stabilised by intramolecular disulphide bonds (Kühn, 1994), it was apparent that the 
CB3[TV] region of preparation B was more like the native molecule.
To assess the effect of GLA action on integrin binding to coUagen IV, cell attachment to 
intact monomers was compared with attachment to cleaved monomers. Cleavage of 
preparation A with GLA at 30°C to the 1/4 and 3/4 fragments did not affect HT1080 or 
RuGLi cell adhesion, indicating that the a ip i  and a2pi integrin binding sites remained 
intact. However, fragmentation of preparation A with GLA at 37°C severely affected cell
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adhesion to the monomers, with greater effect on a2pl integrin interactions than a lp l  
integrin interactions. This data was confirmed in Prof. Kühn's group, using isolated a2pl 
and a ip i  integrins to study integrin binding to GLA cleaved preparation A (Eble et al., 
1996). The reduced a2pl integrin binding most likely reflects a loss of the N-terminal 
a2pl integrin binding site (Fig. 3.1), which is close to the initial GLA cleavage site. The 
C-terminal a2pi integrin binding site is of much lower affinity (Kem et al., 1993) and may 
be protected from proteolytic attack by the nearby disulphide stabilised region. Treatment 
of preparation B with GLA at 37°C did not affect cell adhesion to the molecule, or 
adhesion of isolated integrins (Eble et al., 1996), a result predicted due to the greater 
resistance of this preparation to GLA attack.
Attempts to determine the gelatinase cleavage site in preparation A did not generate 
identifiable sequences (Eble et al., 1996). The cleavage sites of GLA within denatured 
CB3[rV] and the triple helical segment of CB3|TV] (fragment FI) were mapped by Prof. 
Kühn's group. In denatured CB3|TV], sequences Gly-X-Y were cleaved between Gly and 
X, if position X was occupied by a hydrophobic or polar charged residue (Fig. 3.15). 
Hydroxyproline in position Y prevented cleavage. In the triple-helical fragment FI, GLA 
cleavage only occurred where the triple-helical structure appeared to be relaxed. No 
cleavage occurred in the region between the two disulphide knots (Fig. 3.15). Binding of 
a ip i  integrin to fragment FI was unaltered by GLA treatment, whereas binding of a2pi 
integrin was reduced slightly, due to the loss of the N-terminal a2pl integrin binding site 
(Eble et al., 1996).
Several commercial preparations of ÉHS-derived collagen IV monomers were compared 
with preparations A and B. From non-reducing SDS-PAGE, it was apparent that the 
commercial preparations varied in the extent of disulphide bonding. GLA incubation 
studies showed that the preparations which resembled the native molecule (with interchain 
disulphide bridging intact) required a higher temperature for cleavage to occur. It is likely 
therefore, that the choice of commercial preparation of collagen IV monomers will have 
significant bearing on experimental results, if gelatinase degradation of the collagen is a
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requirement of the experiment. For future studies, it would be interesting to compare 
preparations of Matrigel (the Commercial preparation of basement membrane from the 
EHS tumour) to see whether variations in the level of collagen IV intramolecular 
disulphide bonding occur between preparations. .One would predict that cells expressing 
active GLA would show an altered rate of invasion through preparations of Matrigel 
containing mostly reduced collagen IV. This may not necessarily reflect the in vivo 
situation.
Collagen IV preparations extracted by several methods were compared in this study. 
Dimeric collagen IV was purified from human placenta by treatment of the tissue with 
bacterial collagenase at 25°C. Bacterial collagenase preferentially cleaves the collagen IV 
network at an N-terminal site, close to the CB3|TV] region (Timpl et al., 1981). An 
attempt was made by Prof. Kühn's group to obtain an N-terminal sequence for bacterial 
collagenase-cleaved dimers, however a unique sequence could not be identified. Other 
studies with preparation A showed that soluble collagen IV was cleaved by bacterial 
collagenase between residues Pro-393 and Gly-394 (at(TV)) and between Pro-390 and 
Gly-391 (a2(TV); Eble et al., 1996), 20 residues away from the first a2pl integrin 
recognition site (Fig. 3.15). Dimers in solution were susceptible to further attack by 
bacterial collagenase, particularly at 37°C (A. Ries and Prof. K. Kühn, personal 
communication). However, studies here showed that GLA, in contrast to bacterial 
collagenase, was unable cleave the dimers, even at 37°C. At this temperature the non- 
triple helical interruptions in the vicinity of CB3[TV] should be relaxed. Lack of GLA 
action in comparison with bacterial collagenase may reflect the different specificities of the 
two enzymes. Bacterial collagenase will attack all Pro-Gly and Hyp-Gly bonds in the 
relaxed regions, thus bacterial collagenase may cleave at many more sites in the relaxed 
regions than GLA (Eble et al., 1996).
Cell attachment sites in the CB3[TV] region of the dimers were unaffected by GLA 
treatment, as evidenced by HT1080 and RuGLi ceU adhesion studies. Additionally, studies 
with isolated a lp l  and a2pl integrins showed that GLA treatment did not affect integrin
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binding to collagen IV (Eble et al., 1996), supporting the cell adhesion results. It is likely 
that intramolecular disulphide bonds within the CB3[TV] region protected this region from 
GLA attack and that the C-terminal ends of the dimers were protected by the interactions 
between adjacent NCI domains.
In contrast to collagen IV dimers, tetramers prepared by pepsin extraction of human 
placenta were particularly susceptible to MMP action. Mackay et al. (1990) also reported 
gelatinase-induced fragmentation of pepsin-extracted type IV collagen, and noted that 
tetramers were more susceptible to gelatinase action than monomers. In the current study, 
despite extensive fragmentation of tetramers by MMPs at 37®C, the attachment of HT1080 
cells and RuGLi cells was not affected. This indicates that the CB3|TV] region remained 
intact, and as the N-terminal end is sealed by interactions in the 7S domain, it can be 
assumed that fragmentation occurred from the C-terminal end.
Several MMPs were used in the studies with tetramers, which highlighted the different 
cleavage specificities of the MMPs, and confirmed that enzymes other than the gelatinases 
are capable of cleaving collagen IV. SL-1 is a potent type IV collagen-degrading enzyme 
(Collier et al., 1988). In addition to its action on the tetramers, SL-1 also cleaved 
preparation B monomers at 37®C, fragmenting the a2(TV) chain (data not shown). Okada 
et al. (1990) also reported cleavage of EHS-derived, monomeric a 2 (TV) chain with SL-1 
(at 32®C); interestingly, GLA failed to cleave the collagen under the same conditions. 
Studies in our laboratory with CL-3 have shown that it is more efficient at cleaving type IV 
collagen preparation B than the gelatinases (Knâuper et al., 1996a). In combination, these 
observations question the validity of referring to the gelatinases as 'type IV coUagenases', 
in agreement with Mackay et al (1990).
It is an unfortunate consequence of these studies that the methods used to extract soluble 
collagen IV from the basement membrane network compromised the structural integrity of 
the molecule. For future studies, it would be interesting to compare the extracted and 
solubilised collagen IV preparations used here with soluble coUagen IV expressed by PF-
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HR9 mouse teratocarcinoma cells. These cells secrete collagen IV monomers into the 
culture medium, and can be induced to secrete disulphide-linked collagen IV tetramers by 
culturing the cells in medium devoid of cysteine (Fessier et al., 1984). Monomers and 
tetramers can be purified fi'om PF-HR9 conditioned medium using DEAE-chromatography 
and velocity sedimentation. Interestingly, 1/4 and 3/4 collagen IV fiagments were 
obtained fi'om digestion of these monomers and tetramers with a 'type IV collagenase' 
isolated fi'om the culture media of mouse metastatic PMT sarcoma (Fessier et al., 1984). 
As the type IV collagenase in these studies was only partially purified, this raises the 
possibility that several MMPs may act in concert to cleave collagen IV. Thus future 
studies designed to compare extracted collagen IV with soluble secreted collagen FV 
should also investigate the degradative action of combinations of MMPs.
In summary, this chapter was designed to test the hypothesis that cell attachment to type IV 
collagen (via a lp l  and a2p2 integrins) is impaired by the prior action of gelatinases on the 
collagen. The data collected fi'om studies with solubilised collagen IV suggests that the 
integrin recognition sites are resistant to degradation by the gelatinases. However, it is an 
open question whether the recognition sites are accessible to proteolytic attack when 
incorporated into the macromolecular network, and whether several proteases act in 
concert on the collagen IV network. The discovery that the CB3[TV] region is particularly 
resistant to MMP degradation raises the intriguing possibility that a ip i  and a2pi integrin 
receptors on migrating cells may remain occupied by protease resistant recognition sites, 
even when the surrounding collagen IV network is largely degraded. This may prevent the 
cell fix>m interacting with intact molecules of the macromolecular membrane and may in 
turn modify the migration of the cell throughout the basement membrane.
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Figure 3.1 Amino acid sequence of the CB3[IV] region o f human collagen IV
(ad^ted from Eble et al., 1996)
The triple helical area of the cyanogen bromide derived fragpient CBSpV] extends from position 408-571, 
The N-terminal protruding ends of the a  i (TV) chains (positions 291-407) of CD3[IV] 'are non-triple-helical. 
The cysteine residues involved in intramolecular disulphide bonds are located in two non-triple-helical areas 
numbered I (positions 449-456) and II (positions 486-496). The two areas containing the N- and C-terminal 
recognition sites of o2pi integrin, as well as the essential residues of the a ip i  integrin recognition site are 
shaded: Dots over P and K in Y positions indicate hydroxyproline and hydroxylysine, respectively. Position 
numbers of the aligned ai(IV) and a 2(TV) chains do not coincide with the residue numbers of the single 
chains (Brazel et al., 1988).
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Figure 3.2 Schematic representation of the collagen IV preparations used in this study
(adapted from Eble et al., 1996)
Collagen IV monomers were isolated under reducing conditions from the murine EHS tumour. In preparation 
A the intramolecular disulphide bonds of the CB3[IV] region and the N-terminal telopeptides (7S domain) 
are split by reduction, whereas the interchain disulphide bonds in the NCI domains remain intact. In 
preparation B the three a(IV) chains are connected by disulphide bonds in the NCI domains, the CB3[IV] 
region, and possibly also in the area o f the telopeptides.
Collagen IV dimers were isolated from human placenta after treatment with bacterial collagenase, which 
removed the lOO-nm-long N-terminal region of the triple helical domain. The intramolecular disulphide 
bonds o f the CB3[IV] region are intact and the C-terminal end o f the triple-helical domain is sealed by the 
hexameric NCI complex.
Tetrameric collagen IV was isolated from human placenta by treatment with porcine pepsin, which removed 
the NCI globular domain o f each molecule. Tetramer formation is a result o f interactions between the four 
molecules in the area o f the telopeptides.
N-terminal telopeptides and the CB3[IV] region with intact intramolecular disulphide bonds are shaded.
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Figure 3.3 Preparation A collagen IV monomers treated with GLA at 30®C and 37®C
Monomers were incubated with or without added GLA for 20 hours at 30°C or 37®C. Cleavage products 
were separated by SDS-PAGE under reducing conditions, and analysed by silver stain.
A. Preparation A incubated at 30®C, followed by 6% SDS-PAGE. Monomers incubated alone (lane 2), or in
the presence of GLA (lane 3). Control monomers, unincubated (lane 1). The a ] (IV) and a 2(IV) chains are 
marked with black arrows. The blue arrows indicate the 3/4 and 1/4 fragments generated by GLA cleavage 
(lane 3).
B. Preparation A incubated at 37°C, followed by 8% SDS-PAGE. Monomers incubated alone (lane 2), or 
in the presence of GLA (lane 3). Control monomers, unincubated (lane 1).
The arrowheads indicate the boundary between the stacking gel and the separating gel. The migration
positions of type I collagen (3 and a  chains and molecular mass markers are indicated on the right.
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Figure 3.4 Preparation B collagen IV monomers treated with GLA at 37®C
Monomers were incubated with or without added GLA for 20 hours at 37®C. Cleavage products were 
separated by 8% SDS-PAGE under reducing conditions, and analysed by silver stain. Preparation B 
incubated alone (lane 3), or in the presence of GLA (lane 4). Unincubated preparation B (lane 2), 
unincubated preparation A (lane 1). The migration positions o f type I collagen (3 and a  chains and molecular 
mass markers are indicated on the right.
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Figure 3.5 Collagen IV monomers (preparations A and B) treated with gelatinases at 30®C. Separation 
of fragments by non-reducing SDS-PAGE
Monomers were incubated with or without added GLA or GLB for 20 hours at 30®C. Cleavage products 
were separated by 6% SDS-PAGE under non-reducing conditions, and analysed by silver stain.
Preparation A incubated alone (lane 2); or in the presence o f GLA (lane 3), or GLB (lane 4). Preparation A, 
unincubated (lane 1). Preparation B incubated alone (lane 6); or in the presence o f GLA (lane 7), or GLB 
(lane 8). Preparation B, unincubated (lane 5).
The arrowhead indicates the boundary between the stacking gel and the separating gel. The migration 
positions o f  type I collagen p and a  chains and molecular mass markers are indicated on the right.
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Figure 3.6 Collagen IV monomers (preparations A and B) treated with gelatinases at 37®C. 
Separation of fragments by non-reducing SDS-PAGE
Monomers were incubated with or without added GLA or GLB for 20 hours at 37®C. Cleavage products 
were separated by 6% SDS-PAGE under non-reducing conditions, and analysed by silver stain.
Preparation A incubated alone (lane 2); or in the presence o f GLA (lane 3), or GLB (lane 4). Preparation A, 
unincubated (lane 1). Preparation B incubated alone (lane 6); or in the presence of GLA (lane 7), or GLB 
(lane 8). Preparation B, unincubated (lane 5).
The arrowhead indicates the boundary between the stacking gel and the separating gel. The migration 
positions o f type I collagen P and a chains and molecular mass markers are indicated on the right.
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Figure 3.7 Treatment of collagen IV monomers purchased from Sigma with gelatinases at 30®C
Monomers were incubated with or without GLA or GLB for 20 hours at 30®C. Cleavage products were 
separated by 6% SDS-PAGE under reducing conditions, and analysed by silver stain. Monomers incubated 
alone (lane 2); or in the presence o f GLA (lane 3), or GLB (lane 4). Unincubated monomers (lane 1).
The migration positions o f type I collagen p and a  chains and molecular mass markers are indicated on the 
right.
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Figure 3.8 Treatment of collagen IV monomers purchased from Collaborative Biomedical Products 
with gelatinases at 37®C
Monomers were incubated with or without GLA or GLB for 20 hours at 37®C. Cleavage products were 
separated by 6% SDS-PAGE under reducing conditions, and analysed by silver stain. Monomers incubated 
alone (lane 2); or in the presence o f GLA (lane 3), or GLB (lane 4). Unincubated monomers (lane 1).
The migration positions of type I collagen p and a  chains and molecular mass markers are indicated on the 
right.
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Figure 3.9 HT1080 adhésion to collagen IV is a2 p i integrin mediated
HT1080 cells were incubated for 30 minutes alone, or in the presence o f 10 pg/ml mouse anti-a2pi integrin
antibody Gi9. Cells were then seeded onto a substrate o f collagen IV dimers and incubated at 37®C for 35 
minutes. Adherent cells were stained with methylene blue and the absorbance o f the wells was read at 630 
nm. Values are the mean +/- standard deviation o f triplicate wells.
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Figure 3.10 Attachment of HT1080 and RuGLi cells to immobilised preparation A and preparation B 
monomers after treatment with GLA at 30®C and 37®C
Collagen IV monomers were incubated with or without GLA for 20 hours at 30®C or 37®C. Culture plates
were coated with collagen IV overnight at 4®C. Cells were allowed to attach to collagen IV substrates for 35
minutes at 37®C. Adherent cells were stained with methylene blue and the absorbance of the wells read at 
630 nm. Attachment of cells is expressed as a percentage o f the control (monomers incubated in the absence 
of GLA). HT 1080 cells are represented by the grey bars and RuGLi cells by the black bars. Values are the 
mean +/- standard deviation for a representative experiment.
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Figure 3.11 Collagen IV dimers treated with GLA at 37®C
Dimers were incubated with or without added GLA for 20 hours at 37®C. Cleavage products were separated 
by SDS-PAGE under reducing conditions, and analysed by silver stain. Dimers incubated alone (lane 3), or 
in the presence o f GLA (lane 4). Control dimers, unincubated (lane 2) and monomers (preparation A, lane 1). 
The migration positions o f type I collagen p and a  chains and molecular mass markers are indicated on the 
right.
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Figure 3.12 Attachment of HT1080 and RuGLi cells to immobilised collagen IV dimers after treatment 
with GLA at 37»C
Collagen IV dimers were incubated with or without GLA for 20 hours at 37®C. Culture plates were coated
with collagen IV dimers overnight at 4®C. Cells were allowed to attach to the dimers for 35 minutes at 37®C. 
Adherent cells were stained with methylene blue and the absorbance of the wells read at 630 nm. Attachment 
of cells is expressed as a percentage o f the control (dimers incubated in the absence of GLA). HT 1080 cells 
are represented by the grey bars and RuGLi cells by the black bars. Values are the mean +/- standard 
deviation for a representative experiment.
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Figure 3.13 Collagen IV tetramers treated with MMPs at 37®C
Tetramers were incubated with or without added GLA, SL-I or CL-3 for 20 hours at 37°C. Cleavage 
products were separated by 6%SDS-PAGE under reducing conditions, and analysed by silver stain. 
Tetramers incubated alone (lane 2,3); or in the presence o f GLA (lane 4,5), SL-1 (lane 6,7), or CL-3 (lane
8,9). Control tetramers, unincubated (lane 1,2). The migration positions o f type I collagen p and a  chains 
and molecular mass markers are indicated on the right.
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Figure 3.14 Attachment of HT1080 and RuGLi cells to immobilised collagen IV tetramers after 
treatment with MMPs at 37®C
Collagen IV tetramers were incubated with or without GLA, SL-1, CL-3 for 20 hours at 37®C. Culture plates
were coated with collagen IV tetramers overnight at 4®C. Cells were allowed to attach to collagen IV
tetramer substrates for 35 minutes at 37®C. Adherent cells were stained with methylene blue and the 
absorbance of the wells read at 630 nm. Attachment o f cells is expressed as a percentage o f the control 
(tetramers incubated in the absence of MMPs). HT 1080 cells are represented by the grey bars and RuGLi 
cells by the black bars. Values are the mean +/- standard deviation for a representative experiment.
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Figure 3.15 Gelatinase A cleavage sites within the CB3[IV] region of human collagen IV
(adapted from Eble et al., 1996)
Many o f  the features o f this figure were described in the figure legend fo r Fig. 3.1. Shown below is additional 
information regarding gelatinase A cleavage sites in the triple helical region o f  collagen IV.
The largest trypsin derived fragment o f CB3[IV], FI, comprises almost the entire triple helical region 
(positions 408-533) of the CB3[1V], depicted by horizontal arrows. Arrows with blue heads designate 
cleavage sites o f gelatinase A within the denatured a(lV) chains. Arrows with black heads designate peptide 
bonds cleaved by gelatinase A within the triple-helical FI fragment. Arrowheads show the cleavage sites of 
bacterial collagenases determined after incubation o f murine preparation A with purified collagenase matched 
to the human sequences. Integrin recognition sites are shaded.
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Chapter 4 Extracellular matrix regulation o f gelatinase A activation
4,1 Introduction
Despite evidence to suggest that gelatinases are important in processes of cell migration 
and invasion, the precise role of these enzymes has yet to be defined. It may be that these 
enzymes destroy existing adhesion sites (as discussed in Chapter 3) or expose cryptic 
adhesion sites, or promote the release of matrix fragments, matrix-bound growth factors 
and cytokines (reviewed by Werb, 1997). GLA may be particularly important in 
pericellular degradation events, by virtue of its activation at the cell surface.
Processes governing the cell surface activation of proGLA have been a focus o f studies in 
our group. Most o f these studies have required the use of agents such as concanavalin A or 
phorbol esters to induce activation. There is little known of the factors that influence GLA 
activation in vivo, however, there is increasing evidence to suggest that signals from the 
ECM may influence both GLA expression and activation. Increases in GLA activation 
have been reported following culture of several cell types on or within collagen type I gels 
(Azzam and Thompson, 1992; Gilles et al., 1997; Haas et al., 1998). The increased GLA 
activation in collagen gels probably reflects the level of mechanical stress, as cells in 
stressed collagen lattices show a marked reduction in GLA activation in comparison with 
mechanically relaxed lattices (Tomasek et al., 1997). These authors showed that activation 
of GLA may be linked to changes in the actin cytoskeleton, for the treatment o f fibroblasts 
with cytochalasin D, (which disrupts stress fibres) caused an increase in GLA activation. 
Other matrix components also affect GLA activation. Ligation of the vitronectin receptor 
is reported to stimulate GLA expression by melanoma cells and to stimulate invasion of 
these cells through Matrigel (Seftor et al., 1992). Recently, soluble vitronectin has been 
shown to stimulate increases in GLA and TIMP-2 secretion by B16-F1 and B16-F10 
melanoma cells (Bafetti et al., 1998).
The aim of this thesis was to further investigate ECM molecules that regulate the cellular 
activation o f GLA. The fibrosarcoma cell line HT 1080 was chosen as a model, as this cell 
line was used previously for studies of collagen I induced activation of GLA (Azzam and
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Thompson, 1992). In this chapter the ECM molecules fibronectin and laminin-1 were 
compared in GLA activation studies. The data collected showed that culture of HT 1080 
cells on fibronectin up-regulated processing of proGLA to the active form. Furthermore, 
activation was induced by firagments of fibronectin encompassing the RGD integrin 
binding site. In marked contrast, culture of HT1080 cells on laminin-1 did not promote 
GLA processing. Anti-integrin antibodies were used in this study to deteraiine whether 
integrin receptors binding fibronectin can elicit signals leading to proGLA activation.
4,2 Results
4,2,1 A comparison o f the effects o f fibronectin and laminin-1 substrates on HT1080 
ejq>ression and activation of gelatinases
HT1080 cells cultured on plastic constitutively express GLA and GLB as detected by 
gelatin zymography (Fig. 4.1). Cells cultured on laminin-1 expressed mainly latent, 
proGLA, molecular mass 66 kDa (Fig. 4.1). In contrast, cells cultured on fibronectin 
displayed an apparent increase in processing of proGLA fi"om the 66 kDa latent form, via 
an intermediate at 62 kDa, to the fully active 59 kDa protein. This increase in GLA 
processing induced by fibronectin was similar to the levels of processing induced by PMA 
(Fig. 4.1), a known stimulator of GLA activation for these cells (Foda et al., 1996; Lohi et 
al., 1996). By phase contrast microscopy, it was apparent that GLA activation was not 
linked to changes in cell sh^e, for the cells spread well on fibronectin and laminin-1, but 
rounded up when treated with PMA.
To confirm the increases in GLA processing observed using zymography, secreted GLA 
was biosynthetically labelled with p^SJ-methionine. Labelled GLA was then 
immunoprecipitated firom the conditioned medium and the precipitates analysed by SDS- 
PAGE and fluorography. Time course studies indicated that levels of fully processed GLA 
were highest after 28 hours in culture (Fig. 4.2). Several attempts were made to compare 
GLA processing by HT1080 cells cultured on fibronectin or lam inin-1 using this 
technique. However the levels of GLA synthesised proved to be at the limit of detection. 
Although processing of GLA appeared greater when cells were cultured on fibronectin in
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comparison with laminin-1, the quality of the data was poor (not shown) and so 
zymography was used routinely to monitor GLA processing.
The purification of fibronectin firom plasma involves gelatin-Sepharose chromatography, 
which results in the copurification of plasma gelatinases. Analysis of the fibronectin 
preparation by zymogram (developed overnight at 37°C) showed low levels of 
contaminating gelatinases (data not shown). This raised the possibility that the increase in 
GLA processing observed when cells were cultured on fibronectin was due to the addition 
of small amounts of exogenous active GLA, associated with the fibronectin substrate. A 
fibronectin preparation with the contaminating gelatinases removed was kindly provided 
by A. Messent (Strangeways Research Laboratory, Cambridge, UK) who used a zinc 
iminodiacetic acid Sepharose column to separate out the gelatinases (d'Ortho et al., 1997). 
This purified fibronectin also promoted increases in GLA processing, with levels of active 
GLA apparently identical to that induced by unpurified fibronectin (data not shown).
GLB secretion was up-regulated by PMA treatment (Fig. 4.1), however, neither fibronectin 
nor laminin-1 substrates affected GLB expression. Activated GLB was not detected in 
this system; activation of GLB is known to proceed via different mechanisms to GLA 
(Murphy et al., 1992c).
When laminin-1 and fibronectin were added in solution to HT1080 cells cultured on 
plastic, no increases in GLA processing were noted in comparison with the plastic control 
(Fig. 4.3). Reich et al. (1995) reported that soluble laminin added to HT1080 cultures for 
6 hours increased GLA mRNA and protein expression, but no comment was made as to 
whether GLA activation was affected. In the current study, soluble laminin-1 added to 
cultures of HT1080 cells for 24 or 48 hours did not appear to alter GLA protein 
expression, or GLA activation.
Studies have shown that at high concentrations GLA self-activates, in a process that is 
concentration dependent and is enhanced by the presence of heparin (Crabbe et al., 1993).
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One way in which inunobihsed fibronectin might induce GLA processing is by binding 
GLA, thereby increasing pericellular concentration of the enzyme. Solid phase studies 
have demonstrated the binding of a recombinant C-terminal domain fi-agment of GLA to 
fibronectin (Wallon and Overall, 1997). In the current study, the binding of full length 
pro- and active GLA to fibronectin was measured using the ELISA method of Allan et al. 
(1995). GLA bound to collagen type I as described (Allan et al., 1995), but binding of pro- 
or active GLA to fibronectin was not significant (Fig. 4.4). Therefore, it was considered 
unlikely that pericellular fibronectin locates GLA to the cell surface.
4,2,2 Fibronectin fragments from the CCBD promote proGLA activation by HT1080 
cells
To identify whether specific regions of fibronectin have the potential to affect GLA 
activation, defined peptide firagments of fibronectin were coated to culture plastic. 
HT1080 cells were cultured on the 120 kDa fi-agment comprising the fibronectin type m  
repeats 2-11 (Fn III 2-11) of the central cell binding domain (CCBD; Fig. 4.5). This 
fi-agment supported HT1080 cell adhesion and spreading. Analysis of the conditioned 
media by zymography showed that GLA was processed to the fully active form, in contrast 
to cells cultured on laminin-1 (Fig. 4.6). A second fragment of 110 kDa, which lacked the 
alternatively spliced ED-B domain (Fig. 4.5) also induced GLA activation (data not 
shown), indicating that regions in the CCBD other than the ED-B domain effect changes in 
GLA activation.
It is interesting to note that the effect of the 120 kDa fi-agment of fibronectin on GLA 
activation was equivalent to that observed for full length fibronectin (Fig. 4.6). Werb et al. 
(1989) reported that rabbit synovial fibroblasts respond to the 120 kDa fi-agment by up- 
regulating the synthesis of CL-1 SL-1 and GLB, but do not respond to full length 
fibronectin. A later study by the same group (Huhtala et al., 1995) demonstrated that the 
reason full length fibronectin did not signal MMP synthesis was due to additional 
interactions between a4pi integrins and the alternatively spliced CS-1 region of 
fibronectin (Fig. 4.5). They showed that a4pi integrin/CS-1 interactions signalled a
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dowQ-regulation in MMP expression, opposing the signals generated in response to a5pi 
integrin/CCBD binding (Huhtala et al., 1995). In view of this report, it was considered 
possible that HT1080 cells were not receiving information transduced by 
a4pi integrin/CS-1 interactions. FACS analysis of HT1080 cells with an anti-a4 integrin 
antibody (HP2/1) showed that whilst these cells expressed detectable levels of the a4 
subunit (Fig. 4.7), levels were less than that expressed by the human myeloid leukaemic 
cell line HL60, which is considered to express relatively low levels of the a4 subunit 
(Hemler et al., 1987). The antibody HP2/1 has been shown to inhibit a4 subunit mediated 
adhesion of osteosarcoma cell lines to VCAM-1 (Mattila et al., 1992). In the current study 
this antibody failed to inhibit HT1080 adhesion to fibronectin (Fig. 4.8), whereas an 
antibody to the a5 subunit (mAb 16) completely inhibited HT1080 cell adhesion to 
fibronectin (Fig. 4.8). The latter observation that HT1080 adhesion to fibronectin is 
mediated by the a5pi integrin is in agreement with the studies by Yamada et al. (1990). 
From this data it was considered unlikely that interactions between HT1080 cells and the 
CS-1 region of fibronectin occur.
To further identify regions in the CCBD that may be important in the processing of GLA, 
HTl080 cells were cultured on the fibronectin fi-agment Fn III 6-10 (Fig. 4.5), which 
comprises the RGD sequence, and subregions in Fn III 8 and 9 that act synergistically with 
the RGD sequence for full adhesion activity (Danen et al., 1995). Unfortunately, cell 
adhesion and spreading on this fragment 6-10 was poor, and the reason for this was 
unclear. It is possible that other regions in the 120 kDa fi-agment of fibronectin are vital 
for HTl080 cell adhesion and spreading, and also possible that Fn HI 6-10 adsorption to 
plastic was poor. It was interesting to note, however, that despite the lack of cell adhesion 
and spreading, the activation of GLA by cells cultured on this fragment appeared greater 
than activation by cells cultured on a laminin-1 (Fig. 4.9).
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4,2,3 Antibodies to the aS and p i integrin subunits promote proGlui activation by 
HT1080 cells
To assess the importance of CCBD integrin receptors in signalling GLA activation, 
HTl 080 cells were cultured directly on a substrate of anti-integrin antibodies. As HTl 080 
cell adhesion to fibronectin is aSpi mediated, monoclonal antibodies to the a5-integrin 
subunit (mAb 16 and mAb 11) and pi-integrin subunit (mAb 13) were chosen for this 
study. HTl080 cells spread well on a mAh 16 substrate, and GLA processing was up- 
regulated, with a processing profile comparable to cells cultured on fibronectin (Fig. 4.10). 
Interestingly, mAb 11 substrate failed to promote GLA activation (Fig. 4.10). Both mAh 
16 and mAh 11 have been shown to stimulate integrin receptor clustering, but mAb 16 (in 
contrast to mAb 11) also mimics the action of the fibronectin ligand (Miyamoto et al., 
1995b). Fibronectin receptor occupancy would therefore appear to be important in the 
signalling of GLA activation by HTl 080 cells. Consistent with this hypothesis, mAh 13 to 
the pi integrin subunit also promoted GLA activation (Fig. 4.10); this antibody also 
mimics receptor occupancy (Chen et al., 1995).
HTl080 cells adhere to laminin-1 via a6pl integrin (von der Mark et al., 1991; confirmed 
in our laboratory by Dr J. Gavrilovic). An antibody to the a6 subunit (GoH3; Sonnenberg 
et al., 1988) supported cell adhesion and spreading, but failed to promote the processing of 
GLA to the levels seen when fibronectin or mAb 16 were used as a substrate (Fig. 4.10). 
The GLA processing profile on a GoH3 substrate was similar to that observed for a 
laminin-1 substrate (Fig. 4.10), suggesting that the a6 integrin subunit is unlikely to be 
involved in signalling GLA activation.
The combined data firom the CCBD firaigment study and the anti-integrin antibody study 
suggest that a5pl integrin receptor occupancy signals GLA activation in HTl080 cells. It 
is presumed that mAh 11 failed to signal GLA activation because this antibody does not 
mimic the action of the fibronectin ligand. It follows that the addition of a fibronectin 
ligand to cells cultured on mAb 11 should restore signals to increase GLA activation. To 
test this hypothesis, soluble RGD peptides were added to HTl080 cells cultured on mAb
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11. The addition of GRGDdSP peptide (based on the fibronectin sequence) to cells 
cultured on mAb 11 failed to restore GLA activation to the levels observed for mAb 16 or 
fibronectin substrates (Fig. 4.11). Using this approach, larger peptide firagments of 
fibronectin could have been tested, for it is well documented that soluble RGD peptides do 
not always mimic the action of ECM ligands. However, the stocks of mAh 11 available 
did not permit such studies.
4,3 Discussion
Fibronectin matrices influence cellular functions including adhesion, migration, and 
differentiation via interactions with cell surface integrin receptors. Following tissue injury, 
fibronectin is expressed locally and deposited in the provisional matrix where it forms a 
conduit for the inward migration of cells involved in early wound repair (Greiling and 
Clark 1997). Fibronectin is also re-expressed in tumour tissues, and several peptide and 
antibody inhibitors of fibronectin/integrin function effectively inhibit metastasis (Akiyama 
et al., 1995).
This chapter demonstrates that fibronectin up-regulates the activation of GLA by HTl 080 
fibrosarcoma cells, and that fibronectin induces a change in the levels of processed GLA 
which is similar to that induced by phorbol ester. In comparison, the processing of GLA 
by cells on laminin-1 appeared to be quite low. Both fibronectin and laminin-1 supported 
cell spreading, which suggests that changes in the level of GLA activation were 
independent of major changes in cell shape.
Steffensen et al. (1995) showed by ELISA studies that the fibronectin type Il-like modules 
of GLA bind fibronectin. Unfortunately, the interaction of full-length GLA with 
fibronectin was not addressed in this report. We hypothesised that binding of GLA to cell 
surface-bound fibronectin could potentially increase GLA activation, by providing a pool 
of GLA at the cell surface for activation by MTl-MMP. Hence the binding of pro- and 
active recombinant GLA to fibronectin was assessed by ELISA studies, but no interaction 
was detected. Subsequent to the completion of practical work for this thesis, a very
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interesting report was published by Steffensen et al. (1998), demonstrating interaction of 
the GLA fibronectin type Il-like modules with cell surface-bound collagen I. These 
interactions promoted proGLA binding to the cell surface, but contrary to our original 
hypothesis, the pool of proGLA bound to cell surface collagen proved less likely to be 
activated than GLA bound to MTl-MMP via TIMP-2.
Several reports have demonstrated that adsorbing fibronectin to a solid surface causes the 
molecule to adopt an unfolded and extended shape (Fukai et al., 1995; Ugarova et al., 
1995). This exposes sites important for cellular interaction, including both the RGD 
sequence and the CS-1 peptide region. In the current study, soluble fibronectin added to 
the culture medium had no effect on GLA activation, indicating that exposure of specific 
sites was required for GLA activation. This prompted a closer examination of specific 
regions of fibronectin in these studies.
The 120 kDa fi-agment of fibronectin, comprising most of the CCBD region, induced a 
level of GLA processing comparable to levels induced by full length fibronectin. This 
contrasted with the study by Werb ct al. (1989) who demonstrated induction of MMP 
synthesis (CL-1, SL-1, GLB) by rabbit synovial fibroblasts in response to the 120 kDa 
fi-agment, but not full length fibronectin. Results fix>m the current study differed on 
several points fix)m the study by Werb et al. Firstly, HTl080 synthesis of GLB did not 
appear to be induced by fibronectin substrates and secondly, no activation of rabbit 
synovial fibroblast GLA was noted when these cells were cultured on fibronectin or 
fibronectin fi-agments (Werb et al., 1989). The differing responses of the two cell types to 
fibronectin may reflect different integrin expression patterns. Rabbit synovial fibroblasts 
interact with fibronectin via a5pi and a4pl integrins (Huhtala et al., 1995), whereas the 
HT1080 cells used in this study expressed only low levels of a4pl integrin and adhered to 
fibronectin solely via a5pi integrin. It was considered unlikely that the CS-1 region of 
fibronectin affects GLA activation by HTl080 cells and so attention was focussed on other 
regions of the fibronectin molecule.
99
Smaller fragments of the CCBD, encompassing the RGD integrin recognition site were 
tested. Problems were encountered with impaired cell adhesion and spreading on 
fragments such as Fn III 6-10, possibly as a result of poor adsorption of these molecules to 
plastic (Dr K. Yamada, personal communication). Interestingly, despite a low level of 
adhesion to Fn HI 6-10, the processing of GLA indicated that this molecule contained 
regions capable of promoting GLA processing by HT1080 cells. A second Fn HI 6-10 
fragment was available for these studies, in which the pentapeptide sequence in Fn HI 9 
(PHSRN), that synergistically enhances the cell adhesion promoting activity of the RGD in 
FN IH 10, was mutated to an inactive SPSDN (Fn HI 6-10 SPSDN; Danen et al., 1995). It 
was hoped that this fragment would further define whether the synergy site is necessary for 
signalling GLA activation, but HTl080 cells failed to attach to this fi-agment in adhesion 
studies (data not shown).
To circumvent the problems encountered working with small peptide firagments of 
fibronectin, integrin receptors were perturbed directly by culturing the cells on a substrate 
of anti-integrin antibodies. Previous studies have shown that anti-integrin antibodies 
support cell adhesion, cause integrin receptor clustering, and in some cases mimic the 
action of the ligand, inducing transmembrane accumulation of signal transduction 
molecules at the cell surface (Miyamoto et al., 1995b). HTl080 cells spread well on 
antibodies to the a5, a6 and pi integrin subunits (mAb 16, GoH3 and mAbl3, 
respectively). Adhesion to mAh 16 and mAh 13 promoted GLA processing, whereas 
adhesion to GoH3 (anti-a6) did not, consistent with induction of GLA activation by 
fibronectin substrates but not laminin-1. Further information regarding integrin signalling 
of GLA activation was gained from a comparison of two anti-a5 integrin antibodies. mAb 
16 and mAb 11 to the a5 integrin subunit both induce integrin receptor clustering, but 
mAb 16 additionally mimics the action of the fibronectin ligand (Miyamoto et al., 1995b). 
The lack of GLA activation on a mAh 11 substrate in comparison with mAh 16 indicated 
the need for fibronectin receptor occupancy in signalling GLA activation by HTl080 cells. 
Miyamoto et al. (1995b) described an interesting study in which mAh 11 and mAh 16 
coated latex beads were added to foreskin fibroblasts in culture. mAb 16 caused integrin
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receptor clustering and the aggregation of actin associated cytoskeletal proteins, whereas 
mAh 11 promoted only receptor clustering. When a soluble RGD peptide was added to 
the mAh 11 cultures, an aggregation of six actin associated cytoskeletal proteins was 
observed, implying that fibronectin receptor occupancy was achieved. Although RGD 
peptides added to HTl 080 cells cultured on plastic did not induce GLA activation (data 
not shown), it was predicted that addition of the peptide GRGDdSP to cells cultured on 
mAbl 1 would restore GLA activation. However this was not observed. It is possible that 
the RGD peptide chosen did not have sufficient secondary structure to mimic fibronectin 
action, and that larger CCBD firagments were needed (Dr K. Yamada, personal 
communication). It is also possible that the approach of coating mAh 11 to latex beads is a 
more successful technique for these studies. Unfortunately there was not sufficient mAh 
11 to pursue these studies.
Several other reports have described the regulation of gelatinase expression in response to 
treatment with anti-integrin antibodies (Seftor et al., 1992; Laijava et al., 1993; Seftor et 
al., 1993). In a study with human gingival kératinocytes, GLB expression was up- 
regulated by the addition of soluble anti pi antibody (mAb 13) and an anti-a3 antibody, 
but not by anti-a5 or a2 integrin antibodies (Laijava et al., 1993). No differences in the 
expression of GLA were observed in this study. Kubota et al. (1997) demonstrated that 
soluble anti-a2 and anti-a3 integrin antibodies induced proGLA secretion and activation 
by human rhabdomyosarcoma cells. Studies with two glioblastoma cell lines showed that 
GLA expression was increased by treatment with anti-a3pi or anti-a5pl integrin 
antibodies (Chintala et al., 1996). Clearly, increases in GLA expression and activation 
may be signalled by several of the integrin receptors and the response to individual 
integrins is cell type specific. In our laboratory, human foreskin fibroblasts (HFF) are 
commonly used to investigate GLA activation systems, and so a comparison was made 
between HT1080 cells and HFF. Although HFF express aSpl integrin, neither full length 
fibronectin nor the 120 kDa fi-agment of fibronectin induced GLA activation (data not 
shown). This diilerential response may indicate diverging intracellular signalling
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pathways following integrin ligation in these two cell types and further work is needed to 
elucidate the mechanisms involved.
As the experiments described in this chapter were conducted over 24-48 hours, there is the 
possibility that fibronectin induces the expression of an endogenous cytokine or growth 
factor, that in turn signals changes to GLA activation. Preliminary experiments indicated 
that the protein synthesis inhibitor cycloheximide inhibits fibronectin induced GLA 
activation, implying that protein synthesis is required (data not shown). It has been 
reported that several soluble fibronectin firagments induce SL-1 expression by 
chondrocytes in cartilage explant culture and that this involves an IL-1 autocrine loop 
(Homandberg et al., 1997). Furthermore, IL-1 has been shown to induce GLA activation 
by smooth muscle cells in culture (Galis et al., 1994). IL-1 synergises with signals via the 
fibronectin receptor, as substrate bound fibronectin is permissive for IL-1 induced up- 
regulation of IL-6 mRNA by fibroblasts (Ostberg et al., 1995). In an extensive study 
published recently, Kheradmand et al (1998) showed that soluble ligands for the 
fibronectin receptor induce CL-1 expression by rabbit synovial fibroblasts via the GTP- 
binding protein Racl. Signalling via Racl was accompanied by cell rounding and induced 
the expression of IL-1, which was in turn responsible for the induction of CL-1 expression. 
Future studies should investigate whether an IL-1 autocrine loop is involved in fibronectin 
up-regulation of GLA activation. De novo synthesis of growth factors should also be 
considered. Reports have shown that growth factors synergise with extracellular 
matrix/integrin mediated signalling pathways (Schwartz et al., 1995). Ligand-mediated 
integrin clustering leads to the accumulation of growth factor receptors and synergy 
between growth factors and integrins leads to a marked increase in growth factor receptor 
tyrosine phosphorylation (Plopper et al., 1995; Miyamoto et al., 1996). pi integrin 
receptor occupancy results in the enhancement of EGF and PDGF growth factor receptor 
tyrosine phosphorylation, which in turn leads to the transient activation of MAP kinases 
(Miyamoto et al., 1996). Others have shown that the fibronectin receptor synergises with 
PDGF to promote inositol lipid metabolism (McNamee et al., 1993). Clearly, the 
possibility that a cytokine or growth factor is involved in the fibronectin up-regulation of
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GLA activation should be addressed in future studies. A discussion of the signalling 
mechanisms involved following fibronectin receptor ligation is included in Chapter 7.
In summary, HT 1080 cells cultured on fibronectin activated endogenous GLA, to a level 
comparable with that elicited by treatment with phorbol ester. In contrast, cells cultured 
on laminin-1 secreted mainly proGLA. Work with a 120 kDa fragment of fibronectin 
encompassing the CCBD indicated that this region of fibronectin alone is sufficient to 
signal the up-regulation of GLA activation. Studies with anti-integrin antibodies 
implicated the a 5 p i fibronectin receptor as a mediator o f GLA activation in HTl 080 cells 
and suggested that a 5 p l integrin receptor occupancy is essential to signal activation. The 
following chapter describes a study of the effect of fibronectin on other molecules 
involved in the GLA activation cascade.
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Figure 4.1 Increased processing of proGLA to the active form by H Tl080 cells cultured on fibronectin 
in comparison with laminin-1
HT 1080 cells were cultured under serum free conditions on substrates o f fibronectin or laminin-1, or on 
culture plastic with or without PMA for 48 hours. Samples of conditioned media were analysed for gelatin 
degrading activity by zymography. Cells cultured on fibronectin (lane 1), cells cultured on laminin-1 (lane 
2); cells cultured on plastic in the presence of PMA (lane 3) or in the absence of PMA (lane 4). Arrows 
indicate the electrophoretic mobility of recombinant pro-GLB and recombinant pro and active GLA. 
Molecular mass markers are indicated on the right.
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Figure 4.2 Biosynthetic labelling and immunoprécipitation of GLA secreted by HT1080 cells
H Tl080 cells were cultured under serum free conditions on a substrate o f fibronectin. Cells were
biosynthetically labelled with [^^S]-methionine and the conditioned media was immunoprecipitated with a 
polyclonal antibody to GLA. Immunoprecipitates were separated by SDS-PAGE and analysed by 
fluorography. Cells were labelled for 0-14 hours (lane 1), 14-28 hours (lane 2), 28-42 hours (lane 3) or 38-52 
hours (lane 4) after cell seeding.
Molecular mass markers are indicated on the right.
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Figure 4.3 Soluble fibronectin and laminin-1 do not affect proGLA processing by HT1080 cells
HT 1080 cells were cultured under serum free conditions on substrates o f fibronectin or laminin-1, or on 
culture plastic with or without soluble fibronectin (30 pg/well) or soluble laminin-1 (30 pg/well). Samples 
of conditioned media were analysed for gelatin degrading activity by zymography. Cells cultured on 
fibronectin (lane 1), cells cultured on laminin-1 (lane 2); cells cultured on plastic alone (lane 3) or in the 
presence of soluble fibronectin (lane 4) or soluble laminin-1 (lane 5). Molecular mass markers are indicated 
on the right.
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Figure 4.4 An ELISA study to determine whether MMP-2 binds to a substrate of fibronectin
Fibronectin or collagen type I were coated onto plastic wells at 100 pg/ml. GLA was added to the wells at
100 nM and incubated for 2 hours at 4®C. Bound enzyme was revealed using a polyclonal antibody to 
gelatinase A, followed by a horse-radish peroxidase conjugated second antibody and 3,3', 5,5'- 
tetramethylbenzidine substrate. Absorbance o f the wells was read at 450nm. ProGLA is represented by
grey bars and active GLA by black bars. Values are the mean +/- the standard deviation o f triplicate wells.
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Figure 4.6 Levels of proGLA processing by H T l080 cells cultured on the 120 kDa fragment of 
fibronectin are similar to the levels effected by full length fibronectin
HTl 080 cells were cultured under serum free conditions on substrates o f fibronectin, 120 kDa fibronectin or 
laminin-1 for 48 hours. Samples o f conditioned media were analysed for gelatin degrading activity by 
zymography. Cells cultured on fibronectin (lane 1), cells cultured on laminin-1 (lane 2) cells cultured on 120 
kDa fibronectin (lanes 3). Molecular mass markers are indicated on the right.
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Figure 4.8 HT1080 adhesion to fibronectin is aSpi integrin mediated
HT1080 cells were incubated for 30 minutes alone, or in the presence o f 10 pg/ml o f the following: rat anti- 
a5 integrin antibody mAb 16 (anti-a5); non-immune rat IgG control (NRJgG); mouse anti-a4 integrin 
antibody HP2/1 (anti-a4); or non-immune mouse IgG control (NMlgG). Cells were then seeded onto
fibronectin coated plastic and incubated at 37®C for 35 minutes. Adherent cells were fixed and stained with 
methylene blue and the absorbance o f the wells was read at 630 nm. Values are the mean +/- standard 
deviation o f triplicate wells.
111
m 2
kDa 
-  97
-  78
-  68 
I—  55
1 2 3
Figure 4.9 ProGLA processing by HT1080 cells cultured on the Fn III 6-10 fragment of fibronectin
HT1080 cells were cultured under serum free conditions on substrates of fibronectin, 120 kDa fibronectin, Fn 
III 6-10 or laminin-1 for 48 hours. The number of cells/well was determined at the end o f the incubation. 
Samples o f conditioned media were analysed for gelatin degrading activity by zymography. The volume of 
conditioned medium loaded per lane was adjusted to reflect the number o f cells/tissue culture well at the end 
of the culture period. Cells cultured on fibronectin (lanes 1-2), cells cultured on laminin-1 (lane 3-4) cells 
cultured on 120 kDa fibronectin (lanes 5-6). Molecular mass markers are indicated on the right.
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Figure 4.10 Processing of proGLA to the active form by HT1080 cells is up-regulated by culture of the 
cells on an antibodies to the a5 and p i integrin subunits
HT 1080 cells were cultured under serum free conditions for 48 hours on substrates of fibronectin, laminin-1, 
or on immobilised monoclonal antibodies to integrin subunits. Samples o f conditioned media were analysed 
for gelatin degrading activity by zymography. Cells cultured on fibronectin (lane 1 ), cells cultured on anti-a5 
antibody mAb 16 (lane 2), on anti-pi antibody mAb 13 (lane 3), on anti-a5 antibody mAb 11 (lane 4), on 
anti-a6 antibody GoH3 (lane 5). Cells cultured on laminin-1 (lane 6). Molecular mass markers are indicated 
on the right.
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Figure 4.11 Addition of RGD peptides to HT1080 cells cultured on the monoclonal anti-aS integrin 
antibody m Abll does not restore processing of proGLA to the levels effected by anti-a5 integrin 
antibody mAb 16
HT 1080 cells were cultured under serum free conditions for 48 hours on substrates o f fibronectin, laminin-1, 
or on immobilised monoclonal antibodies to integrin subunits. Soluble RGD peptides (200 pg/ml) were 
added to the culture media at the start o f incubation. Samples o f conditioned media were analysed for gelatin 
degrading activity by zymography. Cells cultured on fibronectin (lane 1), or on anti-a5 antibody mAb 16 
(lane 2). Cells cultured on anti-a5 antibody mAb 11 alone (lane 3), or in the presence of GRGDdSP (lane 4) 
or GRGESP (lane 5). Cells cultured on laminin-1 (lane 6). Molecular mass markers are indicated on the 
right.
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Chapter 5 Extracellular matrix regulation o f MTl-MMP processing
5.1 Introduction
The physiological mechanism by which proGLA is activated has been the subject of 
intense study by many laboratories. Evidence from early studies with transformed or 
concanavalin A treated cells implicated cell membrane-bound molecules in the activation 
process (Overall and Sodek, 1990; Ward et al., 1991b). Several laboratories demonstrated 
that proGLA activation was initiated by binding of GLA to the cell surface via its C- 
terminus (Murphy et al., 1992b; Strongin et al., 1993; Ward et al., 1994). Work was then 
directed at identifying the cell surface molecule(s) that bind the C-terminal domain of GLA 
and the enzyme responsible for activating surface-bound GLA.
The discovery of membrane-bound MT-MMPs (Sato et al., 1994; Takino et al., 1995; Will 
and Hinzmann, 1995; Puente et al., 1996) led to the hypothesis that MT-MMPs participate 
in the activation of proGLA. MTl-MMP is the best characterised, and is located at the 
surface o f activated cells (Sato et al., 1994; Strongin et al., 1995) where it may be 
associated with TIMP-2 (Strongin et al., 1995; Imai et al., 1996). ProGLA binds to TIMP- 
2 via its C-terminus, which has led to the hypothesis that M Tl-MMP and TIMP-2 form a 
'receptor' complex, that binds proGLA (Strongin et al., 1995; Imai et al., 1996; Butler et al., 
1998). Evidence for this trimolecular complex has been provided by cross-linking 
experiments (Strongin et al., 1995) and by incubation of proGLA and TIMP-2 with M Tl- 
MMP immobilised on agarose beads (Kinoshita et al., 1998). A model for GLA activation 
has been described in which proteolysis of GLA bound in the complex requires an adjacent 
M Tl-M M P molecule that is TIMP-2 free and therefore catalytically active (Butler et al, 
1998; Kinoshita et al., 1998; see Fig. 1.3).
In this chapter, the effects of fibronectin on HT1080 MTl-MMP and TIMP-2 expression 
were assessed. A new polyclonal antibody to MTl-MMP was characterised for these 
studies. By Western blot, this antibody recognised the 63 and 60 kDa forms of MTl-M M P 
commonly reported in the literature, but also detected a processed form of M Tl-M M P at
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45 kDa. This processed form of MTl-MMP was up-regulated when HT1080 cells were 
cultured on fibronectin, implying that fibronectin stimulates the action o f an (unknown) 
protease which cleaves MTl-MMP to a 45 kDa form. Attempts were made to identify this 
protease.
5.2 Results
5.2.1 Expression o f TlMP-2 protein by HT1080 cells cultured on fibronectin or 
laminin-1
The effect of culture substrate on HT 1080 TIMP-2 expression was investigated using 
several methods. Reverse zymography was used to measure secreted TIMP-2, however the 
levels detected were too low to allow an accurate comparison of the effects of fibronectin 
and laminin-1 substrates (data not shown). Newly synthesised TIMP-2 was radiolabelled 
with p^S]-methionine and immunoprecipitated with the sheep anti-TIMP-2 antibody H225 
(Ward et al., 1991a). This technique also did not prove sensitive enough to allow an 
accurate comparison (data not shown). TIMP-2 bound to GLA in the conditioned medium 
was concentrated by gelatin-Sepharose chromatography and analysed by Western blot 
using H225. The TIMP-2 was easily detected using this technique and no difference was 
noted in the levels of TIMP-2 secreted when cells were cultured on fibronectin or laminin- 
1 (Fig. 5.1 A). Cell lysates were then prepared and analysed by Western blot; no obvious 
differences in the levels of cell-associated TIMP-2 were noted between the substrates (Fig. 
5. IB).
5.2.2 MT-MMP expression by HT1080 cells 
5.2.2a Western blot
Western blot analysis was used to characterise the expression of MT-MMPs by HT 1080 
cells. To detect MTl-MMP, a polyclonal antibody raised in a sheep to GST-AMTl-MMP 
(N175) was affinity purified and characterised as described (d'Ortho et al., 1998; also 
detailed in Chapter 2). By Western blot, this antibody recognised recombinant M Tl-MMP 
(^502-559) recognising pro-enzyme at 60 kDa and major processed forms at approximately 
55 and 31 kDa (Fig. 5.2, lane 1), but did not cross react with MT2-MMP, GLA, GLB; CL -
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1, -2 and -3; SL -1 and -2; TIMPs -1, -2, -3 or GST (data not shown). N175 recognised 
wild-type MTl-MMP present in membranes prepared from HT1080 cells, detecting a 
major band at 60 kDa, a doublet at 63 kDa and a minor band at 45 kDa (Fig. 5.2, lane 2). 
This profile is very similar to that reported by Lohi et al. (1996), who described two 
polyclonal antibodies to MTl-MMP that detected the doublet at 63 kDa and bands at 60 
and 43 kDa in HT1080 cell lysates.
The monoclonal antibody to MT2-MMP detected the recombinant catalytic domain of 
MT2-MMP at 30 kDa, but did not detect MT2-MMP in HT1080 cell membranes (Fig. 5.2, 
lanes 3 and 4). Similarly, the monoclonal antibody to MT3-MMP failed to detect MT3- 
MMP in the HT1080 membranes, but reacted with a band of 66 kDa corresponding to 
recombinant proMT3-MMP (Fig. 5.2, lanes 5 and 6). For both MT2- and MT3-MMP the 
chemiluminescent detection reaction was allowed to develop to completion overnight, but 
no MT2- or MT3- protein was detected in HT1080 cell membranes (data not shown). To 
test for MT4-MMP expression, a new polyclonal antibody to MT4-MMP was used. This 
antibody (N33) was developed and characterised in our laboratory by Dr M. Butler. It 
recognises MT4-MMP, does not cross react with MTl-MMP, gelatinases, collagenases or 
TIMPs; but does cross react with SL-1 and MT3-MMP (Dr M. Butler, personal 
communication). N33 recognised the recombinant catalytic domain of MT4-MMP at 33 
kDa (Fig. 5.2, lane 7) and reacted with protein at 62 kDa in HT1080 cell lysates, as well as 
several bands between 30 and 45 kDa (Fig. 5.2, lane 8). The identity of the bands could 
not be confirmed as MT4-MMP however, as there was no recombinant MT4-MMP 
available for affinity purification of the antibody, and to date there is no cell type available 
in our laboratory that is known to express MT4-MMP.
5,2,2b Northern blot
Based on the data from Western analysis, HT1080 cells were tested for MTl-MMP and 
MT4-MMP mRNA expression. Cells were cultured on plastic for 24 hours prior to RNA 
preparation. Northern blots of the prepared total RNA were probed with a digoxygenin- 
labelled MTl-MMP riboprobe. A single band of MTl-MMP was detected (Fig. 5.3),
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consistent with the 4.5 kilobase transcript for HT1080 cells reported by Sato et al. (1994). 
Northern blots were probed with a digoxygenin-labelled MT4-MMP riboprobe, but MT4- 
MMP, if present, was below the level of detection (data not shown).
5,2,2c Intmunolocalisation
MTl-MMP: Immunolocalisation studies were used to determine the cellular distribution of 
MTl-MMP in HT1080 cells. To detect intracellular MTl-MMP, the cells were treated 
with the ionophore monensin, which prevents secretion and results in the intracellular 
accumulation of MMPs (Hembry et al., 1985). Cells were fixed and permeabilised after 3 
hours monensin treatment and incubated with N175. Weak perinuclear 
immunofluorescence was apparent (Fig. 5.4A). To study cell surface expression of MTl- 
MMP, cells cultured in the absence of monensin were fixed and stained with N175. In 
some experiments, cell surface staining of MTl-MMP was detected (Fig. 5.4B). Confocal 
microscopy was used to collect sections through the cells, and staining was seen to cover 
the entire cell surface (Fig. 5.5). However, over several experiments the results were 
variable, and often the level of MTl-MMP was below, or at the limits of detection.
MT4-MMP: Although Northern blot analyses failed to detect MT4-MMP mRNA in 
HT1080 cells, the Western blot analyses did suggest that the protein might be present. An 
attempt was made to immunolocalise MT4-MMP in these cells. Several antibodies were 
tested: two rabbit anti-peptide antibodies (anti-KLH-PEEP and anti KLH-RTLR); a rabbit 
polyclonal antibody to a C-terminal fi-agment of MT4-MMP; and the sheep polyclonal 
antibody N33. The two peptide antibodies stained the perinuclear region of monensin 
treated HT1080 cells very brightly and also gave bright cell surface staining, however, 
these antibodies failed to react to HT1080 lysate proteins on Western blot (data not 
shown). Both the rabbit polyclonal antibody to MT4-MMP and N33 failed to stain HT1080 
cell surfaces, and did not stain intracellularly (data not shown). It is possible that the 
peptide antibody staining was non-specific, and so no conclusion could be drawn regarding 
HT1080 expression of MT4-MMP prulein.
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In summary, the expression of MTl-MMP by HT1080 cells was verified by Northern and 
Western blot analyses, and by immunolocalisation. The presence of other MT-MMPs in 
HT1080 cells could not be confirmed. Therefore, further studies were designed to 
determine whether the ECM substrates fibronectin and laminin-1 regulate MTl-MMP 
expression.
5.2.3 Messenger RNA levels for MTl-MMP expressed by HT1080 cells are not altered 
by culture on fibronectin or laminin-1 substrates
Fibronectin and lam inin-1 were examined for their potential to regulate MTl-MMP 
expression at the mRNA level. RNA was prepared firom HT1080 cells cultured on 
fibronectin or lam inin-1 for 24 hours, and analysed by Northern Blot. No differences in 
the steady state levels of MTl-MMP mRNA were noted between the culture substrates 
(Fig. 5.6, lanes 2 and 3).
5.2.4 Immunolocalisation of MTl-MMP expressed by HT1080 cells cultured on 
fibronectin or laminin-1 substrates
HT1080 cells were cultured on fibronectin and lam inin-1 substrates and the cell surface 
expression of MTl-MMP protein was compared using the immunolocalisation techniques 
described above. Cell surface staining of MTl-MMP was low on both substrates, and did 
not photograph successfully (data not shown). However, it appeared that the levels of 
MTl-MMP expressed on the cell surface were sim ilar when the cells were cultured on 
either fibronectin or laminin-1.
5.2.5 Processing of MTl-MMP protein on fibronectin substrates
Western blot analysis was used to compare the total MTl-MMP protein levels present in 
HT1080 cells cultured on fibronectin or lam inin-1 Using the anti-MTl-MMP antibody 
N175, it was apparent that the levels of MTl-MMP protein were increased when the cells 
were cultured on fibronectin in comparison with lam inin-1 More specifically, the levels of 
the 45 kDa form were increased, whereas levels of the 63 kDa doublet and the 60 kDa band
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were unaffected by the different culture conditions (Fig. 5.7A). Scanning densitometry of 
the bands in Figure 5.7A  revealed that the overall MTl-MMP protein was 1.6 times greater 
when cells were cultured on fibronectin versus lam inin-1 substrates, and the levels of 45 
kDa MTl-MMP were 3 times greater. In subsequent experiments, the levels of the 45kDa 
form were up to 8 times greater on the fibronectin substrates (data not shown). PMA 
treatment also induced the expression of 45 kDa MTl-MMP (Fig. 5.7A, lane 3). 
Strikingly, where increases in the 45 kDa band were detected, there was a concomitant 
increase in the processing of GLA to the active form as detected by zymography (Fig. 
5.7B).
The remainder of this chapter describes a) studies to identify the protease(s) involved in 
MTl-MMP processing to 45 kDa and b) investigations to determine whether GLA 
activation and MTl-MMP processing to 45 kDa are interdependent events, or the result of 
separate effects of fibronectin.
S.2.6 Inhibition o f MTl-MMP processing to 45 kDa by MMP inhibitors
To investigate which protease(s) are involved in the processing of MTl-MMP to 45 kDa, 
HT1080 cells were cultured on fibronectin in the presence of protease inhibitors for 46 
hours prior to harvest. Inclusion of the hydroxamate inhibitor CT1746 at 1 pM abolished 
the 45 kDa band (Fig. 5.8A, lane 2). This inhibitor is a general metalloproteinase inhibitor 
when used at micromolar concentrations (Dr J. O'Connell, personal communication), thus 
indicating that a metalloproteinase is involved in the processing of MTl-MMP to 45 kDa. 
Exogenously added TIMP-2 also inhibited processing of MTl-MMP to 45 kDa, further 
defining the processing enzyme as an MMP (Fig. 5.8A, lane 3).
A zymogram of the conditioned media firom this experiment showed that the activation of 
GLA paralleled increases in the levels of the 45 kDa band, and was inhibited by CT1746 
and TIMP-2 (Fig. 5.8B, lanes 1-3). Based on this observation, it was considered possible 
that active GLA at the cell surface was involved in processing MTl-MMP to 45 kDa. 
However, MTl-MMP self processing to 45 kDa was also considered a possibility. Our
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laboratory has demonstrated that MTl-MMP activity is not susceptible to inhibition by 
TIMP-1 (Will et al., 1996), which distinguishes MTl-MMP from other MMPs (including 
GLA). Therefore, to indicate whether MTl-MMP self-processing was occuring, TIMP-1 
was included in the cultures. Even at high concentrations (150 nM), TIMP-1 was 
ineffective as an inhibitor of MTl-MMP processing to 45 kDa (Figure 5.8A, lane 4), 
implicating MTl-MMP self-processing to the 45 kDa form.
Notably, the result from this experiment was not clear-cut, for when the conditioned 
medium was examined by zymography it was apparent that TIMP-1 also failed to inhibit 
GLA activation (Fig. 5.8B, lane 4). Although it was expected that the processing of 
proGLA to the intermediate form would not be inhibited by TIMP-1 (this cleavage is 
performed by MTl-MMP), the processing from the intermediate to fully active form of 
GLA should have been susceptible to TIMP-1 inhibition, as this cleavage is due to GLA 
autolysis (Atkinson et al., 1995).
It has been shown previously that a mutant of GLA, with the C-terminal hemopexin 
domain removed (NGL) is poorly inhibited by TIMP-1, but is inhibited by a C-terminally 
truncated form of TIMP-1 (N-TIMP-1; Nguyen et al., 1994). It is possible in the current 
study that GLA bound by its C-terminus to the MTl-MMP:TIMP-2 complex behaved 
similarly to NGL and was therefore not susceptible to inhibition by TIMP-1. Therefore, it 
was predicted that N-TIMP-1 should inhibit GLA processing from the intermediate to the 
fully active form. When N-TIMP-1 was added to HT1080 cells cultured on fibronectin the 
processing of GLA to the fully active form was indeed inhibited (Fig. 5.9A, lane 4), in 
contrast to full length TIMP-1 which failed to inhibit (Fig. 5.9A, lane 3).
The processing of MTl-MMP to 45 kDa was examined when N-TIMP-1 was included in 
the culture and it was observed that wliilst N-TIMP-1 prevented the production of fully 
active GLA (Fig. 5.9A, lane 4), it did not inhibit the processing of MTl-MMP to 45 kDa 
(Fig. 5.9B, lane 4). This suggested that active GLA is not required for MTl-MMP 
processing to 45 kDa.
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5.2.7 Addition o f antibodies to MTl-MMP and GLA to HT1080 cells on fibronectin: is 
MTl-MMP processing to 45 kDa inhibited?
Blocking antibodies would help to determine whether MTl-MMP or GLA are involved in 
MTl-MMP processing to 45 kDa. Our laboratory has not yet identified blocking 
antibodies to MTl-MMP, and so several MTl-MMP antibodies of unknown activity were 
added to HT1080 cells cultured on fibronectin. The antibody N175 (purified by Protein-G 
Sepharose chromatography) failed to prevent the activation of GLA, and did not affect the 
processing of MTl-MMP to the 45 kDa form (Fig. 5.10A and B respectively, lane 4). 
MTl-MMP monoclonals kindly provided by Dr P. Basset (Université Louis Pasteur, 
Strasbourg, France) were tested. These antibodies (3A10 and 4G6, to the catalytic and 
hemopexin domain of rat MTl-MMP respectively) reacted with human MTl-MMP on 
Western blot, recognising bands of 63 and 60 and 45 kDa as well as additional bands at 50 
and 68 kDa in HT1080 cell lysates (data not shown). As 3A10 and 4G6 were provided as 
culture supernatants, a third culture supernatant (2G12) was chosen as a control, on the 
basis that it did not cross react with MTl-MMP on Western blot (data not shown) or stain 
MTl-MMP in cells (Dr R. Hembry, personal communication). Neither 3A10 (data not 
shown), nor 4G6 (Fig. 5.10A and B, lane 2), nor the control antibody inhibited the 
activation of GLA, or the processing of MTl-MMP to the 45 kDa form. Thus none of the 
antibodies tested inhibited MTl-MMP activity, and the hypothesis that MTl-MMP 
autolytically processes to 45 kDa could not be verified using the antibodies available
Anti-GLA antibodies were tested for their ability to block GLA activation and the 
processing of MTl-MMP to 45 kDa. We have recently raised a new polyclonal antibody 
to GLA (K399) using the same procedure as reported for the anti-GLA antibody X670, that 
was raised in our laboratory (Hipps et al., 1991). This antibody was characterised by 
Western blot analysis, and recognised recombinant human GLA, but did not cross react 
with GLB, CL -1, -2, -3, SL-1, -2 or TIMPs -1, -2, -3 (data not shown). NSO mouse 
myeloma cells stably transfected with GLA cDNA stained brightly with this antibody 
using immunolocalisation techniques (data not shown). The antibody was purified by 
adsorption to Protein-G Sepharose, and added to HT1080 cells cultured on fibronectin.
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Analysis of the conditioned medium by zymography showed that this antibody sequestered 
all GLA secreted, such that none was detected (Fig. 5.11 A), but failed to inhibit the 
processing of MTl-MMP to the 45 kDa form (Fig. 5.1 IB). Preliminary data also 
suggested that a monoclonal antibody to the C-terminal domain of GLA (VB3) inhibited 
GLA activation, but did not affect the processing of MTl-MMP to 45 kDa (data not 
shown). Thus the data from these studies did not support the hypothesis that GLA 
processes MTl-MMP to the 45 kDa form.
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5.3 Discussion
The aim of this chapter was to determine whether fibronectin up-regulates the expression 
of molecules important for the cell-surface activation of GLA in HT1080 cells. Studies 
focussed on TIMP-2 and the MT-MMPs, based on the hypothesis that TIMP-2 and MTl- 
MMP together form a 'receptor* complex that binds and initiates GLA activation. 
However, other hypotheses for GLA binding to the cell surface were also considered when 
designing and interpreting these studies, and these deserve mention.
Interactions between the integrin avp3 and C-terminus of GLA have been demonstrated in 
human melanoma cells (Brooks et al., 1996; Brooks et al., 1998), although the enzyme 
involved in the cleavage of the GLA propeptide was not identified in these reports. 
Certainly, avp3 integrin is widely expressed, however there are many examples of cell 
types which activate GLA but do not express avp3 integrin. Therefore, whether 
integrin/proGLA binding is a general mechanism for concentrating GLA at the cell surface 
has yet to be determined. In the current study it was considered unlikely that GLA/avp3 
integrin interactions were important, since immunolocalisation studies of our HT1080 cells 
with several anti-av or avp3 integrin antibodies indicated that these cells apparently do not 
express avp3 integrin (A. Messent and J. Gavrilovic, unpublished observations). Another 
mechanism for GLA binding to the cell surface was described recently. Steffensen et al. 
(1998) showed GLA binding to cell surface-bound collagen via GLA fibronectin type II 
domains. However GLA bound via this mechanism was less susceptible to activation than 
GLA bound to the surface via TIMP-2. As fibronectin acts to increase GLA activation in 
HT1080 cells, the coIIagen-GLA interactions were considered unlikely to be relevant to 
this study.
Therefore, to begin the studies, fibronectin was examined for its potential to affect TIMP-2 
expression or distribution. Many reports have demonstrated that the level of TIMP-2 
present is critical for the activation of GLA. An excess of TIMP-2 surrounding the cell 
leads to inhibition of GLA activation, whereas cell surface-bound TIMP-2 is a requirement 
for activation. In the current study, it was considered possible that fibronectin matrices
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might i) alter the levels of secreted TIMP-2 or ii) alter the proportion of cell surface bound 
TIMP-2 such that GLA activation is favoured. Unfortunately, it proved difficult to detect 
TIMP-2 in the conditioned medium from HT1080 cells. Gelatin-agarose was used to 
concentrate GLA-bound-TIMP-2 in the media from fibronectin and laminin-1 cultures; no 
difference in TIMP-2 levels between the cultures was noted. To give an indication of total 
TIMP-2 in the conditioned medium, reverse zymography was attempted, however the 
levels of TIMP-2 were at the detection limit of this technique. The media were 
concentrated and analysed by reverse zymography by S. Atkinson (University of East 
Anglia, Norwich, UK); the results indicated that the levels of TIMP-2 were similar in 
fibronectin and lam inin-1 substrates (S. Atkinson, personal communication). Cell surface 
TIMP-2 was analysed by Western blot, but again no variation in TlMP-2 levels were 
detected in the lysates of cells cultured on fibronectin or laminin-1 matrices. Finally, 
fibronectin was examined for its potential to bind TIMP-2, as an interaction with the matrix 
may help to bind TIMP-2 near the cell surface. The ELISA technique detailed in Chapter 4 
was used to study fibronectin/TIMP-2 interaction, but no binding was observed (data not 
shown).
The next possibility examined was whether fibronectin substrates alter the expression of 
MT-MMPs by HT1080 cells. Firstly, HT1080 cells were analysed to determine which 
MT-MMPs they express. MTl-MMP expression by HT1080 cells was described by Sato 
et al. (1994) and confirmed in the current study using Northern and Western blot analyses, 
and immunolocalisation. MT2- and MT3-MMP protein was not detected by Western blot 
of HT1080 cell lysates. Following completion of studies for this thesis, a study published 
by Lehti et al (1998) confirmed that these cells do not express MT2- or MT3-MMP. The 
polyclonal antibody to MT4-MMP detected a band that approximated to the molecular 
mass of MT4-MMP in the lysates of HT1080 cells, but the presence of MT4-MMP was not 
confirmed by immunolocalisation, and MT4-MMP mRNA was below the level of 
detection. To continue these studies, a cell type that is known to express MT4-MMP is 
needed as a positive control, and the MT4-MMP antibodies require fiirther characterisation. 
However, with respect to GLA activation studies, it is known that MT1-, MT-2- and MT3-
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MMP can initiate GLA activation (Sato et al., 1994; Takino et al., 1995; Butler et al.,
1997), whereas it has ÿet to be shown that MT4-MMP can activate GLA. Therefore MTl- 
MMP was targeted for the current study.
According to the hypothesis of Butler et al. (1998), MT1 -MMP/TIMP-2 binds GLA to the 
cell surface, and an adjacent TIMP-2-free MTl-MMP molecule is needed to initiate the 
activation of GLA. Since fibronectin apparently did not regulate TIMP-2 expression, it 
was hypothesised that MTl-MMP expression might be up-regulated, resulting in a greater 
level of 'fi-ee' MTl-MMP. ECM regulation of MTl-MMP expression was recently 
described by Gilles et al., (1997) and Haas et al., (1998) who showed that the culture of 
several cell types on collagen type I gels or within collagen lattices induces MTl-MMP 
m RN A  expression and a corresponding increase in GLA activation. However, in the 
current study MTl-MMP mRNA levels were similar when cells were cultured on 
fibronectin or lam inin-1 substrates.
To determine whether post-translational regulation of MTl-MMP is affected by 
fibronectin, MTl-MMP protein was analysed by Western blot using a newly described 
antibody to MTl-MMP. Two major immunoreactive bands were detected at 60 kDa and 
45 kDa, and a faint doublet at 63 kDa. Only one other laboratory has described a band of 
similar size (43 kDa) detected in lysates prepared firom HT1080 fibrosarcoma cells and 
stimulated lung fibroblasts (Lohi et al., 1996), Two polyclonal antibodies to MTl-MMP 
were detailed in this study, raised to the hemopexin and cytoplasmic domains of MTl- 
MMP, and these antibodies detected a truncated form of MTl-MMP at 43 kDa. In most 
studies, however, antibodies raised to a peptide in the hinge region of MTl-MMP have 
been used in Western blot analysis (peptide CDGNFDTVAMLRGEM, residues 310-333). 
In our laboratory, we have noted that a monoclonal antibody to this peptide (113-5B7; Sato 
c t a l, 1994) h as  a  v e ry  low a f lm iiy  fo r  th e  45 kDa baud. S uch that in most analyses it fails 
to detect the band (data not shown).
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The 60 kDa band recognised by N175 probably corresponds to the active form of MTl- 
MMP (S. Atkinson, G. Butler, G. Murphy, unpublished results; Strongin et al., 1995). 
Although the level of the 60 kDa form was not affected by the various culture conditions 
employed, it was clear that the overall MTl-MMP protein levels increased when the cells 
were cultured on fibronectin, as the 45 kDa band was up-regulated. Similarly, PMA 
treatment up-regulated the expression of the 45 kDa band, as has been reported by Lohi et 
al., (1996). Increases in the 45 kDa band were noted to be concomitant with the activation 
of GLA, an observation that agrees with the report by Lohi et al. (1996).
Following this initial observation of a truncated 45 kDa form of MTl-MMP, a number of 
cell types were examined in our laboratory to determine whether similar processing events 
occurred. Although HT1080 cells were the only cell type of those analysed to respond to 
culture on fibronectin by increased processing of MTl-MMP to 45 kDa, other cell types 
processed MTl-MMP to 45 kDa in response to concanavalin A (SW1353 human 
chondrosarcoma cells, Cowell, et al. (1998); human foreskin fibroblasts, S. Atkinson, H. 
Stanton, G. Murphy, unpublished results; G361 mouse myeloma cells; H Stanton, G. 
Murphy, unpublished results) or processed MTl-MMP to 45 kDa in response to PMA 
(endothelial cells, C. Lindsay, G. Murphy, personal communication). Transfection of 
MTl-MMP mto Chinese hamster ovary cells (d'Ortho et al., 1998) or HT1080 
fibrosarcoma cells (J. Gavrilovic, H. Stanton, J. Clements, G. Murphy, unpublished results) 
also resulted in a greatly up-regulated 45 kDa band. The combined data indicate that 
processing of MTl-MMP to a 45 kDa form occurs in response to various stimuli and is 
common to many cell types. With the exception of the PMA-treated endothelial cells, the 
processing of MTl-MMP to the 45 kDa form was always mirrored by an increase in the 
activation of GLA.
Studies with the protease inhibitors CT1746 and TTMP-2 indicated that the culture of 
HT1080 cells on fibronectin up-regulated the activity of an (unknown) MMP, responsible 
for the processing of MTl-MMP to 45 kDa. GLA was considered a likely candidate, as the 
activation of GLA was up-regulated by fibronectin and concomitant with MTl-MMP
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processing to 45 kDa. However, the lack of inhibition of MTl-MMP processing to 45 kDa 
by TIMP-1 implied MTl-MMP autolysis. Studies with N-TIMP-1 further supported this 
hypothesis, for N-TIMP-1 prevented the processing of GLA to the fully active form, but 
did not inhibit MTl-MMP processing to 45 kDa. As an interesting aside, the final step in 
the activation of GLA was susceptible to N-TIMP-1 but not TIMP-1, possibly because 
GLA bound to the cell surface by its C-terminus behaves more like N-terminally truncated 
GLA, and is therefore not susceptible to TIMP-1 inhibition (Nguyen et al., 1994).
Antibodies to MTl-MMP and GLA were added to HT1080 cells cultured on fibronectin, 
with the intention of blocking enzymatic activity and unravelling the sequence of events 
involved in fibronectin up-regulation of MMP processing. None of the MTl-MMP 
antibodies tested inhibited MTl-MMP or GLA processing, implying i) that the antibodies 
were not blocking antibodies or ii) that antibody access to the MTl-MMP/GLA complex 
was impeded in some way, or iii) that GLA activation by HT1080 cells was not dependant 
upon MTl-MMP activity. Unfortunately, with the antibodies available, the hypothesis that 
MTl-MMP processing to 45 kDa is autolytic could not be proved or disproved. The new 
anti-GLA polyclonal antibody K399 bound all secreted GLA, such that none was detected 
in the conditioned medium. This was probably due to endocytosis of the antibody/GLA 
complex during the course of the experiment. Interestingly, K399 did not prevent MTl- 
MMP processing to 45 kDa. The combination of the TIMP inhibition studies and the anti- 
GLA antibody studies indicated that active GLA is not involved in processing MTl-MMP 
to 45 kDa and implied that a culture substrate of fibronectin stimulates two separate events: 
the increased activation of GLA and an up-regulation of an unknown protease that cleaves 
MTl-MMP to 45 kDa,
In summary, HT1080 TIMP-2 levels were not up-regulated by a substrate of fibronectin. 
The overall expression o f MTl-MMP protein was increased by fibronectin, but more 
specifically, the proteolytic processing of active 60 kDa MTl-MMP to a 45 kDa product 
was promoted. This processing was MMP-mediated and concomitant with GLA 
activation, but TIMP and antibody inhibition studies indicated that active GLA was not
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involved in the processing of MTl-MMP to 45 kDa.
It is apparent from these studies, and from the studies by Lohi et al. (1996) that the 45 kDa 
form MTl-MMP is still membrane-associated. Hence MTl-MMP must be cleaved within 
the catalytic domain to yield a band of 45 kDa. It is likely that this would render the 
molecule inactive, which would represent an important regulatory step in MTl-MMP 
activation cascades. An N-terminal sequence of the 45 kDa form would shed more light on 
its role, and Chapter 6 details strategies to purify sufficient 45 kDa MTl-MMP for 
sequencing.
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Figure 5.1 TIMP-2 protein expression by HT1080 cells cultured on fibronectin or laminin-1
HT 1080 cells were cultured under serum free conditions on substrates of fibronectin or laminin-1 for 48 
hours.
A. Western blot analysis o f secreted TIMP-2. TIMP-2/GLA complexes were purified from the conditioned 
medium by adsorption to gelatin-Sepharose. Bound proteins were eluted using reducing sample buffer and 
separated by SDS-PAGE. Proteins were transferred to nitrocellulose by electroblotting and probed with a 
polyelonal antibody to TIMP-2. Two separate experiments are depicted. Cells cultured on fibronectin (lanes 
1, 3), eells cultured on laminin-1 (lanes 2, 4). Recombinant TIMP-2 (2 ng; lane 5).
B. Western blot analysis o f HT1080 cell lysates. Cells were lysed in a buffer containing Triton-X-100. 
Lysate proteins from three separate experiments were separated by 10% SDS-PAGE, transferred to 
nitroeellulose and probed with a polyclonal antibody to TIMP-2. Two separate experiments are depicted. 
Cells cultured on fibronectin (lane 1, 3), eells cultured on laminin-1 (lane 2, 4); TIMP-2 standard (2 ng; lane
5).
Moleeular mass markers are indicated on the right.
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Figure 5.2 Western blot analysis of MT-MMP protein expression
Cell membranes were prepared from HT 1080 cells cultured in serum. Membrane proteins (10 pi) were 
separated by 10% SDS-PAGE, electroblotted to nitrocellulose and probed with antibodies to MTl-MMPs. 
Reeombinant proteins: MTl-MMP (lane 1), MT2-MMP (lane 4), MT3-MMP (lane 5) and MT4-MMP (lane 
7). HT 1080 cell membranes (lanes 2, 3, 6, 8). Lanes 1 and 2 were developed with sheep anti-human M Tl- 
MMP antibody; lanes 3 and 4 with a rabbit anti-human MT2-MMP antibody; lanes 5 and 6 with a mouse 
monoclonal antibody to human MT3-MMP; lanes 7 and 8 with a sheep anti-human MT4-MMP antibody.
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Figure 5.3 Expression of MTl-MMP mRNA by HT1080 fibrosarcoma cells
Northern blot o f RNA from HT1080 cells cultured on plastic. Cells were cultured for 24 hours prior to 
extraction o f RNA. Total RNA (5 pg) was separated on an agarose gel, transferred to a nylon membrane and 
MTl-MMP mRNA detected by hybridisation with a digoxygenin-labelled riboprobe. The position of the 28S 
and 18S ribosomal RNA is shown. A GAPDH riboprobe was used as an internal standard.
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Figure 5.4 Immunolocalisation of MTl-MMP in HT1080 cells
HT1080 cells were cultured on glass slides in the presence o f fetal calf serum.
A. Intracellular staining: Monensin was added for the last 3 hours o f culture. Cells were fixed, permeabilised 
and stained by indirect immunofluorescence with sheep anti-MTl-MMP antibody, followed by pig anti- 
sheep-Fab’-FlTC.
B. Cell surface staining: cells were fixed and stained with sheep anti-MTl-MMP antibody, followed by pig 
anti-sheep Fab’-FITC.
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Figure 5.5 MTl-MMP covers the entire surface of HT1080 cells
HT 1080 cells were cultured on glass slides in the presence o f fetal calf serum. Cells were fixed and stained 
by indirect immunofluorescence with sheep anti-MTl-MMP antibody, followed by pig anti-sheep Fab’-FITC. 
A confocal microscope was used to collect serial 1 pm sections through cells. Four sections from the series 
were chosen to illustrate cell surfaee staining: a) staining at the basal surface of the cells; b), c) staining o f the 
cells in the middle o f the series; d) staining at the dorsal surface o f the cells.
Bar = 10 pm
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Figure 5.6 HT1080 fibrosarcoma mRNA levels for MTl-MMP are not altered by culture on
fibronectin or laminin-1
Northern blot o f RNA from HT1080 cells cultured on fibronectin, laminin-1 or on plastic. Cells were 
cultured for 24 hours prior to extraction of total RNA. Samples (5 pg/lane) were separated on agarose gels, 
transferred to a nylon membrane and MTl-MMP mRNA detected by hybridisation with a digoxygenin- 
labelled riboprobe. The position o f the 288 and 188 ribosomal RNA is shown. A GAPDH riboprobe was 
used as an internal standard. Cells were cultured on plastic (lane 1) on laminin-1 (lane 2); or cultured on 
fibronectin (lane 3).
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Figure 5.7 The processing of MTl-MMP protein to a 45 kDa form by HT1080 fibrosarcoma cells is 
increased by culture on fibronectin
HT 1080 ceils were cultured under serum free conditions on substrates o f fibronectin or laminin-1, or on 
culture plastic with or without PMA for 48 hours.
A. Western blot analysis o f HT1080 cell lysates. Cells were lysed in a buffer containing Triton-X-100. 
Lysate proteins were separated by 10% SDS-PAGE, transferred to nitrocellulose by electroblotting and 
probed with a polyclonal antibody to MTl-MMP. Cells cultured on fibronectin (lane 1), cells cultured on 
laminin-1 (lane 2); cells cultured on plastic in the presence or absence of PMA (lanes 3 and 4, respectively).
B. The conditioned media were analysed for gelatin degrading activity by zymography. Cells cultured on 
fibronectin (lane 1), cells cultured on laminin-1 (lane 2); cells cultured on plastic in the presence or absence 
of PMA (lanes 3 and 4, respectively).
Molecular mass markers are indicated on the right.
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Figure 5.8 Cellular processing of MTl-MMP to the 45 kDa form is mediated by a matrix 
metalloproteinase
HT 1080 cells were cultured on fibronectin under serum free conditions, with or without protease inhibitors 
for 48 hours. The conditioned medium was harvested for zymography and the cells lysed for Western blot 
analysis.
A. Western blot: HT 1080 cell lysates were prepared and subjected to 10% SDS-PAGE. Proteins were 
transferred to nitrocellulose by electroblotting and probed with a polyclonal antibody to MTl-MMP. Cells 
cultured on fibronectin (lanes 1-4), alone (lane 1), or in the presence o f metalloproteinase inhibitor CT1746 at 
1 pM (lane 2), recombinant MMP inhibitors TIMP-2 and TIMP-1 at 150 nM (lanes 3 and 4, respectively). 
Cells cultured on laminin-1 (lane 5).
B. The conditioned medium was analysed by gelatin zymography. Cells cultured on fibronectin (lanes 1-4), 
alone (lane 1), or in the presence of metalloproteinase inhibitor CT1746 at 1 pM (lane 2), recombinant MMP 
inhibitors TIMP-2 and TIMP-1 at 150 nM (lanes 3 and 4 respectively). Cells cultured on laminin-1 (lane 5). 
Molecular mass markers are indicated on the right.
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Figure 5.9 Cellular processing of MTl-MMP to the 45 kDa form is inhibited by TIMP-2, but not 
TIMP-1 or N-TIMP-1
HT 1080 cells were cultured on fibronectin under serum free conditions, with or without added recombinant 
TIMPs (150 nM). The conditioned medium was harvested for zymography and the cells lysed for Western 
blot analysis.
A. The conditioned medium was analysed by gelatin zymography. Cells cultured on fibronectin (lanes 1-4), 
alone (lane 1), or in the presence o f TIMP-2 (lane 2), TIMP-1 (lane 3) or N-TIMP-1 (lane 4). Cells cultured 
on laminin-1 (lane 5).
B. Western blot: HT1080 cell lysates were prepared and subjected to 10% SDS-PAGE. Proteins were 
transferred to nitrocellulose by electroblotting and probed with a polyclonal antibody to MTl-MMP. Cells 
cultured on fibronectin (lanes 1-4), alone (lane 1), or in the presence of TIMP-2 (lane 2), TIMP-1 (lane 3) or 
N-TIMP-1 (lane 4). Cells cultured on laminin-1 (lane 5), or treated with PMA (lane 6).
Molecular mass markers are indicated on the right.
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Figure 5.10 The addition of anti-MTl-MMP antibodies to HT1080 cells cultured on fibronectin: 
effects on GLA activation and MTl-MMP processing to the 45 kDa form
HT 1080 cells were cultured on fibronectin under serum free conditions, alone or in the presence of a 
antibodies to MTl-MMP. The conditioned medium was harvested for zymography and the cells lysed for 
Western blot at 48 hours.
A. Gelatin zymography: cells cultured on fibronectin (lanes 1-4), in the presence o f control antibody 2G12 
(lane 1), anti-MTl-MMP antibody 4G6 (lane 2), non-immune sheep IgG (lane 3) or sheep anti-MTl-MMP 
antibody N 175 (lane 4).
B. Western blot: HT1080 cell lysates were prepared and subjected to 10% SDS-PAGE. Proteins were 
transferred to nitrocellulose by electroblotting and probed with a polyclonal antibody to MTl-MMP. Lane 
order as for part A.
Molecular mass markers are indicated on the right.
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Figure 5.11 The addition of a polyclonal anti-GLA antibody to HT1080 cells cultured on fibronectin: 
effects on GLA activation and MTl-MMP processing to the 45 kDa form
HT1080 cells were cultured on fibronectin under serum free conditions, in the presence o f a sheep anti-GLA 
antibody (K399; lane 2), or in the presence o f non-immune sheep IgG control (lane 1). The conditioned 
medium was harvested for zymography (A) and the cells lysed for Western blot at 48 hours. Lysate proteins 
were transferred to nitrocellulose by electroblotting and probed with a polyclonal antibody to anti-MTl-MMP 
(B).
Molecular mass markers are indicated on the right.
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Chapter 6 Purification o f 45 kDa MTl-MMP
6.1 Introduction
Precise details of the 45 kDa cleavage site in MTl-MMP would aid in determining the role 
of this molecule in cell surface proteolysis/MMP activation cascades. To obtain the 45 
kDa MTl-MMP sequence, strategies are required for the purification of native MTl-MMP. 
Several difficulties may be encountered in the purification of integral membrane proteins. 
Large quantities o f cells or tissue are required to compensate for tiny amounts of target 
protein present in the membrane. Often, high concentrations o f detergents are needed 
throughout the purification procedure to maintain the solubility of the membrane protein. 
In this chapter, native MTl-MMP was extracted from detergent-solubilised HT1080 cells 
by immunoprécipitation, using a specific anti-MTl-MMP antibody. The yield from this 
technique was typically very low. Therefore, as an alternative, recombinant M Tl-MMP 
was cleaved with MMPs in an attempt to generate the '45 kDa' truncation.
Knowledge of the N-terminal sequence of 45 kDa MTl-M M P is needed to engineer 
recombinant 45 kDa MTl-MMP. This could be used to predict whether M Tl- 
MMP/TIMP-2 interactions are destroyed upon truncation to 45 kDa. Furthermore, the 
hypothesis that 45 kDa MTl-MMP is catalytically inactive could be tested with 
recombinant 45 kDa MTl-MMP. N-terminal sequence data would also aid in the design of 
neo-epitope antibodies. An antibody that recognises the newly exposed N-terminus of the 
45 kDa form would enable tracking of 45 kDa MTl-MMP throughout the cell. As the 
generation of 45 kDa MTl-MMP is concomitant with GLA activation, a neo-epitope 
antibody may prove a useful marker of M T1 -MMP/GLA activity in diseased tissue.
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6.2 Results
6.2.1 Purification o f native 45 kDa MTl-MMP for N-terminal sequencing 
6.2.1a Cleavage o f MTl-MMP in vitro to yield the 45 kDa form
A cell lysate or membrane preparation in which the majority o f M Tl-M M P is converted to 
45 kDa would make an ideal starting material for purification purposes. As the cleavage of 
60 kDa MTl-MMP to 45 kDa is MMP mediated, the ability of MMPs to process 
membrane-bound MTl-MMP to 45 kDa in vitro was tested.
Firstly, cell membranes were prepared from HT1080 cells stably transfected with wild type 
M Tl-M M P (details of this cell line in Chapter 2). To monitor cleavage to 45 kDa, a 
membrane preparation enriched in 60 kDa MTl-MMP was generated by culturing the cells 
in the presence o f the inhibitor CT1746 prior to harvest. The CT1746 was then washed 
from the membrane preparation (see methods. Chapter 2). A quenched fluorescent peptide 
assay was used to estimate the amount of free (active) M Tl-M M P in the preparation 
(kindly performed by Dr G. Butler, University of East Anglia, Norwich, UK). Active 
M Tl-M M P was estimated at 23 pmol/mg of membrane protein, which was considered a 
highly significant activity, as Butler et al. (1998) showed that a similar membrane 
preparation of 1.52 pmol active MTl-MMP per mg of protein was capable o f activating 
recombinant proGLA.
Based on the value of 23 pmol/mg protein, active MMPs were added at a 1:1 molar ratio 
with native MTl-MMP, with the exception of recombinant MTl-MMP, which was added 
at a 5:1 molar ratio. Incubation at 37°C for 4 hours resulted in the generation of the 45 
kDa form of MTl-MMP, with active preparations o f GLA, MTl-M M P, SL-1 and CL-3 all 
capable of cleaving native MTl-MMP to a form apparently identical to 45 kDa MTl-MMP 
(Fig. 6.1). Incubation of the membrane preparation alone also resulted in the generation of 
a 45 kDa band, but to a lesser extent than when active MMPs were added, demonstrating 
intrinsic MTl-MMP processing activity in the membrane preparation (Fig. 6.1).
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The proteolytic processing of 60 kDa MTl-MMP was monitored over 8 hours at 37°C, to 
select a time point at which the majority of MTl-MMP is cleaved to 45 kDa. As expected 
from the results in Figure 6.1, a three hour incubation with GLA resulted in a considerable 
increase in the level of the 45 kDa band (Fig. 6.2). However, incubations of five hours or 
longer resulted in a loss of both 60 and 45 kDa MTl-MMP, presumably due to non specific 
proteolysis.
It was apparent that cleavage of native MTl-MMP in the test tube would not lead to a 
preparation of MTl-MMP that was predominantly 45 kDa. This method showed no 
advantage over stimulating HT1080 cells in culture to produce 45 kDa MTl-MMP prior to 
harvest. PMA treatment was chosen as the best option for stimulating 45 kDa MTl-MMP 
production; culturing the cells on fibronectin was considered impractical due to the costs 
involved in coating the 175 cm^ culture flasks.
6,2,1b Immunoprécipitation of MTl-MMP and Protein-G Sepharose purification
The polyclonal antibody to MTl-MMP (N175) was used to immunoprecipitate MTl-MMP 
from HT1080 cell lysates. Lysates prepared from PMA treated HT1080 cells were pre­
cleared with pre-immune sheep IgG, treated with N175, and the resulting 
immunoprecipitates collected by Protein-G Sepharose chromatography. Western blot 
analysis of the immunoprecipitates showed that 63, 60 and 45 kDa MTl-MMP were 
precipitated by N175 (Fig. 6.3). Unfortunately, diffuse bands of IgG at approximately 55 
kDa overshadowed the 63 and 60 kDa forms of MTl-MMP, a consequence of using the 
same antibody for both immunoprécipitation and Western analysis. In this case, the anti­
sheep IgG secondary antibody used in the Western blot detected the N175 IgG added 
during immunoprécipitation (Fig. 6.3). This problem could have been avoided if a second 
anti-MTl-MMP antibody (raised in different species) was available. However, the mouse 
anti-MTl-MMP peptide antibody 113 failed to immunoprecipitate MTl-MMP from cell 
lysates (S.J. Atkinson, personal communication), and was not suitable for the Western blot 
detection of immunoprecipitated MTl-MMP. 113 has a weak affinity for the 45 kDa form 
of MTl-MMP, the reason for which is unclear.
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MTl-MMP was immunoprecipitated from lysates with N175 and transferred to PVDF 
membrane. The membrane was stained with Ponceau S, and the 45 kDa band of MTl- 
MMP positively identified by Western blot analysis (data not shown). This band was 
excised from the PVDF membrane, subjected to N-terminal sequencing (performed by Dr 
Bryan Smith, Celltech Ltd, Slough, UK), and found to be N-terminally blocked. Further 
purifications of MTl-MMP using this technique also proved to be N-terminally blocked.
Reverse-phase HPLC chromatography was investigated as an alternative method for the 
purification of MTl-MMP from immunoprecipitated cell lysates. Immunoprecipitates 
were adsorbed to a column of Protein-G Sepharose, and bound proteins were eluted with 
guanidinium-HCl. A second elution of Laemmli reducing sample buffer was used to 
remove any proteins remaining on the column. Western blot analysis of the column 
fi-actions showed that guanidinium-HCl was successful in eluting the bound protein (Fig. 
6.4), but distorted the gel, making it difficult to distinguish MTl-MMP and IgG bands. 
The proteins eluted with guanidinium-HCl were applied to a C4 column, and subjected to 
reverse-phase HPLC (performed by W. English, School of Biological Sciences, University 
of East Anglia, Norwich, UK). A gradient of 0-100% A-B (A=H20/ 0.1% trifluoroacetic 
acid, B= 60% isopropanol/40% acetonitrile/0.1% trifluoroacetic acid) eluted a single peak 
(data not shown). The peak was analysed by W. English, using SDS-PAGE (reducing 
conditions), followed by silver stain. Two bands were visible at approximately 55 kDa and 
29 kDa, the molecular mass of the heavy and light chains of IgG respectively (Harlow and 
Lane, 1988). No 45 kDa MTl-MMP was apparent.
In this case, it is likely that the level of MTl-MMP applied to the C4 column was too low. 
Fig. 6.4, lanes 2 and 3 show that most of the MTl-MMP present in the 
immunoprécipitation mixture did not bind Protein-G Sepharose. It would appear that the 
problem did not lie with N175/Protein-G Sepharose binding, as tiiere were no IgG bands of 
55 kDa apparent in the unbound material (Fig. 6.4, lane 2). Rather, the data suggests that 
much of the MTl-MMP was not immunoprecipitated by N 175. This antibody was raised 
to partially refolded A5 n _582 TM-MTl-MMP (d'Ortho et al., 1998). By dot-blot analysis
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N I75 recognised reduced, SDS-denatured A 5 0 2 -5 5 9  TM-MTl-MMP very well, but reacted 
poorly with untreated ('native') A 5 0 2 -5 5 9  TM-MTl-MMP (data not shown). In conclusion, 
immunoprécipitation of MTl-MMP from HT1080 cell lysates with N175 did not yield 
sufficient material to support further purification by HPLC.
Chromatographic procedures used to purify other MMPs were considered, in order to 
bypass the immunoprécipitation step prior to HPLC purification. Red Sepharose CL-6B 
has been used to purify recombinant human stromelysin (Koklitis et al., 1991), but does not 
perform well in concentrated detergent conditions. The concentration of Triton X-100 in 
the lysis buffer was reduced from 1% to 0.1% (v/v), but unfortunately MTl-MMP did not 
extract into the aqueous phase (data not shown).
6,2.2 MMP cleavage o f recombinant MTl-MMP
An alternative approach was needed to generate 45 kDa MTl-MMP for sequencing. As 
native MTl-MMP is susceptible to cleavage by MMPs to yield a 45 kDa form, 
recombinant MTl-MMP should likewise be susceptible. A soluble recombinant 
transmembrane deletion mutant of MTl-MMP (A502-559 TM-MTl-MMP) was incubated 
with active MMPs for four hours at 37®C. Cleavage products were analysed by SDS- 
PAGE and silver stain. Incubation of pro-ATM-MT1 -MMP alone resulted in a drop in 
molecular mass of from 60 kDa to 52 kDa (Fig. 6.5A, lanes 1 and 2), probably 
corresponding to the loss of the pro-peptide (Will et al., 1996). Further processing 
products at 34 and 32 kDa were evident (Fig. 6.5A, lane 2). Allowing for the lack of a 
transmembrane domain (approximately 5 kDa) in ATM-MTl -MMP, the predicted 
molecular mass of the '45 kDa' form of MTl-MMP was approximately 40 kDa. However, 
no band of 40 kDa was apparent when ATM-MTl-MMP was incubated alone (Fig. 6.5 A, 
lane 2), or when ATM-MTl-MMP was incubated with equimolar quantities of pre­
activated ATM-MTl-MMP (Fig. 6.5 A, lane 4). This indicated that self cleavage of ATM- 
MTl-MMP to 40 kDa did not occur. Incubation of ATM-MTl-MMP with equimolar 
concentrations of active SL-1 or active CL-3 (Fig. 6.5A, lanes 5 and 6 respectively) also 
did not result in bands of 40 kDa. Very faint bands between 35 and 45 kDa were apparent
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in GLA treated MTl-MMP (Fig. 6.5A, lane 3), however, these bands corresponded to GLA 
break down products, and were also present in the active GLA control (Fig. 6.5A, lane 7). 
Interestingly, incubation with active GLA and CL-3 resulted in the processing of 60 and 52 
kDa bands of ATM-MTl-MMP to the 34/32 kDa doublet (Fig. 6.5 A, lane 6). Active CL-3 
incubated alone autocatalytically degraded (lane 10), as has been observed previously in 
our laboratory (Knâuper et al., 1997).
It is possible that low levels of 40 kDa fragment were generated by MMP cleavage, but not 
detected by silver stain. Cleavage products were analysed by Western blot with N175 
antibody, which detects nanogram quantities of MTl-MMP. Incubation of pro-ATM-MT 1- 
MMP alone (Fig. 6.5B, lane 2), or with active ATM-MTl-MMP (Fig. 6.5B, lane 4) did not 
generate bands of 40 kDa. The autocatalytic breakdown of active ATM-MTl-MMP 
(incubated alone for four hours) also did not apparently proceed via a 40 kDa step (Fig. 
6.5B, lane 2). Active GLA, SL-1 and CL-3 did not cleave soluble ATM-MTl-MMP to 40 
kDa (Fig. 6.5B, lanes 3, 5 and 6, respectively). The chemiluminescent detection step for 
the Western blot was left to develop overnight, but no bands of 40 kDa appeared (data not 
shown). ATM-MTl-MMP was incubated with active GLA for longer periods, after 18 
hours the ATM-MTl-MMP was processed entirely to the 34/32 kDa doublet, but no 40 
kDa was detected by silver stain analysis (data not shown).
Native MTl-MMP may be complexed with TIMP-2, which could alter the susceptibility of 
MTl-MMP to MMP cleavage. Recombinant active ATM-MT 1 -MMP/TIMP-2 complexes 
were formed, and then incubated with active GLA for five hours at 37°C. Silver stain 
analysis of the cleavage products (Fig. 6.6) show that the addition of TIMP-2 did not alter 
the susceptibility of ATM-MTl-MMP to GLA action, and no 40 kDa bands were detected. 
This data does not rule out a rapid transition from the 52 kDa recombinant MTl-MMP to 
34 kDa via an unstable 40 kDa intermediate. It is possible that the 40 kDa form of MTl- 
MMP is rapidly broken down to 34 kDa.
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6.3 Discussion
Several predictions can be made about the nature of the 45 kDa form of MTl-MMP. It is 
associated with the membrane fraction of cells, implying that the transmembrane domain is 
intact. Consistent with this observation, Lohi et al. (1996) described a 43 kDa form o f  
MTl-MMP that was detected using a peptide antibody raised to the C-terminal intracellular 
domain of MTl-MMP. Simple calculations therefore predict that the proteolytic truncation 
occurs in the catalytic domain.
Pin-pointing the exact cleavage site in MTl-MMP is difficult due to discrepancies between 
the predicted molecular mass (calculated from the amino acid sequence) and the molecular 
mass estimated by Western blot. In HT1080 cell lysates, active MTl-MMP has an 
apparent molecular mass of 60 kDa; calculations from the amino acid sequence predict that 
the catalytic, hinge and C-terminal domains (including the transmembrane region and 
cytoplasmic tail) account for 54 kDa. MTl-MMP has two potential glycosylation sites: 
one in the catalytic domain at position Asn 130, and the other in the hinge region at 
position Asn 311 (Fig. 6.7). Each glycosylation has the potential to add 3-5 kDa to the 
molecular mass of MTl-MMP. One could assume, therefore, that at least one of the sites 
is glycosylated. However, results from our laboratory would indicate otherwise, for 
treatment of native MTl-MMP with N-glycanase (a de-glycosylating enzyme), did not lead 
to a reduction in molecular mass (Dr G. Butler, S. Atkinson, personal communication).
A firagment of MTl-MMP comprising residues 187-582 would have a mass of 45 kDa, 
assuming that MTl-MMP is not glycosylated. Several authors describe a truncated form of 
MTl-MMP at 43 kDa (Lohi et al., 1996; Cowell et al., 1998), which would correspond to 
residues 207-582. The estimation of molecular mass from SDS-PAGE is subject to a 
reasonable degree of error. Therefore, taking an average of 44 kDa, and assuming a +/- 2 
kDa deviation, the cleavage site in MTl-MMP may occur anywhere between residues 178 
and 215 (see Fig. 6.7). Further predictions can be made on the basis that proteolysis of 
MTl-MMP to the 45 kDa form is MMP dependent. Nagase et al. (1991) published a 
listing of seventy ECM, MMP and serpin sequences cleaved by MMPs (but not MT-
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MMPs). These sequences were compared by eye with residues 178-215 of MTl-MMP, 
but there was no obvious sequence homologous to the cleavage site sequences published in 
the report by Nagase and co-authors. However, a set of fluorigenic peptides has been used 
to examine the Pi' specificity of MTl-MMP itself, and the rate of hydrolysis was greatest 
for peptide Dnp-Arg-Pro-Leu-Ala-Tyr-Trp-Arg-Ser-NH2 , with the cleavage occurring 
between Ala and Tyr, at Pi and P f respectively (Imper and van Wart, 1998). An Ala-Tyr 
pair occurs at position 202-203 in the sequence of MTl-MMP (Fig. 6.7), fiirthermore, 
residue 204 is a phenylalanine, and bulky hydrophobic residues are favoured by MMPs in 
the P2 ' position (Imper and van Wart, 1998). There is limited information available 
regarding the P3 ' specificity of MMPs, so it is difficult to predict how the proline at residue 
205 would affect cleavage specificity; however the P4 ' position on the substrate probably 
does not interact with the enzyme (Imper and van Wart, 1998). Therefore, based on the 
information available, a cleavage between Ala 202 and Tyr 203 residues is the best 
prediction.
Any cleavage between residues 178-215 of the catalytic domain of MTl-MMP would lead 
to a loss of the insert unique to MT-MMPs (Fig. 6 .6 ), but would leave the zinc box intact. 
Furthermore, cleavage between residues 178-215 could interfere with the coordination of 
the second zinc ion and the two calcium ions. These ions are essential for maintaining the 
stability of the catalytic site of the homologous structures stromelysin and neutrophil 
collagenase (Bode et al., 1994; van Doren et al., 1995). Most of the residues that 
coordinate 'structural' zinc and calcium ions in neutrophil collagenase are conserved in the 
MMPs, and are located between residues 180 and 200 of MTl-MMP. Therefore, it is 
hypothesised that if MTl-MMP is cleaved to 45 kDa somewhere between residues 178 and 
215, the severe disruption to the catalytic site would not only render it catalytically 
inactive, but could also interfere with the binding of TIMP inhibitors.
To test these hypotheses, quantities of purified 45 kDa MTl-MMP suitable for N-terminal 
sequencing were required. Metiiods for generating 45 kDa MTl-MMP enriched cell 
lysates/membranes were investigated. The first approach taken was to incubate
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membranes enriched in the 60 kDa form of MTl-MMP with active MMPs in vitro. 
Interestingly, bands apparently identical to the 45 kDa form were generated by all of the 
MMPs tested, including a gelatinase, stromelysin, collagenase and MTl-MMP itself. 
Clearly the cleavage site is very susceptible to MMP action. After 4 hours incubation with 
the enzymes, only a proportion of the MTl-MMP had been cleaved to 45 kDa, and so 
longer incubations were attempted. Unfortunately, extending the incubation did not 
increase the quantities of 45 kDa MTl-MMP generated. In fact, a 3 hour incubation 
yielded, at best, a membrane preparation that was approximately 1:1 of 60/45 kDa, 
according to the Western blot. Therefore, the next approach was to promote cleavage to 45 
kDa in cell culture.
PMA treatment proved the simplest method for promoting conversion to 45 kDa MTl- 
MMP in HT1080 cells. The polyclonal anti-MTl-MMP antibody N175, which performed 
well in Western blots, was used to immunoprecipitate 45 kDa MTl-MMP from PMA 
treated cell lysates. 45 kDa MTl-MMP was transferred to PVDF membrane; Ponceau S 
staining of the membrane revealed that sufficient 45 kDa MTl-MMP was obtained for N- 
terminal sequencing. However, repeated attempts to sequence the excised band were 
frustrated by N-terminal blocking of the protein. Assuming that the 45 kDa form of MTl- 
MMP is not naturally blocked, a blockage must have occurred during the lysis, 
immunoprécipitation or electroblotting procedures. Care was taken to use high quality 
reagents, and to remove reactive species from the SDS-polyacrylamide gel, but to no avail.
Immunoprécipitation procedures were repeated, but reverse-phase HPLC was substituted 
for SDS-PAGE as a means of separating the MTl-MMP. Material eluted from the Protein- 
G Sepharose column did not contain sufficient MTl-MMP to obtain a peak from the 
HPLC column. Failure to purify enough MTl-MMP by immunoprécipitation reflected the 
inability of N175 to recognise epitopes on native MTl-MMP, as this antibody was raised 
to denatured material. Other antibodies were sought that have a strong affinity for the 45 
kDa form of MTl-MMP. At the time of writing, there were no suitable antibodies 
available.
149
Alternative strategies were needed to partially purify MTl-MMP, ready for a final step of 
reverse-phase HPLC purification. The high concentrations of detergent used in the cell 
lysis ruled out chromatographic procedures traditionally used for MMP purification. Other 
extraction methods were tried, but those that successfully extracted MTl-MMP all 
contained detergents such as Lubrol, NP40 and sodium deoxycholate. MMP/hydroxamate- 
inhibitor interactions have been used to purify MMPs (Moore et al., 1986). Although 
severe disruption of the catalytic domain is predicted on truncation of MTl-MMP to 45 
kDa, binding to hydroxamate inhibitors may be retained. Future experiments could test the 
binding of membrane-bound MTl-MMP forms to Pro-Leu-Gly-Leu linked to Sepharose. 
This is known to be an affinity ligand for the soluble form of MTl-MMP.
Surprisingly, attempts to generate a '45 kDa' form of MTl-MMP fi’om cleavage of 
recombinant material failed. The recombinant ATM-MTl-MMP employed for these 
studies was susceptible to MMP action; incubation with GLA and CL-3 generated a 
doublet of 34/32 kDa. Incubation of active ATM-MTl-MMP alone also generated the 
doublet, but the proteolytic degradation did not appear to proceed via a form equivalent to 
the 45 kDa MTl-MMP. The MTl-MMP/TIMP-2 'receptor' hypothesis discussed in 
Chapter 5 predicts that the majority of MTl-MMP is bound to TIMP-2 at the cell surface, 
with adjacent, proteolytically active TIMP-2 'fi-ee' MTl-MMP molecules. It is an open 
question as to which MTl-MMP molecule is cleaved to 45 kDa, however, it is possible that 
TIMP-2 acts to stabilise MTl-MMP in a conformation that exposes the 45 kDa cleavage 
site. In an attempt to cleave recombinant ATM-MTl-MMP to a '45 kDa' equivalent, the 
recombinant active MTl-MMP was complexed with TIMP-2 prior to incubation with 
active GLA, but no 45 kDa equivalent was generated.
Alternatively, transmembrane anchorage of MTl-MMP may induce a conformation that 
exposes the 45 kDa cleavage site. One option that was not explored was the linkage of 
ATM-MTl-MMP to a solid phase, such as heparin-agarose. Data fi*om our laboratory has 
indicated that both ATM-MTl-MMP and GLA have heparin binding sites in the
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hemopexin domain (Butler et al., 1998). The addition of soluble heparin potentiates the 
rate of proGLA activation by ATM-MTl-MMP, presumably by concentrating and 
colocalising the two components (Butler et al., 1998). Future experiments could 
investigate whether the binding of ATM-MTl-MMP to heparin or heparin-agarose is 
enough to induce a conformational change, such that the molecule is cleaved to 45 kDa, 
either autolytically, or by heparin bound active GLA.
In conclusion, future attempts to generate sufficient MTl-MMP for N-terminal sequencing 
will require either i) an antibody that has a high affinity for native 45 kDa MTl-MMP for 
immunoprécipitation purposes, or ii) the development of other chromatographic procedures 
to partially purify 45 kDa MTl-MMP from cell lysates/membranes. A cell line 
overexpressing MTl-MMP would be an advantage, due to increased levels of the 45 kDa 
form in overexpressing cells.
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6.4 Addendum
Subsequent to the completion of this chapter, a report was published describing the 
purification and N-terminal sequencing of a recombinant soluble MTl-MMP truncated to 
43 kDa. The authors (Lehti et al., 1998) also reported difficulties with obtaining the N- 
terminal sequence of the wild type truncated (43 kDa) form of MTl-MMP. Therefore, a 
novel approach was used to obtain sufficient enzyme for sequencing. A recombinant 
ATM-MTl-MMP vector was engineered with six additional histidine residues at the C- 
terminal end and transfected into HT1080 cells. Stably transfected clones were selected 
and the conditioned medium immunoblotted to show that the main forms of MTl-MMP 
migrated on SDS-PAGE at slightly less that wild-type 60 and 43 kDa forms of MTl-MMP. 
The soluble '43' kDa form was then purified firom the conditioned medium using a metal- 
affinity resin, transferred to PVDF membrane and analysed by N-terminal sequencing. 
This form of MTl-MMP had an N-terminM amino acid of He 256, with a calculated 
molecular mass of 37.8 kDa, although it migrated at approximately 43 kDa on SDS-PAGE. 
As we had predicted, this truncated form of MTl-MMP lacked the insert region in the 
catalytic domain that is unique to MTl-MMP, but also, surprisingly, the zinc-binding 
region (Fig. 6.7). Of great concern, the predicted Ala 255- He 256 cleavage occurs in the 
region of the 'methionine-tum', a conserved region in the MMPs. This tight turn at Met 
257 is buried adjacent to the highly hydrophobic active site helix (Femandez-Catalan et al.,
1998) and one would predict that it is not accessible for MMP cleavage. In view of our 
experience that soluble forms of MTl-MMP are processed differently to the membrane 
associated enzyme, it is not clear whether this soluble cleavage event is comparable to the 
membrane-bound product. Efforts to sequence wild-type 45 kDa MTl-MMP are ongoing 
in our laboratory, for comparison with the sequence reported by Lehti and coworkers.
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Figure 6.1 Incubation of membrane bound native MTl-MMP in vitro with MMPs
Cell membranes enriched in the 60 kDa form o f MTl-MMP were prepared from cultures of MTl-MMP 
transfected HT 1080 cells grown in the presence of CT1746 inhibitor. Membrane preparations were incubated 
alone, or in the presence o f active MMPs for 4 hours at 37°C. The cleavage reaction was stopped by the 
addition of Laemmli sample buffer, and the protein mixture separated by 10% SDS-PAGE, electroblotted to 
nitrocellulose and probed with the polyclonal antibody to MTl-MMP. Cell membranes incubated alone (lane 
2), or in the presence of active GLA (lane 3), active ATM MTl-MMP (lane 4), active SL-1 (lane 5), active 
CL-3 (lane 6). Cell membranes, unincubated (lane 1). Recombinant active ATM MTl-MMP, incubated 
alone (lane 7). Molecular mass markers are indicated on the right.
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Figure 6.2 Cleavage of native MTl-MMP with MMPs: a time course study
Cell membranes enriched in the 60 kDa form o f MTl-MMP were prepared from cultures o f MTl-MMP 
transfected HT1080 cells grown in the presence o f CTI746 inhibitor. Membrane preparations were incubated 
alone, or in the presence o f active GLA at 37°C for the times indicated. The cleavage reaction was stopped 
by the addition o f Laemmli sample buffer, and the protein mixtures separated by 10% SDS-PAGE, 
eiectrobiotted to nitroeeiiulose and probed with the polyclonal antibody to MTl-MMP. Molecular mass 
markers are indicated on the right.
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Figure 6.3 Immunoprécipitation of MTl-MMP from HT1080 cell lysates
Cell lysate was prepared from HT1080 cells treated with PMA. MTl-MMP was immunoprecipitated from 
the lysate using a polyclonal antibody to MTl-MMP (N175). Immunoprecipitates were reduced and 
separated by 10% SDS-PAGE, transferred to nitrocellulose by electroblotting and probed N175. The blue 
arrow indicates the immunoprecipitated MTl-MMP and the black arrows indicate the N175 IgG present in 
the immunoprécipitation mixture, which was detected by the secondary antibody. Molecular mass markers 
are indicated on the right.
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Figure 6.4 Purification of MTl-MMP immunoprecipitates for reverse-phase HPLC
Lysates from HT1080 cells treated with PMA were immunoprecipitated with a sheep anti-MTl-MMP 
antibody. Immunoprecipitates were passed down a column o f Protein G Sepharose and eluted with 25 mM 
Tris/HCl pH 7.5 containing 8 M guanidinium-HCl (eluate 1), followed by Laemmli reducing buffer (eluate 
2). Column fractions (10 pi) were separated by 10% SDS-PAGE, proteins transferred to nitrocellulose by 
electroblotting and probed with the sheep anti-MTl-MMP antibody. PMA treated HT1080 lysate (lane 1); 
proteins not bound by Protein G Sepharose (lane 2); column washes (lanes 3-7); eluate 1 (lanes 8-11); column 
washes (lanes 12-14) and eluate 2 (lane 15). Molecular mass markers are indicated on the left.
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Figure 6.5 Cleavage of recombinant ATM MTl-MMP with active MMPs
Recombinant ATM MTl-MMP was incubated alone, or in the presence o f recombinant MMPs for 4 hours at 
37°C. The eleavage reaction was stopped by the addition o f Laemmli sample buffer, and the protein mixture 
separated by 10% SDS-PAGE.
A. Silver stain analysis: recombinant ATM MTl-MMP incubated alone (lane 2) or in the presence o f active 
GLA (lane 3), active ATM MTl-MMP (lane 4), active SL-1 (lane 5), active CL-3 (lane 6). Control MMPs, 
unincubated: pro-ATM MTl-MMP (lane 1), active GLA (lane 7), active SL-1 (lane 8), active CL-3 (lane 9). 
Molecular mass markers are indicated on the right.
B. Western blot analysis: proteins separated by SDS-PAGE were electroblotted onto nitrocellulose and 
probed with a polyclonal antibody to MTl-MMP. Recombinant ATM MTl-MMP incubated alone (lane 2) or 
in the presence o f active GLA (lane 3), active ATM MTl-MMP (lane 4), active SL-1 (lane 5), active CL-3 
(lane 6). Control MMPs, unincubated: pro-MTl-MMP (lane 1), active GLA (lane 7), active SL-1 (lane 8), 
active CL-3 (lane 9). Molecular mass markers are indicated on the right.
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Figure 6.6 Cleavage of recombinant ATM MTl-MMP/TIMP-2 complex with GLA
Recombinant active ATM MTl-MMP was complexed with recombinant TIMP-2 for 1 hour at 25°C. Active 
ATM MTl-MMP/TIMP-2 complexes were then incubated alone or in the presence o f recombinant active 
GLA for 5 hours at 37°C. The cleavage reaction was stopped by the addition o f Laemmli sample buffer, the 
protein mixture separated by 10% SDS-PAGE and analysed by silver stain. Active ATM MTl -MMP/TIMP-2 
complexes incubated alone (lane 5), or in the presence o f active GLA (lane 6). Active ATM MTl- 
MMP/TIMP-2 complexes unincubated (lane 4). Control lanes: unincubated pro-ATM MTl-MMP (lane 1); 
pro-ATM MTl-MMP incubated alone (lane 2), pro-ATM MTl-MMP incubated with active GLA (lane 3); 
unincubated TIMP-2 alone (lane 7) and unincubated active GLA (lane 8). Molecular mass markers are 
indicated on the right.
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Figure 6.7 Schematic representation and amino acid sequence of MTl-MMP
Reproduced with kind permission from Cowell, 1997.
A. Schematic representation of MTl-MMP domains.
B. Amino acid sequence, modified from Sato et al, 1994. The colour code used for the sequence corresponds 
to the colours used in A., which represent the various functional domains of MTl-MMP. The furin cleavage 
site is marked with an arrow and the potential glyeosylation sites are marked with stars. The arrowhead 
indicates the Ala 255-Ile 256 cleavage site at the N-terminus of the 43 kDa form of MTl-MMP reported by 
Lehti et al., 1998.
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Chapter 7 General Discussion
Cell-matrix interactions affect a diverse range of cellular functions including cell 
differentiation, migration, proliferation and survival. Information provided by the ECM 
via cell surface receptors can control processes of embryonic growth and differentiation, 
tissue remodelling and repair. It follows that localised proteolytic degradation of the ECM, 
and the release of matrix fragments and matrix bound growth factors and cytokines will 
have a profound effect on cell behaviour. This thesis examines the role of MMPs in the 
cellular response to the pericellular environment, with particular reference to GLA and its 
activators. Data from this thesis has led to two main publications and this discussion has 
been divided accordingly.
A. The recognition sites o f the integrins a ip i  and a ip i  within collagen IV  are 
protected against GLA attack in the native protein
The aim of this study was to assess the susceptibility of three different solubilised forms of 
type IV collagen to GLA cleavage, and to investigate the concomitant effects on cell 
binding to the collagen. The study was based on the observation that GLA cleaves 
collagen IV in close proximity to the CB3[IV] region of collagen IV, that contains the 
recognition sites for a i p i  and a2 p l integrins. It was hypothesised that cleavage in this 
region might impair integrin/collagen IV interactions, thus affecting cell attachment. The 
approach of the study was to compare cell adhesion to intact collagen IV preparations with 
cell adhesion to collagen IV fragments generated by prior incubation with GLA. Collagen 
IV preparations solubilised by different methods were compared.
This study yielded unexpected results, which are o f significance to the design of future 
experimental models incorporating solubilised collagen IV. Two preparations of collagen 
IV monomers, extracted from EHS tumours using ostensibly identical conditions, proved 
to have markedly different susceptibilities to GLA action. Preparation B was not cleaved 
by GLA even when the temperature was raised to 37°C. A closer examination of the 
preparations by non-reducing SDS-PAGE, revealed that the intramolecular disulphide 
bonds were reduced to a greater extent in preparation A than in preparation B. Cell
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adhesion studies showed that the integrin binding sites in preparation A were largely 
destroyed by GLA action, whereas the integrin binding sites in preparation B remained 
intact.
Clearly, with regards to our original hypothesis, the interpretation of the data depended 
upon the preparation of collagen IV chosen for the study. This was of great concern, as the 
preparations of collagen IV monomers available commercially are isolated from EHS 
tumours under the same conditions as those used for preparations A and B. Several 
commercial preparations of collagen IV monomers were investigated using non-reducing 
SDS-PAGE, and cleaved with GLA. The results confirmed that the commercial 
preparations are subject to the same degree of variation in disulphide bonding as 
preparations A and B.
Collagen IV preparations solubilised by alternative extraction methods were then 
investigated. Dimeric collagen IV extracted from human placenta by bacterial collagenase 
proved resistant to GLA attack, reflecting the protection offered by the intact disulphide 
bonds in the NCI region. Cell attachment to the collagen IV dimers was unaffected by 
GLA treatment. In contrast, tetrameric collagen IV isolated from the EHS tumour by 
pepsin treatment was very susceptible to cleavage by GLA, and this was attributed to the 
loss o f the C-terminal NCI domains upon pepsin extraction. Despite the extensive 
degradation by GLA apparent on SDS-PAGE analyses, the cell attachment to collagen IV 
was not affected.
It would make an interesting study to compare the collagen IV preparations as barriers in a 
cell invasion study, using a cell line that expresses high levels of active GLA (such as 
HT1080 cells). The original hypothesis for tumour cell migration put forward by Liotta 
and Stetler-Stevenson (1991) predicted that proteolytic dissolution of the matrix is required 
to allow movement of the cell through tissue barriers. Based on this hypothesis, one would 
predict that collagen IV preparations with intact intramolecular disulphide bonds would 
prove to be a greater barrier to cell invasion than preparations in which the disulphide
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bonds were reduced, as the latter would be more susceptible to protease action. Such 
studies might highlight the need for careful choice of soluble collagen IV preparations 
when planning investigations in which GLA degradation is an issue.
Studies reported in this thesis shed light on some of the discrepancies in the literature 
regarding the susceptibility of collagen IV to gelatinase action. For instance, it can be 
surmised that the study by Mackay et al. (1990) in which collagen IV monomers were 
found to be resistant to GLA attack, reflects a high degree of intramolecular disulphide 
bonds in the CB3[IV] region of the monomers used. These authors make the point that 
GLA is a poor 'type IV collagenase' in comparison with other members o f the MMP family 
such as stromelysin. Studies carried out in our laboratory agree with this statement, as both 
SL-1 and CL-3 proved to more efficient at degrading preparation B monomers than GLA 
or GLB.
Studies have shown that the presence of active GLA correlates with the invasive phenotype 
of breast and non-small lung carcinoma (Brown et ah, 1993a; 1993b). This has been 
attributed to the type IV collagenolytic properties of GLA, which may facilitate invasion 
through host membranes. Support for this hypothesis has come from studies showing that 
TIMP-2 inhibits tumour cell invasion through amnion basement membrane, smooth muscle 
cell generated basement membrane, and Matrigel (Albini et ah, 1991; DeClerck et ah, 
1991; DeClerck et ah, 1992). It remains to be seen whether collagen IV incorporated into 
the macromolecular network is susceptible to GLA action. As the tumour cell invasion 
studies did not distinguish between GLA action and action of other MMPs, future studies 
should address whether the combined action of several MMPs leads to invasion of 
basement membranes.
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B. The activation o f GLA by HT1080 cells is promoted by culture on a fibronectin 
substrate and is concomitant with an increase in processing o f MTl-MMP to a 45 kDa 
form
The aim of this study was to search for ECM molecules that influence the cellular 
activation of GLA. The study focussed on fibronectin, which is a multifunctional ECM 
protein that controls diverse cellular functions such as adhesion, migration, differentiation 
and cell fate. Fibronectin in solution is a highly flexible molecule, but adsorption to plastic 
or deposition into the matrix exposes activities of fibronectin that are latent in the soluble 
molecule (discussed in Chapter 1). Studies have shown that adsorption o f plasma 
fibronectin onto plastic exposes cell adhesive activities (Ugarova et al., 1995). The 
approach taken in the current study was to examine GLA activation by HT 1080 cells 
cultured on adsorbed fibronectin. Analysis of gelatinase expression by zymography 
revealed that the processing of GLA to the active form was promoted by fibronectin. A 
substrate of laminin-1 proved to be a suitable reference for these studies, as the GLA 
secreted by HT 1080 cells cultured on laminin-1 was mostly in the pro-form. It has been 
published previously that PMA induces GLA activation by HT1080 cells (Lim et al., 1996; 
Lohi et al., 1996) and a comparison of the GLA activation induced by fibronectin and that 
induced by PMA treatment indicated that fibronectin had a potent effect on the GLA 
activation pathway. The fibronectin effect was a novel finding, as previously the induction 
of GLA activation had been attributed to collagen matrices only (Azzam and Thompson, 
1992; Seltzer et al., 1994; Gilles et al., 1997; Tomasek et al., 1997; Haas et al., 1998).
The next approach was to use peptide fragments of fibronectin to determine whether the 
up-regulation of GLA activation was linked to interactions with a particular domain of 
fibronectin. Several fragments from the central cell binding domain encompassing the 
RGD integrin binding site of fibronectin induced GLA activation when adsorbed to culture 
plastic. This implied that integrin receptors might be signalling GLA activation. Cell 
adhesion studies to full length fibronectin confirmed that HT 1080 cells adhere to 
fibronectin via aS p i integrin only. Accordingly, antibodies to the a5 and p i integrin 
subunits were used as substrates for HT 1080 cell adhesion. The activation of GLA was
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induced by both mAh 16 (anti-a5) and mAh 13 (anti-pl), both of which are known to 
cause integrin receptor clustering (Akiyama et ah, 1989). For comparison, HT1080 cells 
were cultured on an antibody to the a6  integrin subunit, as HT 1080 cells attach to laminin- 
1 via a6 p i integrin. The GLA secreted by cells cultured on this antibody was mostly in 
the pro-form, which correlated well with the level of GLA activation effected by a 
substrate laminin-1. The data implied that signals via the a 5 p l integrin promote GLA 
activation by HT1080 cells. Further insight into the integrin signalling mechanism 
involved was gained by a comparison of two different anti-a5 integrin antibodies as culture 
substrates. GLA activation was promoted when the cells were cultured on mAh 16, which 
clusters integrins and mimics the action of the fibronectin ligand, whereas mAh 11, which 
clusters integrins but does not mimic ligand occupancy (Akiyama et al., 1989) failed to 
effect GLA activation.
Current models for integrin mediated signalling postulate that integrin cytoplasmic tails are 
associated with large aggregates of signal transduction molecules, immobilised on the 
membrane-associated cytoskeleton. Clustering of integrins caused by a multivalent ligand 
such as an ECM molecule, or an anti-integrin antibody has been shown to cause the 
transmembrane accumulation of a wide variety of cytoskeletal proteins and signalling 
molecules (reviewed by Yamada and Geiger, 1997). Anti-integrin antibodies have proved 
to be an invaluable tool in dissecting out these associations. Miyamoto et al. (1995b) used 
latex beads coated with mAh 11 in a fibroblast culture model to show that integrin 
clustering triggers the accumulation of twenty signal transduction molecules (including 
RhoA, Racl, Ras, R afl, ERKl and 2, JNK l, PI3-kinase and PLC-y ), along with focal 
adhesion kinase (FAK) and the cytoskeletal protein tensin. Significantly, beads coated 
with mAh 16 or mAh 13 induced the further accumulation of the cytoskeletal proteins 
vinculin, talin, and a-actinin, as well as F-actin, filamin and paxillin. This process 
appeared to require tyrosine kinase activity in addition to cytoskeletal organisation, as in 
the presence of tyrosine kinase inhibitors, mAb 11 induced the transmembrane 
accumulation of tensin and FAK only, and mAb 16 and mAb 13 induced the accumulation 
of tensin, vinculin, talin, a-actinin and FAK only (see Fig. 7.1). As discussed in Chapter 4,
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the addition of a monovalent ligand (such as an RGD peptide) to cells stimulated with mAh 
11 restored the full complement of cytoskeletal proteins and signal transduction molecules 
attributed to treatment with mAb 16. Future studies could be aimed at investigating the 
importance of tyrosine kinase activity in the signalling of GLA activation in the HT 1080 
model. The tyrosine kinase inhibitors genistein and herbimycin A would be useful tools 
for preliminary studies (Miyamoto et al., 1995b), and might give some insight into the 
types of cytoskeletal proteins and signalling models required for GLA activation to 
proceed.
An exciting development over the last few years has been the discovery that integrin 
receptors colocalise and act in synergy with growth factor receptors. Many of the 
signalling pathways downstream of integrin clustering are in common with signalling 
pathways activated by growth factor receptor ligation (for review, see Dedhar and 
Hannigan, 1996). Using a similar approach to that described above, Miyamoto et al. 
(1996) used beads coated with fibronectin, mAb 13 or mAb K20 (similar in action to mAb 
11) to show that the ERK class o f MAP kinases is activated by integrin aggregation alone, 
or by various growth factors. However, in the presence of integrin receptor occupancy the 
growth factors EGF, PDGF or bFGF caused a marked and additive increase in ERK 
activity. Each of the receptors for EGF, PDGF or bFGF were induced to accumulate at 
sites o f integrin-ligand aggregation, even in the absence of the growth factor ligands. The 
combination of integrin occupancy and growth factor ligand also led to a synergistic 
increase in growth factor receptor tyrosine phosphorylation (Miyamoto et al., 1996). 
Others have also reported colocalisation and synergism between growth factors and 
integrin receptors (Plopper et al., 1995; Schwartz et al., 1995; Schneller et al., 1997). 
Fibroblast adhesion to fibronectin in the presence of PDGF stimulates phosphatidyl 
inositol hydrolysis (McNamee et al., 1993). Specifically, McNamee and coworkers 
reported that integrin ligation increases the activity of PI5-kinase via the regulatory 
molecule Rho, generating the substrate 4,5-PIP2, while PDGF concomitantly activates 
PLC-y to hydrolyse the substrate and generate second messengers. These studies highlight 
the need to consider the presence of endogenous growth factors in the current experimental
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model. However, it must be stressed that the cultures were serum-free and it has been 
reported that after extensive serum starvation integrins cannot synergise with growth 
factors for MAP kinase activation (Miyamoto et al., 1996).
Foda et al. (1996) reported that PMA induction of GLA activation by human umbilical 
vein endothelial cells is mediated by protein kinase C (PKC) and is accompanied by an 
increased synthesis of MTl-MMP. Others have shown that PKC mediates the IL -la  
induced increase of CL-1 and SL-1 expression in cervical fibroblasts (Takahashi et al., 
1993) and the collagen stimulated induction of CL-1 expression in a keratinocyte cell 
model (Sudbeck et ah, 1994). Although it has yet to be demonstrated whether PKC is 
associated with the accumulation of signalling molecules induced by integrin clustering, 
the activation of PKC has been shown to precede aS p i integrin mediated cell spreading on 
fibronectin (Vuori and Ruoslahti, 1993). Given these associations, future experiments 
could determine whether PKC mediates fibronectin induced GLA activation, by 
incorporating PKC inhibitors such as chelythrine chloride (De Nichilo and Yamada, 1996) 
into the HT 1080 culture model.
In a recent report, Kheradmand et al. (1998) examined the role o f the Rho family of GTP- 
binding proteins in signalling changes to the actin cytoskeleton that up-regulate MMP 
expression. They demonstrated two divergent signalling pathways involved in the a5 p i 
mediated up-regulation of CL-1 synthesis by rabbit synovial fibroblasts. Surface-bound 
120 kDa fragment of fibronectin, or surface-bound anti-a5 integrin subunit antibody 
promoted cell spreading and increased CL-1 expression by the fibroblasts. In contrast, 
addition o f soluble anti-a5 antibody to cells cultured on fibronectin caused cell rounding 
and disruption of the cytoskeleton, but also induced CL-1 expression. As members of the 
Rho family (Rho, Rac and Cdc42) control the organisation and dynamics of the actin 
cytoskeleton, an investigation of the contribution of Rho family members to CL-1 
expression was made. The transient transfection of dominant interfering mutants of Rho, 
Rac and Cdc42 into synovial fibroblasts revealed that Rac mutants (but not Rho or Cdc42 
mutants) inhibited the induction of CL-1 by soluble anti-a5 integrin antibodies.
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Furthermore, the transient expression of constitutively activated Rac 1 reduced actin stress 
fibres, increased the formation of actin-rich lamellipodia and stimulated CL-1 expression 
by the cells. Transient expression of Rac 1 also induced the rapid nuclear translocation and 
constitutive activation of the transcription factor NF-kB. This in turn promoted IL-1 gene 
transcription. Finally, study including the IL-1 receptor antagonist confirmed that IL-1 is 
an autocrine mediator involved in the induction of CL-1 expression by soluble anti-a5 
antibodies in these cells. This report clearly and comprehensively showed that soluble 
anti-a5 integrin antibodies induce Rac activity in fibroblasts, which disrupts the 
cytoskeleton, and activates NF-kB mediated IL-1 synthesis, leading to increase in CL-1 
expression.
Other studies have also shown that MMP expression and activation is linked to changes in 
the cytoskeleton. Cytoskeletal disrupting agents such as the cytochalasins have been 
shown to increase GLA activation by fibroblasts cultured in collagen lattices (Tomasek et 
ah, 1997) and increase CL-1 synthesis by synovial fibroblasts (Aggeler et ah, 1984). 
Tomasek and coworkers showed that activation of GLA is associated with the mechanical 
relaxation of collagen lattices. In contrast, in a similar study, work with two adhesion 
blocking anti-pl integrin antibodies led to the observation that lattice contraction and GLA 
activation were separate events (Seltzer et ah, 1994). Both events were controlled by the 
p i integrin subunit, but specifically stimulated by different antibodies. The authors 
speculated that one antibody might cause more torsion of the p i integrin than the other, 
leading to two sets of intracellular signals. Alternatively, there may be branch points in the 
signal transduction pathway that lead to GLA activation (Seltzer et ah, 1994).
It is apparent that surface bound anti-a5 integrin antibody may signal changes to MMP 
expression via separate mechanisms to soluble anti-a5 integrin antibody. The study by 
Kheradmand and coworkers (1998) did not identify the signalling pathway involved in the 
up-regulation of CL-1 induced by surface-bound anti-a5 integrin antibody. However, 
immobilised antibody did not induce Racl or NF-kB activity, suggesting a second distinct 
pathway promoting CL-1 synthesis in synovial fibroblasts. Studies for this thesis showed
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that GLA activation by HT1080 cells was induced by fibronectin, peptide fragments of 
fibronectin, or by anti-a5pl integrin antibodies adsorbed to culture plastic. All of these 
ligands promoted cell spreading, and the activation of GLA appeared to proceed 
independently of discernible changes in cell shape. Immunolocalisation o f actin 
microfilaments with rhodamine-phalloidin would confirm whether actin stress fibre 
formation was associated with GLA activation in this model. However, future studies 
could address whether agents that disrupt the cytoskeleton, such as cytochalasin D also 
stimulate GLA activation. The effect of soluble anti-a5 integrin antibodies added to cells 
cultured on fibronectin should be tested. A positive link between cytoskeletal re­
organisation and GLA activation could be followed up by transfection of the dominant- 
interfering mutants o f the Rho family members into HT1080 cells, as detailed by 
Kheradmand and co-workers (1998). The requirement for an IL-1 autocrine loop in the 
aS p l integrin-mediated up-regulation of GLA activation could easily be tested by the 
addition of IL-1 neutralising antibodies or the IL-1 receptor antagonist to HT1080 cells 
cultured on fibronectin. Both approaches have been used to show that fibronectin 
fragments or anti-a5 integrin antibodies stimulate cellular expression of MMPs via an IL-1 
autocrine loop (Homandberg et al., 1997; Kheradmand et al., 1998).
Several members of our laboratory cultured other cell types on fibronectin and did not 
observe up-regulation of GLA activation. These cell types included A375M human 
melanoma cells, human foreskin fibroblasts, human endothelial cells and the human 
chondrosarcoma cell line SW1353. This may reflect the differing integrin expression 
patterns between HT1080 cells and the other cell types tested. Other studies have shown 
that A375M cells, foreskin fibroblasts and endothelial cells express avp3 integrin (Massia 
and Hubbell, 1991; Seftor et al., 1993; S catena et al., 1998), which also recognises the 
RGD sequence in fibronectin. In contrast, our HT1080 cell line did not appear to express 
avp3 integrin, and adhered to fibronectin solely via aS p l. One could hypothesise that the 
other cell types tested used predominantly avp3 integrin to adhere to fibronectin, and that 
signals via a 5 p l integrin were not activated. A study by Seftor et al. (1993) lends support 
to this hypothesis. These authors compared the moderately invasive A375M cells, which
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express higher levels of avp3 integrin than aS p i integrin, with highly invasive C8161 
melanoma cells, which express higher levels of aS p i than avp3 integrin. The C8161 cells 
responded to anti-aSpi integrin antibodies by increased levels o f proGLA synthesis and 
increased invasion through a Matrigel barrier. In contrast, the invasion of A375M cells 
through Matrigel was not increased in the presence o f anti-a5pl integrin antibodies. 
A375M cells were subjected to fluorescence activated cell sorting to select a population of 
cells deficient in avp3 integrin. These cells proved to be 30-50% more invasive than the 
parent A375M line. It is worth noting that, in general, avP3 integrin is associated with 
highly invasive melanomas (Marshall et al., 1991). Nevertheless, in the study by Seftor 
and coworkers, it would have been interesting to compare the proGLA secretion by parent 
and cloned A375M cells cultured on a fibronectin substrate, but this was not addressed. 
However, the current study could be extended by transfection of HT1080 cells with avp3 
integrin, as one would predict that transfected cells would activate less GLA on fibronectin 
than the parent HT 1080 cells.
The apparently unique response of HT1080 cells to fibronectin may also reflect their 
tumourigenicity. Although these cells synthesise fibronectin, they do not lay down a 
fibronectin matrix (Mardon et al., 1993). Overexpression of plasma-type fibronectin in 
HT 1080 cells was shown to promote the deposition of a fibronectin matrix, but reduced 
cell motility and cell proliferation (Akamatsu et al., 1996). The levels of a 5 p l integrin on 
the surface of cells overexpressing fibronectin were apparently unchanged. Fukai et al. 
(1995) showed that proteolytic cleavage of fibronectin by GLA releases the C-terminal 
fibrin binding domain of fibronectin that can simulate cell migration. It is possible that the 
HT1080 cells in the current study secreted increased levels of active GLA in response to a 
fibronectin matrix in order to maintain cell motility. This hypothesis could be tested by 
time lapse video microscopy of migrating cells. To assess the importance of GLA activity, 
HT1080 cell motility could be monitored in the presence and absence of blocking 
antibodies to GLA (such as K399). Similarly, HT1080 cells stably transfected with M Tl- 
MMP (used in studies for Chapter 6) may migrate on fibronectin more efficiently than the 
parent line, as these cells activate greater levels of GLA than the parent line (Dr J.
170
Gavrilovic, personal communication). It would also make a very interesting study to 
include soluble fibronectin fragments in HT 1080 cultures, particularly as the study by 
Fukai and coworkers identified a fragment that stimulates cell migration. There are well 
established methods for the purification of fibronectin fragments, and many fragments are 
now available commercially.
Studies such as those described above would aid our understanding of the significance of 
increased GLA activation in response to fibronectin. Other studies have shown that 
HT 1080 cells and various breast cancer cell lines activate GLA in response to collagen I 
(Azzam and Thompson, 1992; Gilles et al., 1997). The synthesis and activation of MMPs 
in response to matrix may be crucial for the invading tumour cell to pass through host 
interstitial matrices which are rich in fibrillar collagens and fibronectin. As discussed 
earlier, proteolysis of these matrices may lead to the release of fibronectin fragments that 
stimulate migration (Fukai et al., 1995; Fabunmi et al., 1996); the exposure of cryptic RGD 
sites in collagen I (Mackay et al., 1990; Montgomery et al., 1994); or the remodelling of 
the matrix such that directional migration is maintained (Pilcher et ah, 1997). Many 
parallels can be drawn between normal physiological remodelling processes and tumour 
cell invasion. However, the migration of untransformed cells during physiological 
remodelling is tightly controlled by various factors including the surrounding matrix. For 
instance, the migration of kératinocytes in a wound healing model is dependent upon intact 
collagen I, which induces CL-1 activity (Pilcher et ah, 1997). Laminin-1, which is 
deposited in the newly formed basement membrane of the epidermis, represses the 
collagen-mediated induction of keratinocyte CL-1 (Sudbeck et ah, 1997). The authors 
speculate that the accumulation of laminin-1 may effect the signal to halt keratinocyte 
migration as re-epithelialisation progresses (Sudbeck et ah, 1997). Similarly, tenascin-C 
inhibits oligodendrocyte precursor migration, by a process which is independent o f its anti­
adhesive properties (Kieman et ah, 1996). As tenascin-C is concentrated at the retina-optic 
nerve junction, it may serve as a barrier to inhibit the migration of oligodendrocyte 
precursor cells into the retina (ffrench-Constant et ah, 1988). In the current study, laminin- 
1 did not effect GLA activation by HT 1080 cells, and preliminary studies indicated that
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tenascin-C bound to fibronectin substrates down-regulated fibronectin-induced GLA 
activation (data not shown). Accordingly, the effect of laminin-1 and tenascin-C on 
HT 1080 cell migration could be tested by time lapse videomicroscopy of cells on mixed 
substrates.
Having established that fibronectin induces GLA activation in HT 1080 cells, the next step 
was to determine at what point in the GLA activation cascade fibronectin exerts its effect. 
As discussed in Chapter 1, proGLA activation is initiated by interaction of the C-terminal 
domain of proGLA with cell membranes (Murphy et al., 1992b; Strongin et ah, 1993; 
Ward et ah, 1994). Several models for GLA binding to the cell surface were postulated by 
researchers during the course of this study. Itoh et ah (1998) published recently that 
TIMP-2 binds to the cell surface independently of MTl-MMP and acts as a receptor for 
GLA (discussed in detail later in the chapter), although it is not clear how this binding 
contributes to GLA activation. GLA binding to cell-surface associated collagen via the 
fibronectin type II domains has also been observed (Steffensen et ah, 1998), however the 
authors considered it unlikely that these interactions contribute to GLA activation. Direct 
binding between avp3 integrin and the C-terminal domain of GLA has been reported using 
isolated integrin and GLA in solid-phase assays. Furthermore, full length GLA interferes 
with the binding of a functionally-blocking anti-avp3 integrin antibody to the avp3 
integrin ligand binding site (Brooks et ah, 1996; Brooks et ah, 1998). It has been 
suggested by these authors that this interaction localises proteolytically active GLA to 
discrete regions on the cell surface, facilitating angiogenesis and potentiating invasive 
behaviour. A parallel can be drawn with the well defined interactions between avp3 
integrin and urokinase plasminogen activator receptor (reviewed by Chapman, 1997). It 
has yet to be determined whether avp3/GLA binding contributes to the activation of GLA, 
or whether MTl-M M P colocalises with avp3 integrin, although one possibility suggested 
is that GLA binds to avp3 integrin after activation has occurred (Brooks et ah, 1998). As 
discussed in Chapter 5, it was considered unlikely that this mechanism was important in 
the current study, for immunolocalisation studies of HT 1080 cells cultured on fibronectin 
did not detect avp3 integrin (A. Messent and J. Gavrilovic, personal communication). It is
172
of concern that studies in our laboratory by A. Messent were unable to show direct 
interaction between isolated avp3 integrin and either recombinant chicken GLA (used in 
the studies by Brooks et ah, 1996, 1998) or human recombinant GLA (Messent, 1997). 
Much work is needed to determine whether the avp3 integrin/GLA interactions observed 
by Brooks et ah are a general mechanism, whether GLA colocalises with avp3 in all avp3- 
expressing cells, and whether avp3 integrin/ligand interactions are destabilised by the 
presence of bound GLA. It would also be interesting to determine whether GLA interacts 
with other integrins, although it has been reported by Brooks et ah (1996) that GLA does 
not bind immobilised a 5 p l integrin receptor.
It is clear that the association of TIMP-2 with the cell surface is a key event in the 
activation o f GLA. This study favoured the hypothesis that MTl-M M P and TIMP-2 
complex together to form a receptor for GLA (Strongin et ah, 1995; Butler et ah, 1998; 
Kinoshita et ah, 1998). Efforts were made to measure the TIMP-2 secreted by HT1080 
cells, however the levels were at the detection limit o f several of the techniques tried. 
Nevertheless, there was no apparent variation in the levels of TIMP-2 secreted by cells 
cultured on fibronectin or laminin-1 substrates. The levels of TIMP-2 associated with the 
cells at the end of the culture period were also similar for the two substrates. The data does 
not rule out rapid changes in the concentration of TIMP-2 at the cell surface over the 
culture period, and it is possible that the fibronectin substrate (in comparison to laminin-1) 
promoted the rapid recycling of TIMP-2 'receptors' for GLA. Pulse chase analyses would 
be required to detect such changes.
Fibronectin substrates appeared to exert an effect on the post-transcriptional regulation of 
MTl-MMP. A new antibody to MTl-MMP (N175) was characterised for use in these 
studies and examination of HT1080 cell lysates with N175 revealed that in addition to the 
63 and 60 kDa forms of MTl-MMP reported by others (Strongin et ah, 1995; Gao et al.,
1996), a band at 45 kDa was detected. The level of this form of MTl-M M P was up- 
regulated when cells were cultured on fibronectin, or in the presence o f PMA, and appeared 
concomitantly with processing of GLA to the active form. The 60 kDa form corresponded
173
most likely with active MTl-MMP isolated from HT1080 cells and N-terminally 
sequenced by Strongin et al. (1995). However, only one other group had reported a similar 
truncated form of MTl-MMP (43 kDa), detected by Western blot analyses of HT1080 cell 
lysates using an antibody to the cytoplasmic portion of MTl-MMP (Lohi et al., 1996). 
Assuming therefore, that the truncated form of MTl-MMP must still be membrane bound, 
calculations based on the apparent molecular weight predicted that the cleavage occured in 
the catalytic domain of MTl-MMP. It was hypothesised that this form was catalytically 
inactive.
The ability to process MTl-MMP to 45 kDa was not restricted to HT1080 cells. Work in 
our laboratory showed that human foreskin fibroblasts, human microvascular endothelial 
cells, a human chondrosarcoma cell line and several human melanoma cell lines also 
processed MTl-MMP to 45 kDa, but unlike the HT1080 cells, processing was not 
constitutive, and required concanavalin A or PMA as a cell stimulus. Zymography of the 
conditioned media from all cell types showed that processing to 45 kDa was accompanied 
by GLA activation, with the notable exception of PMA treated microvascular endothelial 
cells, which processed MTl-MMP to 45 kDa in the absence of processing of pro-GLA (C. 
Lindsay, personal communication). MTl-MMP truncation to 45 kDa appeared to be a 
common mechanism in stimulated cells, and we hypothesised that it might represent an 
important regulatory step in MTl-MMP mediated MMP activation cascades.
To purify sufficient 45 kDa MTl-MMP for N-terminal sequencing, several approaches 
were tried. Immunoprécipitation of MTl-MMP from cell lysates using N175 antibody did 
not provide sufficient material for further purification by reverse-phase HPLC 
chromatography, and transferring the immunoprecipitates to PVDF for microsequencing 
was confounded by N-terminal blocking of the protein. Attempts were made to generate 
45 kDa MTl-MMP in vitro, based on the observation that MTl-MMP is cleaved to 45 kDa 
by MMPs (discussed below). Cleavage of recombinant soluble MTl-MMP with MMPs 
did not appear to proceed via a '45 kDa' form and this was of concern. This indicated 
either that soluble ATM-MTl-MMP was folded in such a way that the cleavage site was
174
not accessible to protease action, or that the transmembrane domain and/or other 
membrane-bound molecules were required to facilitate MTl-MMP cleavage. After work 
was completed for this thesis, Lehti et al. (1998) published an N-terminal sequence of a 
truncated form of mutant MTl-MMP. These authors constructed a soluble mutant MTl- 
MMP construct, tagged C-terminally with histidines and expressed the construct in 
HT1080 cells. This approach was innovative, as it relied on the 'machinery' present within 
the HT1080 cell to process MTl-MMP to 45 kDa, but had the added advantage of a 
histidine tag on the recombinant molecule that could be utilised during subsequent 
purification. However, as the cleavage site was located to the hydrophobic 'methionine- 
tum' of MTl-MMP, which is expected to be buried within the molecule, it remains an 
important question as to whether wild-type MTl-MMP is cleaved at this sequence.
Further studies were undertaken to identify the enzyme(s) involved in processing MTl- 
MMP to 45 kDa. The addition of MMP inhibitors to HT1080 cells cultured on fibronectin 
identified the protease activity as an MMP. Work with isolated cell membranes firom 
HT1080 cells showed that MMPs fi'om all subclasses were capable of cleaving MTl-MMP 
to 45 kDa in vitro, implying that the cleavage site is particularly MMP sensitive. For 
future studies it would be interesting to use protease inhibitors specific for other classes of 
protease to determine whether other proteases (such as plasmin) also cleave MTl-MMP to 
45 kDa.
Notably, processing of MTl-MMP to 45 kDa by HT1080 cells was not inhibited by TIMP- 
1, which implied MTl-MMP autolysis to 45 kDa. Unfortunately, antibodies that block 
MTl-MMP activity were not available to test this hypothesis. The transient transfection of 
a catalytically inactive mutant of MTl-MMP into MTl-MMP null cells would provide an 
alternative method for testing the hypothesis, as one would predict that mutant MTl-MMP 
would not be processed to 45 kDa. However identifying a suitable cell line for transient 
transfection that does not express MTl-MMP could prove difficult, as the cell lines 
currently used in our laboratory for this style of study (Chinese hamster ovary cells, COS 
cells) express low levels of MTl-MMP. This study identified a new blocking antibody to
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GLA (K399) and work with this antibody indicated that processing of MTl-MMP to 45 
kDa by HT1080 cells is independent of GLA activity. As mentioned earlier, observations 
by C. Lindsay in our laboratory supported this concept, as PMA treated microvascular cells 
processed MTl-MMP to 45 kDa in the absence of detectable GLA activation. Hence it is 
apparent that whilst GLA activation and MTl-MMP processing to 45 kDa are often 
concomitant, they are not interdependent events.
Other questions remain with respect to the biology of 45 kDa MTl-MMP. What is its 'life 
cycle', does it have a biological role, or is it simply an inactive byproduct of MTl-MMP 
activity that is resorbed back into the cell? With regards to the truncation of MTl-MMP to 
45 kDa, evidence suggests that it is associated with the routing of MTl-MMP to the cell 
surface. Cell surface biotinylation studies by Lehti et al. (1998) showed that the 63, 60 and 
43 kDa forms of MTl-MMP are all present at the surface of HT1080 cells. In our 
laboratory, circumstantial evidence that processing to 45 kDa is associated with the cell 
surface was provided by a comparison between concanavalin A and PMA treated human 
foreskin fibroblasts. Immunolocalisation studies showed that concanavalin A treatment of 
the fibroblasts stimulated MTl-MMP localisation to the cell surface, and concurrent 
Western blot analysis of the cell lysates indicated that MTl-MMP was processed to 45 kDa 
(R. Hembry, H. Stanton, G. Murphy, unpublished data). In contrast, however, PMA 
treatment of the foreskin fibroblasts caused the intracellular accumulation of MTl-MMP in 
the perinuclear region, with no cell surface staining apparent (d'Ortho et al., 1998). 
Strikingly, no 45 kDa MTl-MMP was detected by Western blot analysis of the cell lysates, 
and GLA activation was not stimulated. Although PMA treatment appeared to increase the 
expression of MTl-MMP in the fibroblasts, it did not signal the routing of MTl-MMP to 
the cell surface, or the processing of MTl-MMP to 45 kDa. Clearly, the response to PMA 
is cell type specific, as evidenced by the differences between the fibroblast model, the 
endothelial cell model studied by C. Lindsay and the HT1080 cell model used in this study.
Notably, the HT1080 cells were the only cell type studied that showed constitutive staining 
for MTl-MMP on the cell surface. Staining was apparent over the entire cell surface.
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which differs markedly from the staining patterns reported by Nakahara et al. (1997) who 
observed MTl-MMP localised to the invadopodia of human melanoma cells. Clustering of 
MTl-MMP molecules at the leading edge of migrating cells may be essential for the 
localised degradation of matrix required for directional migration. It is likely that a 
sequence in the transmembrane domain/cytoplasmic domain of MTl-MMP targets it to 
invadopodia, as a chimeric MTl-MMP containing the transmembrane and cytoplasmic 
domains of the interleukin-2 receptor alpha chain was not localised to invadopodia, and 
localised ECM degradation attributable to MTl-MMP was not observed (Nakahara et al.,
1997). Furthermore, concanavalin A prevented the invadopodial localisation of MTl- 
MMP and matrix degradation. In the light of these studies, it would be interesting to 
investigate the matrix-degrading abilities of HT1080 cells, which do not appear to localise 
MTl-MMP molecules at the leading edge. A model system such as that used by d'Ortho et 
al. (1998) may be suitable for this investigation.
Pulse chase analyses by Lehti et al. (1998) have shown that 45 kDa form of MTl-MMP is 
relatively short-lived. Processing of MTl-MMP to 45 kDa by PMA treated HT1080 cells 
occurred within 1.5 hours of stimulation, and levels of 45 kDa MTl-MMP decreased to 
barely detectable levels after 16 hours of stimulation. For the current study, attempts to 
label newly synthesised MTl-MMP with [35S]-methionine failed, compounded by 
problems with using the antibody N175 for immunoprécipitation. However, a preliminary 
time-course study analysed by Western blotting showed that PMA treatment of HT 1080 
cells stimulated MTl-MMP processing to 45 kDa during the first 2 hours of stimulation, 
and that the levels of 45 kDa in the cell lysates then remained constant (data not shown). It 
is possible that continued PMA stimulation caused a constant turn-over of 45 kDa MTl- 
MMP. Certainly the levels of 45 kDa MTl-MMP detected in the lysates of PMA treated 
HT1080 cells were significant after 48 hours of culture (as shown in Chapter 5).
With regards to the biological role of MTl-MMP, it is tempting to speculate that truncation 
of MTl-MMP to 45 kDa accompanies the release of active GLA (although it can also 
proceed independently of GLA activation). It is possible that TIMP-2 'fi-ee' MTl-MMP on
177
the cell surface is involved with processing the MTl-MMP/TIMP-2 receptor complex to 
release GLA, creating 45 kDa MTl-MMP in the process. However, as the 45 kDa 
cleavage site in MTl-MMP is apparently in a highly hydrophobic region of the molecule 
(Lehti et al., 1998), it is difficult to predict the molecular dynamics of the process. It is 
also possible that MTl-MMP is cleaved to 45 kDa following release of active GLA/TIMP- 
2, as a means of regulating the number of 'receptor' complexes available for GLA binding 
to the cell surface.
One question that must be addressed is what is the fate of GLA upon activation at the cell 
surface? Is it immediately inhibited by TIMP-2, or is TIMP-2 degraded upon release from 
the MTl-MMP receptor complex? The recent report by Itoh et al. (1998) presents an 
intriguing hypothesis. Using concanavalin A treated cells, these authors demonstrated that 
TIMP-2 is bound to cell membranes via hydroxamate inhibitor sensitive and insensitive 
mechanisms, implying that TIMP-2 binds to the cell membrane independently of MTl- 
MMP. In addition, TIMP-2 bound to cell membranes in a hydroxamate insensitive way 
specifically inhibited active GLA, but not active SL-1 or GLB. The data implied that upon 
release of active GLA/TIMP-2 from the cell surface 'receptor', the N-terminal domain of 
TIMP-2 then inhibited the catalytic domain of GLA. It follows that all GLA released in 
this manner would be rendered inactive by bound-TIMP-2, which begs the question of how 
catalytically active, TIMP-2-firee GLA is produced. However, using zymography to 
analyse the conditioned medium from concanavalin A treated cultures, the authors noted 
the presence of the 45 kDa truncated form of GLA lacking a C-terminal domain, that was 
shown to be catalytically active. GLA can be processed to 45 kDa autolytically, or by 
other MMPs, and the authors speculated that this form of GLA was responsible for GLA 
catalytic activity, not the 65 kDa 'active' form of GLA seen by zymography. In the current 
study, using fibronectin or PMA treated HT1080 cells, there was no 45 kDa GLA detected 
in the conditioned media. In our laboratory, this form of GLA has only been detected in 
membrane preparations from comparable intact cell studies, but not in the conditioned 
medium from concanavalin A treated cultured fibroblasts, although it may be at levels too 
low to detect.
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In summary, Chapter 4-6 of this thesis show that a substrate of fibronectin promotes GLA 
activation by HT1080 cells and that signals via aSpi integrin are likely to be involved. 
This data adds to a growing body of evidence that integrin receptors play a role in 
transducing signals to regulate MMP synthesis and activity. Both a5pl integrin receptor 
clustering and aSpi integrin receptor occupancy appeared to be required to signal GLA 
activation, and defining the intracellular signalling events involved will form the basis of a 
future project. Data also suggested that fibronectin influences MTl-MMP activity in 
HT1080 cells, stimulating the truncation of MTl-MMP to a 45 kDa form. Further work is 
required to obtain the N-terminal sequence of wild-type 45 kDa MTl-MMP, to compare 
with the sequence of a similarly truncated mutant form of MTl-MMP (Lehti et al., 1998). 
However, it is predicted that the 45 kDa form is catalytically inactive, and as the 
processing of MTl-MMP to 45 kDa is common to many cell types, it may represent an 
important end-point in MTl-MMP activation cascades. Studies presented in this thesis 
implicated MTl-MMP self-processing to 45 kDa, however further work is required to 
confirm this hypothesis. As the truncation of MTl-MMP occurs concomitantly with the 
activation of GLA, future studies should focus on how truncation of MTl-MMP to 45 kDa 
relates to the broader question of GLA activation at the cell surface. The mechanism of 
release of active GLA fi-om the cell also needs to be defined. Certainly, the observation 
made in this thesis that MTl-MMP is processed to a 45 kDa form is a new issue in MTl- 
MMP biology and one that deserves further exploration.
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Figure 7.1 Integrin-mediated transmembrane signalling and organisation of the cytoskeleton
(adapted from Yamada and Miyamoto, 1995 )
A hierarchy o f accumulation of molecules has been established, based on whether an integrin is clustered, 
occupied with a ligand, or both.
(a) If an integrin binds a monovalent ligand it becomes redistributed into a pre-existing site o f integrin and 
cytoskeletal protein accumulation, such as a focal adhesion
(b) If integrin aggregation occurs, certain types o f cytoskeletal proteins accumulate, depending on the state of 
occupancy. If tyrosine phosphorylation can proceed, a large accumulation of signal transduction molecules 
occurs, accompanied by signalling via MAP kinases of the ERK and JNK families.
(c) A combination o f occupancy, aggregation and tyrosine phosphorylation results in the maximal effect, 
including accumulation o f F-actin and cytoskeletal proteins in a massive adhesive, cytoskeletal and signalling 
complex.
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